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SUMMARY 
The mammalian brain is composed of billions of neurons that build functional units by 
forming multiple and complex connections to constitute neuronal networks. Synapses are 
the specialized structures through which neurons connect. The remarkable ability of the 
brain to analyze and generate appropriate responses to an animal’s ever-changing envi-
ronment is based on its power to reshape synaptic connections. Such changes of synaptic 
connections and neuronal network connectivity, termed synaptic and network plasticity, 
respectively, are seen as biological correlates of learning and memory, and deciphering 
their molecular mechanisms may help to understand the function of the brain as a whole. 
HEBBian plasticity is a feed-forward mechanism whereby strongly activated synaptic 
connections get even further strengthened. Therefore, a biological feed-back loop termed 
homeostatic synaptic plasticity (HSP), acts as a natural regulator to avoid excessive 
strengthening of very active connections at the expense of less active ones. Our lab de-
monstrated previously that all-trans retinoic acid (RA) acts as a central signaling molecu-
le during HSP. In the present study, we wanted to ask where and when RA is active du-
ring HSP, and find or develop suitable bioreporter methods to address these questions. 
We first focused on transcription-based reporters that exploit RA’s ability to bind to 
cellular RA receptors (RARs) and thereby activate transcription of specific genes. Our 
previously used transcription-based reporter contains a green fluorescent reporter gene 
(GFP) driven by a weak promoter (TK promoter) that is regulated by a RA response ele-
ment (RARE-TK::GFP). This reporter suffers from a small dynamic range and allows RA 
detection only within a very short time window before getting saturated. We developed an 
improved reporter based on the yeast transcription factor Gal4 and its DNA binding se-
quence “upstream activating sequence” (UAS) which are both foreign to mammalian cells 
and thereby reduce chances of undesired cellular regulation of the reporter. Our novel de-
sign utilizes a chimeric receptor composed of the Gal4 DNA-binding domain (Gal4-
DBD) and a ligand-binding domain from one of three different RARs (RAR-LBD), as 
SUMMARY  IV 
well as a firefly luciferase and enhanced GFP reporter fusion gene (fLuc-EGFP) ex-
pressed by a weak promoter (E4TATA) located downstream of a UAS (UAS-E4TATA::fLuc-
EGFP). The chimeric Gal4-RAR receptor bound to the UAS can enhance transcription 
only in the presence of RA. We show that this reporter design overcomes the limitations 
of our previously used  RARE-TK::GFP reporter and faithfully detects RA production in 
transfected neurons after several days of reporter expression. The stable responsiveness of 
the improved reporter is prerequisite for its utility for in vivo applications which rely on 
viral reporter delivery and long-term expression. We also show with both our previous 
and improved reporters that blocking calcineurin activity in dissociated hippocampal neu-
ron cultures is sufficient to induce cellular RA production, suggesting that calcineurin is 
the critical calcium sensor that senses and relates synaptic activity levels to RA produc-
tion within the HSP signaling cascade. 
We next wanted to develop a method to directly indicate the presence of RA with high 
spatial and temporal resolution. We designed a modular sensor protein that would allow 
the detection of conformational changes by measurements of FÖRSTER resonance energy 
transfer (FRET). We fused the RAR-LBD to a NR box, a specific peptide motif which 
can bind to the RAR-LBD in an RA-dependent manner. This fusion protein is sandwi-
ched between cyan (CFP) and yellow fluorescent proteins (YFP), rendering conformatio-
nal changes amenable to FRET measurements. The sensor assumes an extended confor-
mation in the absence of RA, yielding low FRET efficiency. In the presence of RA, the 
LBD should recruit the NR box peptide leading to a compact conformation, thus yielding 
higher FRET efficiency. Despite various modifications of the sensor design, we failed to 
obtain responsiveness to RA with this method. 
We obtained a different genetically encoded sensor for RA (aGEPRA) which directly 
translates the RA-dependent conformational changes of the RAR-LBD into FRET chan-
ges. We successfully expressed aGEPRA in dissociated hippocampal neurons and recor-
ded FRET changes during pharmacological blockade of synaptic activity. Within two 
hours of synaptic activity blockade some neurons showed increasing reporter activity 
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(“responders”) while others responded with a decrease (“non-responders”). However, al-
most all control cells observed for two hours without synaptic activity blockade behaved 
like “responders”, hampering the interpretation of our results. We tend to exclude techni-
cal reasons and suggest that the lack of signal integration is a central limitation of the 
aGEPRA FRET sensor, prohibiting the detection of low endogenous RA levels. 
Last, we tested the utility of ratiometric FRET for 2-photon microscopy. We show that 
quantitation of ratiometric FRET is feasible with the Clover-mRuby2 FRET pair which 
exhibits a large separation of the 2-photon excitation spectra between donor and acceptor 
fluorophores. FRET changes are also qualitatively detectable with aGEPRA even though 
the spectral overlap between its CFP and YFP fluorophores are spectrally less well re-
solved; therefore, thorough calibration of the method would be required to allow for pre-
cise absolute FRET quantification. 
We conclude that only integrating, transcription-based reporters seem to provide suffi-
cient sensitivity to detect RA levels produced during HSP. The non-integrating aGEPRA 
FRET sensor seems to lack the sensitivity required to visualize endogenous neuronal RA 
levels produced during synaptic activity blockade. 
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ZUSAMMENFASSUNG 
Das Gehirn besteht aus vielen Milliarden Nervenzellen, die komplexe Verbindungen 
eingehen um neuronale Netzwerke, die funktionellen Einheiten des Gehirns, zu bilden. 
Synapsen sind spezialisierte Strukturen, mit denen Nervenzellen untereinander Kontakt 
herstellen. Die Fähigkeit des Gehirns, auf eine sich ständig ändernde Umgebung eines 
Lebewesens zu reagieren basiert auf der Formbarkeit dieser synaptischen Verbindungen. 
Solche Veränderungen synaptischer Verbindungen und neuronaler Netzwerke werden 
synaptische beziehungsweise Netzwerkplastizität genannt, und sie bilden vermutlich die 
biologische Grundlage des Lernens und Gedächtnisses. Die diesen Prozessen zu Grunde 
liegenden Mechanismen zu studieren ist unverzichtbar, um die Funktionsweise des Ge-
hirns als ganzes verstehen zu können. 
HEBB’sche Plastizität ist ein Verstärkungsmechanismus, durch den hochaktive Sy-
napsen weiter verstärkt werden können. Ein biologischer Regulationsprozess, genannt 
homöostatische synaptische Plastizität (HSP), wirkt der HEBB’schen Plastizität entgegen 
und verhindert dadurch eine Überaktivierung stärkerer Verbindungen zu Ungunsten der 
schwächeren. Wir konnten in früheren Untersuchungen zeigen, dass all-trans Retinolsäu-
re (RA) eine zentrale Rolle in der Regulation von HSP spielt. Wir gingen in der vorlie-
genden Arbeit der Frage nach, wo und wann RA während der HSP aktiv ist, und testeten 
oder entwickelten geeignete Methoden zur Untersuchung dieser Fragestellungen. 
RA kann an zelluläre RA Rezeptoren (RARs) binden und dadurch die Transkription 
spezieller Gene aktivieren, was man zur Entwicklung transkriptions-basierter Reporter 
nutzen kann. Unser bislang verwendeter transkriptions-basierter Reporter enthält ein grün 
fluoreszierendes Reportergen (GFP), das von einem schwachen TK Promoter unter Regu-
lation eines RA Responselements exprimiert wird (RARE-TK::GFP). Wir haben einen 
verbesserten transkriptions-basierten Reporter entwickelt, der auf dem Transkriptionsfak-
tor Gal4 und dessen DNA-Bindungsstelle „upstream activating sequence“ aus der Hefe 
beruht, um den dynamischen Bereich und die zeitliche Nutzbarkeit zu erweitern. Die ver-
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wendeten Komponenten kommen in Säugerzellen nicht vor und sollten auch keiner uner-
wünschten zellulären Regulation unterworfen sein. Wir nutzen einen chimären Rezeptor 
bestehend aus der Gal4 DNA-Bindedomäne (Gal4-DBD) und einer RAR Liganden-
Bindedomäne (RAR-LBD), sowie eine mit GFP fusionierte Leuchtkäfer-Luciferase als 
Reportergen (fLuc-EGFP), das von einem schwachen Promoter (E4TATA) hinter einer 
UAS exprimiert wird (UAS-E4TATA::fLuc-EGFP). Der Gal4-RAR Rezeptor bindet an die 
UAS und erhöht in Gegenwart von RA die Transkription des Reportergens. Wir zeigen, 
dass dieses Prinzip unseren vorherigen RARE-TK::GFP Reporter übertrifft, indem ein 
Nachweis der RA-Produktion noch nach mehrtägiger Reporterexpression gelingt, was 
eine Anwendung des neuen Reporters durch Virus-vermittelte Gewebsexpression in vivo 
ermöglicht. Sowohl mit unserem bisherigen als auch dem neu entwickelten Reporter 
konnten wir eine RA-Produktion in Nervenzellen zeigen, in denen Calcineurin pharmako-
logisch inhibiert wurde. Wir schließen daraus, dass Calcineurin der Calcium-Sensor ist, 
der synaptische Aktivität über die Calcium-Konzentration erkennt und auf dieser Grund-
lage die RA-Produktion während der HSP regulieren kann. 
Zum Nachweis von RA mit hoher zeitlicher und räumlicher Auflösung entwickelten 
wir einen modularen Sensor, dessen Konformationsänderungen wir durch FÖRSTER Reso-
nanz-Energietransfer (FRET) sichtbar machen können. Wir fusionierten die RAR-LBD 
mit einer NR Box - einer spezifischen Peptidsequenz, die RA-abhängig an die LBD bin-
den kann. Anfügen von cyan (CFP) und gelbem Fluoreszenzprotein (YFP) an das NR 
Box-LBD Fusionsprotein sollte dessen Konformationsänderungen durch FRET messbar 
machen: Eine in Abwesenheit von RA gestreckte Sensorkonformation zeigt wenig FRET, 
während die NR Box in Gegenwart von RA an die LBD binden und eine geschlossene 
Konformation herbeiführen sollte, was eine höhere FRET-Effizienz bewirken würde. 
Trotz zahlreicher getesteter Modifikationen des Sensors gelang uns mit dieser Methode 
kein Nachweis RA-abhängiger Konformationsänderungen. 
aGEPRA ist ein anderer FRET-basierter RA Sensor, der den Konformationswechsel 
der RAR-LBD direkt in eine Änderung des FRET-Signals übersetzt. Wir konnten diesen 
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Reporter in Nervenzellen exprimieren und FRET-Signale über zwei Stunden während ei-
ner pharmakologischen Blockade synaptischer Aktivität messen. Während der Blockade 
zeigten einige Zellen ein steigendes („Responder“), und andere ein abfallendes Reporter-
signal („Non-Responder“). Die meisten Kontrollzellen, deren synaptische Aktivität nicht 
blockiert wurde, verhielten sich jedoch allgemein ähnlich den „Responder“ Zellen, ob-
wohl in Kontrollzellen keine RA-Synthese stattfinden sollte. Diese Ergebnisse sind wahr-
scheinlich nicht technisch bedingt, sondern womöglich auf eine mangelnde Sensitivität 
des aGEPRA FRET Sensors zurückzuführen, da er das Signal nicht zeitlich oder räumlich 
integrieren und folglich sehr niedrige RA-Konzentrationen nicht anzeigen kann. 
Wir testeten zuletzt, in wieweit ratiometrische FRET-Messungen mit 2-Photonen-
Mikroskopie erfasst werden können und stellen fest, dass quantitative Messungen für 
FRET-Paare mit hinreichender spektraler Separation ihrer 2-Photonen-Anregungsspek-
tren möglich sind, wie wir anhand des Clover-mRuby2 FRET-Paares zeigen. FRET-
Änderungen sind auch bei FRET-Paaren mit weniger deutlicher spektraler Auftrennung 
der Fluorophore zumindest qualitativ messbar, wie bei aGEPRA mit seinem CFP-YFP 
FRET-Paar; eine absolute Quantifizierung kann in solchen Fällen jedoch nur bei sorgfälti-
ger Kalibrierung der Methode gelingen. 
Wir ziehen den Schluss, dass nur integrierende Reporter eine hinreichende Sensitivität 
liefern, um niedrige RA-Konzentrationen während der HSP zu erfassen. Dem nicht-
integrierenden aGEPRA FRET Sensor mangelt es hingegen an Sensitivität, um endogene 
RA-Produktion darzustellen, wie sie während der Blockierung synaptischer Aktivität in 
Nervenzellen aktiviert wird. 
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1. INTRODUCTION 
Mammals are characterized by very dynamic and complex behavior resulting from the 
interplay between the animal’s internal state and its environment. The brain is the organ 
that collects, processes, analyses, and integrates environmental cues and information 
about the internal state to initiate appropriate responses by adjusting behavior or internal 
body homeostasis. To fulfill this task, the brain has evolved to be the most complex and 
sophisticated of all organs, both structurally and functionally: instead of acting as a static 
processor for predefined arithmetical problems, it rather functions as a highly dynamic 
integrator that is continuously shaped by the flow of information it receives from its envi-
ronment. The function of the brain is based upon the various neural networks comprised 
of electrically active neurons. These neurons are connected by numerous synapses, speci-
alized structures that allow information to flow from one neuron to another. Through vari-
ous biochemical processes, the strength and other properties of synapses can be modified 
based on the activity history of the network, thereby optimizing a network’s capacity for 
information processing. This phenomenon is commonly referred to as synaptic plasticity, 
and it has become increasingly clear that deciphering its underlying molecular mecha-
nisms is the first step toward understanding the complex function of the brain as a whole. 
1.1 Neuronal Synaptic Plasticity 
When synapses emerged as the major sites for neuronal signal transmission (Lopez-
Munoz et al., 2006), Donald Hebb proposed that they might also be plastic entities for 
information processing and memory storage (Seung, 2000). It has since been shown that 
synaptic plasticity is critically involved in various forms of brain function (Sweatt, 2016), 
including motor control (Pugh and Raman, 2009), sensory input computation (Singer et 
al., 2009), learning and memory (Di Filippo et al., 2009), and cognition. Forms of synap-
tic plasticity whereby activated synapses become strengthened have been termed HEBBian 
synaptic plasticity, even though the causal relationship between synaptic plasticity and 
brain function has yet to be formally demonstrated (Martin et al., 2000, Takeuchi et al., 
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FIGURE 1.1| Concepts of Neuronal Synaptic Plasticity. A, HEBBian and homeostatic synaptic plasticity. A 
strongly activated synapse (illustrated by lightnings in left panel) is strengthened (LTP, top left panel) while 
moderate or weak synaptic activation leads to a weakening (LTD, bottom left panel) of only the activated 
synapse by a HEBBian mechanism. Homeostatic synaptic plasticity (HSP; right panels), by contrast, affects 
a large subset or possibly all synapses at once. Enhanced activity causes homeostatic synaptic downscaling 
(top right panel), while reduced activity leads to homeostatic synaptic upscaling (bottom right panel). (after 
Chater and Goda, 2014) B, Necessity for HSP. Strong activation of a given synapse (red synapse in left 
panel) induces HEBBian LTP. LTP may eventually cause overflowing synaptic input, saturating the postsy-
naptic neuron’s dynamic range where it can meaningfully respond (middle panel, shaded area in input-
response diagram). HSP can reduce overall input to restore set-point activity level (right panel) by multipli-
catively re-adjusting the strengths of all synapses in two possible ways: in a pre-synaptic way, all synaptic 
inputs are scaled down to push the input level back into the dynamic range on the existing input-response 
curve (right panel, beige input-response curve). Alternatively, by scaling down postsynaptic receptor den-
sity a neuron may adjust its output level to the enhanced input, establishing a new input-response curve with 
a different dynamic range (right panel, red input-response curve). C, Computational models of HSP. 
Changes in synaptic properties of a model neuron (top panel) are computed according to global or local 
modes of HSP. Conductances Gsyn,i and voltages Vi of individual synapses are regulated differently by 
global or local HSP on a microscopic scale (middle panels), but such differences are concealed by ranked 
cumulative histogram plot analysis of miniature EPSCs (bottom panel). (modified from Rabinowitch and 
Segev, 2006b) D, Cell biology of global and local HSP. Both forms of HSP require a reduction of intracel-
lular calcium levels, [Ca2+]i. Prolonged reduction of somatic calcium levels leads to the activation of a tran-
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2014). Two forms of synaptic plasticity with mechanistically and functionally distinct 
characteristics can be distinguished (Yu and Goda, 2009) (Figure 1.1A): The aforementio-
ned HEBBian mechanisms, often expressed as long-term potentiation and depression 
(LTP, LTD), act in an input-specific manner and only affect the subset of synapses that 
are activated (Figure 1.1A, left panel). HEBBian mechanisms therefore alter the properties 
of neuronal circuitry in response to specific inputs. By contrast, homeostatic mechanisms, 
such as synaptic scaling, regulate the synaptic strengths of most, possibly all, synapses 
converging onto one neuron (Turrigiano and Nelson, 2004). Homeostatic mechanisms are 
negative feedback-based processes aimed at maintaining a stable level of activity of the 
affected postsynaptic neuron even under variable overall input conditions (Feldman, 
2009). These synaptic processes are collectively referred to as homeostatic synaptic 
plasticity (HSP) (Figure 1.1A, right panel). 
HEBBian synaptic plasticity was first experimentally reported in the early 1970s in the 
hippocampi of rabbits, where long-term potentiation was observed after high-frequency 
electrical stimulation of the perforant path (Bliss and Lomo, 1973). Two decades later, 
long-term depression of hippocampal synapses was described after low-frequency electri-
cal stimulation of the presynaptic cell (Dudek and Bear, 1992, Mulkey and Malenka, 
1992). These observations laid the grounds to experimentally confirm Hebb’s hypothesis 
that synaptic plasticity might be the structural and functional basis for memory formation 
in the central nervous system. However, a conceptual conflict soon became apparent from 
theoretical considerations (Bienenstock et al., 1982) and computational models of HEBBi-
an plasticity (Oja, 1982, Miller and MacKay, 1994): strengthening of highly active sy-
napses by HEBBian mechanisms might cause overactivation of a neuron by saturating its 
physiological output level (Figure 1.1B, middle panel). Moreover, if the same mecha-
nisms tend to weaken less active synapses, HEBBian plasticity would eventually lead to a 
scription-dependent mechanism that restores normal firing rate by globally increasing the synaptic accumu-
lation of heteromeric AMPA receptors (blue box). Reductions in dendritic calcium activate a biochemical 
cascade that increases local RA production, leading to the disinhibition of dendritic mRNA translation and 
locally increased synaptic insertion of homomeric AMPA receptors (red box). (after Chen et al., 2014)  
FIGURE 1.1| Concepts of Neuronal Synaptic Plasticity.  (continued) 
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“winner-take-all” potentiation of the most active synapses, while all weaker synapses 
would vanish (Goldberg et al., 2002). Because this contradicts our experience that memo-
ry is plastic and non-saturable, and because neuronal networks appear to be stable over 
extensive periods of time in vivo and in vitro, homeostatic mechanisms must exist to sta-
bilize neuronal networks. Simply put, feed-forward neuronal network destabilization by 
HEBBian mechanisms requires a homeostatic, feedback-based means of neuronal network 
stabilization. The homeostatic feedback regulation of synaptic strength therefore counte-
racts the overall long-term activity changes of the network, i.e. increased network activity 
leads to a weakening of excitatory synapse strength, while suppressed network activity 
leads to excitatory synapse strengthening (Figure 1.1B, right panel). To avoid the immedi-
ate neutralization of HEBBian information storage, homeostatic feedback needs to operate 
at much longer time frames than HEBBian processes. While HEBBian plasticity is expres-
sed within seconds to minutes after a stimulus, homeostatic feedback regulation occurs 
hours to days after prolonged network activity perturbation. 
Homeostatic synaptic plasticity has indeed been observed experimentally after phar-
macological activity perturbations of neuronal networks in vitro, either in dissociated neu-
ronal cultures or in slice cultures (Turrigiano et al., 1998, Wang et al., 2011, Ju et al., 
2004, Sutton et al., 2004, Sutton et al., 2006, Thiagarajan et al., 2005, Aoto et al., 2008, 
Sarti et al., 2013). Because bath application of neuronal activity-blocking drugs affects all 
cells and excitatory synapses of the neuronal networks alike, it leads to an overall increase 
in synaptic transmission. When miniature excitatory post-synaptic currents (mEPSCs) 
recorded from a pharmacologically silenced neuronal culture are ranked by amplitude and 
plotted against mEPSCs from an untreated control culture, the slope will be greater than 
one, while two control cultures plotted against each other yield a slope equal to one. It has 
therefore been suggested that homeostatic processes adjust the strengths of all synapses 
(or at least a large subset of synapses) multiplicatively, thereby keeping their relative 
strengths unchanged (Turrigiano et al., 1998, Aoto et al., 2008). Even though this mul-
tiplicative increase of synaptic strength was initially believed to be “global” across the 
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FIGURE 1.2| RA Signaling during Homeostatic Synaptic Plasticity. A, Biochemistry of retinoids. Reti-
noids are stored as retinyl esters which may be hydrolyzed to release free retinol when needed. It is then 
converted to retinal in a chemical equilibrium reaction catalyzed by ROLDHs. Retinal is irreversibly oxi-
dized by RALDHs to yield retinoic acid. B, Retinoic acid receptor structure and function. Retinoid recep-
tors contain 6 domains labeled A-F. The C domain is the DNA binding domain (DBD) and the E domain is 
the ligand binding domain (LBD), connected via a flexible hinge located in the D domain. The N-terminal 
ligand-independent activating function AF-1, and the ligand-dependent C-terminal AF-2 are indicated. Bot-
tom right panel: The ligand-induced conformational switch of the LBD comprises outward rotation of helix 
11 (H11) to form a linear extension of H10. H12 simultaneously flips inward over the ligand binding pocket 
(LBP) to form a hydrophobic groove with H3 and H4 into which transcriptional coactivators can bind 
(modified from Bourguet et al., 2000a). Bottom left panel: Coactivators can interact with ligand-activated 
LBD by means of their consensus “NR box” binding motif (LxxLL), thereby stimulating RA-mediated tran-
scription (white curved arrow) downstream of a “retinoic acid response element”, RARE. C, Molecular 
signaling cascade of RA-mediated homeostatic synaptic plasticity. During normal synaptic activity, postsy-
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these enzymes in the RA synthesis pathway blocks homeostatic synaptic plasticity (Aoto 
et al., 2008). 
RA is a small signaling molecule with a well-established role as a developmental 
morphogen (Maden, 2007), but it is also important in the adult brain to maintain normal 
function (Lane and Bailey, 2005). RA exerts its major biological functions by binding to 
its specific receptors, the retinoic acid receptors (RAR), which act in combination with 
retinoid X receptors (RXR). These two receptor classes are commonly referred to as reti-
noid receptors (Huang et al., 2014). All retinoid receptors belong to the nuclear hormone 
receptor (NR) superfamily, and like other NRs they contain - among other domains - a 
DNA binding domain (DBD) for binding to specific DNA sequences called retinoic acid 
response elements (RARE), and a ligand binding domain (LBD) that binds their respecti-
ve ligands (Brelivet et al., 2012, Sever and Glass, 2013). Binding of RA to any of its re-
ceptors induces a canonical conformational switch of the unliganded apo-form to the li-
gand-activated holo-form of the LBD, comprising an outward rotation of helix 11 (H11) 
and back-folding of H12 over the ligand binding pocket of the LBD (Bourguet et al., 
1995, Renaud et al., 1995, Wurtz et al., 1996, Bourguet et al., 2000a, Bourguet et al., 
2000b, Moras and Gronemeyer, 1998). This rearrangement of superficial helices creates a 
hydrophobic groove to which transcriptional coactivators can bind with a conserved 
“LxxLL” peptide sequence (where L represents leucin, and x represents any amino acid) 
termed “NR box”, a consensus binding motif shared among all transcriptional coactiva-
tors of nuclear receptors (Heery et al., 1997, Darimont et al., 1998, Pogenberg et al., 
2005). The recruitment of transcriptional coactivators enhances retinoid receptor-
mediated transcriptional activation of genes located downstream of the RARE (Huang et 
al., 2014, Moutier et al., 2012, Moras and Gronemeyer, 1998, Perissi and Rosenfeld, 
naptic calcium is maintained at a sufficient level for keeping calcineurin active (left panel). During synaptic 
inactivity (1), calcium concentration drops below a level required for calcineurin activation. Inactivated 
calcineurin leads to disinhibition of RA production (2), causing the dissociation of RAR from synaptic 
AMPA receptor mRNAs to allow their local translation (3). Newly synthesized homomeric AMPA recep-
tors are incorporated into the postsynaptic membrane (4), increasing excitatory synaptic strength to restore 
normal synaptic input levels. (after Chen et al., 2014 )  
FIGURE 1.2| RA Signaling during Homeostatic Synaptic Plasticity. (continued) 
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2005) (Figure 1.2B). 
In contrast to its transcription-modulating activity, the recently discovered function of 
RA in synaptic plasticity and homeostasis is far less understood: RA and RAR have 
been identified as novel regulators of synaptic signaling and homeostatic synaptic plasti-
city that together regulate dendritic protein translation and synaptic insertion of the io-
notropic glutamate receptor subunit GluA1 during chronic activity blockade (Aoto et al., 
2008, Poon and Chen, 2008) (Figure 1.2C). However, the precise intracellular signaling 
pathways leading to the production of RA, recruitment of RAR to synapses and eventu-
ally to the local translation of GluA1 and perhaps other mRNAs remain elusive (Groth 
and Tsien, 2008). 
1.3 Calcineurin Signaling at the Synapse 
After a “phosphodiesterase inhibitory protein” purified and cloned in 1978 was disco-
vered to be expressed abundantly in brain tissue and regulated by calcium/calmodulin in-
teractions, it was soon given the name “calcineurin” (CaN) (Klee and Krinks, 1978, Klee 
et al., 1979). CaN is a protein serine/threonine phosphatase present in multiple neuronal 
compartments, including pre- and postsynaptic terminals, the cytosol, and the nucleus. It 
interacts with and acts upon a wide variety of target proteins and thereby influences a 
multitude of cellular processes such as neuronal morphology, neurotransmission, synaptic 
plasticity, and gene transcription (Groth et al., 2003). At the synapse, CaN plays central 
roles in neurotransmitter and ion channel trafficking and function, structural protein net-
work dynamics, and kinase/phosphatase balance regulation (Figure 1.3A). Many of CaN’s 
rather acute and rapid effects on synaptic function involve the regulation of trafficking 
and ion permeability of neurotransmitter receptors and ion channels (Baumgartel and 
Mansuy, 2012). The most prominent example of CaN’s direct influence on receptor abun-
dance at the postsynaptic membrane is the dephosphorylation-dependent internalization of 
GluA1 subunit-containing glutamate receptors of the -amino-3-hydroxy-5-methyl-4-
isoxazole proprionate (AMPAR) type (Santos et al., 2009). CaN-mediated dephosphory-
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FIGURE 1.3| Calcineurin Signaling at the Synapse. A, Postsynaptic targets of calcineurin signaling. Cal-
cineurin’s major roles are the regulation of synaptic neurotransmitter receptor and ion channel homeostasis 
by dephosphorylating specific phosphosites (P). Another major function is the regulation of the synaptic 
cytoskeleton by depolymerizing actin filaments and destabilizing the post-synaptic density. For further de-
tails and references, see main text. B, Calcineurin domain structure. Calcineurin is a modular protein phos-
phatase with a catalytic Ser/Thr protein phosphatase domain homologous to other Ser/Thr protein phos-
phatases. A unique feature is calcineurin’s regulatory domain which consists of three sub-domains: a cal-
cineurin B binding domain (CaN B binding) to which the accessory calcineurin B subunit binds to complete 
the enzyme complex, a calmodulin binding domain (CaM binding) where Ca2+/calmodulin can bind at suffi-
cient calcium concentrations to activate calcineurin’s enzymatic activity, and an autoinhibitory peptide 
(AIP) that occludes the catalytic cleft under resting conditions until Ca2+/calmodulin binding causes the 
INTRODUCTION  9 
entire neuron and therefore named “synaptic scaling” (Turrigiano et al., 1998), computati-
onal modeling showed that a “local”, dendrite-specific mechanism could yield similar ex-
perimental results (Rabinowitch and Segev, 2006a) (Figure 1.1C). One of the major open 
questions about homeostatic synaptic plasticity therefore is, how “global”, or how “local” 
HSP truly is (Turrigiano, 2012, Chen et al., 2014) (Figure 1.1D). And if it is a truly local 
event, then how is it locally confined, and how are the borders of its local confinement 
regulated and shifted by synaptic activity levels? 
Many forms of synaptic plasticity, both HEBBian and homeostatic mechanisms alike, 
are mediated by neurotransmitter receptor regulation in the postsynaptic membrane. A 
change in synaptic activity leads to the activation of biochemical signaling cascades that 
affect postsynaptic neurotransmitter receptor activity at various levels, including gene 
transcription, local (dendritic) mRNA translation, receptor insertion into the membrane 
from intracellular reserve pools, lateral diffusion in and out of the active zone of the sy-
napse, or modulation of ion permeability by means of phosphorylation or other post-
translational modifications of the receptor molecules (Lee and Kirkwood, 2011). Because 
HEBBian and homeostatic mechanisms seem to share at least some signaling cascades in-
volved in postsynaptic neurotransmitter receptor regulation, but affect synaptic sensitivity 
in opposite directions, it will be interesting to determine how and where the signaling cas-
cades diverge between the two opposing mechanisms (Kotaleski and Blackwell, 2010). 
1.2 Retinoic Acid Signaling and Homeostatic Synaptic Plasticity 
As a membrane-permeable lipophilic signaling molecule, all-trans retinoic acid (RA) 
is produced ad hoc whenever necessary because it cannot be stored in its active form. Re-
tinoid precursors can be stored intracellularly as retinyl esters, which can hydrolytically 
release all-trans retinol when RA is needed. The biosynthetic pathway of RA production 
involves a two-step oxidative reaction; all-trans retinol is first converted into all-trans 
retinal by retinol dehydrogenases (ROLDHs) in a reversible equilibrium redox reaction. 
Retinal then becomes irreversibly oxidized by retinaldehyde dehydrogenases (RALDHs) 
to yield RA (Napoli, 1996) (Figure 1.2A). It has been shown that blocking either one of 
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lation of GluA1 after weak synaptic stimulation and moderate calcium entry leads to rapid 
but prolonged AMPAR internalization (Beattie et al., 2000, Man et al., 2007), which is 
considered the molecular basis for synaptic long-term depression (LTD) (Mulkey et al., 
1993, Mulkey et al., 1994, Kessels and Malinow, 2009, Santos et al., 2009). Another im-
portant group of glutamatergic neurotransmitter receptors are the N-methyl-D-aspartate 
type glutamate receptors (NMDAR). The C-terminal tail of the GluN2A subunit of 
NMDARs can be dephosphorylated by CaN, leading to decreased channel open probabili-
ty and increased receptor desensitization (Lieberman and Mody, 1994, Tong et al., 1995, 
Krupp et al., 2002). Beyond its effects on glutamatergic neurotransmitter receptors, CaN-
mediated dephosphorylation also affects voltage-gated calcium channels (Budde et al., 
2002), leading to receptor inactivation (Lukyanetz et al., 1998, Burley and Sihra, 2000, 
Dittmer et al., 2014) and internalization (Wu et al., 2005). In complete analogy to the mo-
dulation of glutamatergic synapse function, CaN can also regulate inhibitory synaptic 
transmission (Jones and Westbrook, 1997, Robello et al., 1997) by direct dephosphoryla-
tion of the 2 subunit of A-type -amino-butyric acid receptors (GABAAR) (Wang et al., 
2003, Luscher et al., 2011), and thereby decrease GABAergic neurotransmission (Chen et 
al., 1995, Jones and Westbrook, 1997, Robello et al., 1997, Wang et al., 2003). 
The modulation of synaptic neurotransmitter and ion channel abundance and function 
requires active regulation of protein trafficking and motility. Consequently, the regulation 
of cytoskeletal and structural protein dynamics constitutes a second important aspect of 
synaptic CaN function. Consistent with increased dynamics and internalization of synap-
tic receptors and ion channels, CaN activation leads to the depolymerization of filamen-
tous actin (F-actin) to its monomeric form, globular actin (G-actin) (Gomez et al., 2002, 
Morishita et al., 2005). Through its effects on synaptic actin dynamics, CaN also influen-
ces the composition of the complex structural protein network that forms the postsynaptic 
displacement of the AIP from the catalytic domain to allow catalysis to occur. Top panel schematically il-
lustrates domain structure, bottom panel shows space-filling atomic model with domains color-coded as in 
top panel. Accessory CaN B domain is represented as ribbon model in purple, and catalytic cleft is encircled 
in red in the space-filling model without the AIP on the right (PDB: 1AUI).  
FIGURE 1.3| Calcineurin Signaling at the Synapse. (continued) 
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density (PSD). CaN itself is integrated into the PSD (Husi et al., 2000) by binding to A-
kinase anchoring protein (AKAP79/150) (Dell’Acqua et al., 2002), an important signaling 
complex organizer within the PSD that also recruits protein kinases A and C (PKA and 
PKC) (Coghlan et al., 1995, Klauck et al., 1996, Oliveria et al., 2003). AKAP79/150 is in 
turn associated with F-actin, whose depolymerization leads to the dissipation of 
AKAP79/150 complexes (Gomez et al., 2002). Furthermore, AKAP79/150 can bind other 
PSD members of the membrane-associated guanylate kinase (MAGUK) superfamily, lin-
king the AKAP79/150 complex to postsynaptic glutamate receptors (Colledge et al., 
2000, Oliveria et al., 2003). These large signaling complexes assembled around 
AKAP79/150 become either partially disassembled or functionally inhibited by dissociati-
on of AKAP79/150 from the actin cytoskeleton and its migration away from the PSD, lea-
ding to a depression of glutamatergic synaptic transmission (Tavalin et al., 2002). 
The third - and perhaps most complex - of CaN’s synaptic functions is its coordinating 
role in balancing protein kinase and phosphatase activities (Woolfrey and Dell’Acqua, 
2015). Many synaptic protein kinases and phosphatases are themselves subject to 
phosphorylation, and their phosphorylation states can regulate enzymatic activity and/or 
localization. CaN’s most direct action within the postsynaptic protein kinase/phosphatase 
network is the dephosphorylation of the protein phosphatase inhibitor I-1, which leads to 
the dissociation from its target, protein phosphatase 1 (PP1), rendering PP1 catalytically 
active (Mulkey et al., 1994). CaN and PP1 share many downstream targets, and their 
combined activities can shift synaptic protein kinase/phosphatase balance towards a 
phosphatase-dominated state. They can together decrease local PKA and PKC activities 
within the PSD by removal of the PKA and PKC-recruiting scaffold AKAP79/150 
(Oliveria et al., 2003, Colledge et al., 2000, Tavalin et al., 2002), but they also 
dephosphorylate Ca2+/calmodulin-dependent protein kinase II (CaMKII) to eliminate its 
autophosphorylation-induced catalytic “autonomy” (Miller and Kennedy, 1986) and 
restore its catalytic dependence on the activation by Ca2+/calmodulin (Strack et al., 1997). 
At the behavioral level, pharmacological and genetic studies suggest important functi-
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ons of CaN in memory formation, consolidation, and/or extinction (Mansuy et al., 1998a, 
Mansuy et al., 1998b, Winder et al., 1998, Ikegami and Inokuchi, 2000, Malleret et al., 
2001, Zeng et al., 2001). Especially CaN’s prominent role in slow phases of memory such 
as memory consolidation and extinction, its regulation by calcium levels, and its promis-
cuous interactions with a large number of substrates during synaptic plasticity, make it a 
potential regulator of homeostatic plasticity that is believed to act on a similarly slow time 
scale. 
Structurally, calcineurin is composed of two obligatory subunits, one larger catalytic 
calcineurin A subunit (CnA) and the smaller accessory calcineurin B subunit (CnB). The 
catalytic subunit consists of a catalytic domain with structural homology to other protein 
serine/threonine phosphatases, and additional regulatory domains that confer calcineurin’s 
calcium responsiveness (Figure 1.3B): a calcineurin B binding helix (BBH) where the ac-
cessory CnB subunit binds, followed by an autoinhibitory domain (AID) comprising a 
calmodulin binding domain (CaMB) to which Ca2+/calmodulin can bind, and an autoinhi-
bitory peptide (AIP) close to the C-terminal. Under resting conditions, the AIP occludes 
the catalytic cleft, thereby inhibiting substrate access. When intracellular calcium levels 
rise, activated Ca2+/calmodulin can bind to the CaMB region in close proximity to the 
AIP, inducing a conformational change that leads to the displacement of the AIP and ope-
ning of the catalytic cleft, rendering CaN catalytically active (Rusnak and Mertz, 2000). 
Moreover, the very N-terminal and C-terminal portions of the protein are, respectively, 
formed by N-terminal, and C-terminal domains of unknown function that display high 
sequence variation across species or between different CaN isoforms within a single spe-
cies. 
1.4 Cell-based Bioreporter Assays for Biomolecules 
Insight into the internal metabolic state of an organism and its cells is indispensible to 
answer many questions in biology. Classical biochemical methods require lysing or fixing 
the tissues or cells of interest and are therefore limited to static, “snapshot-like” images of 
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FIGURE 1.4| Cell-Based Bioreporter Assays. A, Conceptual comparison of non-integrating and integrating 
reporter assays. Non-integrating reporters combine sensor and reporter activities in a single protein. There-
fore, sensor activity directly translates into reporter activity proportionally and with high spatial 
(subcellular) and temporal (sub-second) resolution. Non-integrating reporters are often based on naturally 
occurring “receptor” proteins fused to one or two fluorescent proteins. Binding of their specific ligand in-
duces a conformational change which translates into a change of fluorescence properties. We refer to these 
reporters as non-integrating systems because reporter activity is strictly confined in time and space to the 
actual presence of analyte. Integrating reporter assays, by contrast, consist of a sensor protein that can 
modulate the transcription or translation (or in rare cases the degradation) of a separate reporter, commonly 
a gene encoding for a fluorescent or luminiscent protein. The sensor protein regulates reporter protein  
abundance without directly affecting activities of individual reporter protein. A transient sensor activation 
during the total assay time is often sufficient for detectable reporter accumulation. Because reporter proteins 
may remain stable well beyond sensor activation, they can accumulate in the target cell even with low or 
fluctuating sensor activity; we therefore refer to such reporters as integrating systems. B, Time courses of 
non-integrating and integrating reporters. Non-integrating reporters (yellow) reliably detect intense signals 
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the biochemical state of the system. After lysis or fixation, a cell or tissue sample is irre-
versibly destroyed and can therefore not be reprobed at a later time point or under diffe-
rent conditions. By contrast, physiological techniques make a living cell or tissue acces-
sible for measurements of parameters of its changing internal states while experimental 
manipulations are made, but are often invasive and the measurements themselves may 
interfere with the parameters to be measured. 
A growing number of cell-based reporter assays have therefore been developed where 
genetically encoded sensor molecules expressed in the cells and tissues of interest are uti-
lized to overcome the limitations of classical biochemical or physiological techniques. 
Such genetically encoded sensor molecules can sense the metabolic state or a particular 
analyte’s concentration and dynamics; sensor activation by the analyte can subsequently 
be translated into a reporter activity which should ideally be detectable by non-invasive 
methods, most commonly by fluorescence or luminescence readouts (Umezawa, 2005, 
Wang et al., 2009, Michelini et al., 2010). 
Two general types of reporters may be distinguished: transcription-based reporters and 
transcription-independent, folding-based reporters (Figure 1.4). Transcription-based re-
porters make use of a sensor molecule that allows to couple a biological parameter to the 
expression level of a reporter gene whose product may accumulate within the cell. There-
fore, reporters of this type may be considered as integrating reporters. Because transcripti-
on is necessary for reporter function, such reporters are limited to the speed of transcripti-
on (hours) and spatial resolution is confined to the whole-cell level without subcellular 
precision. Folding-based reporters, by contrast, are present in the cell independently of the 
examined biological parameter or analyte. In the presence of the analyte, such reporters 
(timepoint t2 in the left panel) but may fail to detect low signals if analyte concentrations fluctuate at low 
levels around detection threshold of the assay (right panel, detection thresholds illustrated as gray shaded 
areas in the bottom diagrams). An integrating assay (red dashed line) has the advantage of steadily building 
up reporter signal during the time course of the assay, but endpoint assay readout (black arrowhead at time-
point tx) obscures the fluctuation of  analyte concentration over time. Therefore, a short burst of analyte (left 
panel) may yield a similar integrated assay signal as an analyte concentration moderately increased over 
background for an extended time period (right panel).  
FIGURE 1.4| Cell-Based Bioreporter Assays. (continued) 
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will undergo a conformational switch that allows the specific detection of signaling 
events in real-time (sub-second response time) and with subcellular resolution without 
signal integration over space and time (non-integrating reporters). 
1.5 FÖRSTER Resonance Energy Transfer 
Fluorescence is a phenomenon whereby a light-absorbing molecule (the fluorophore) 
can be excited by light of a specific wavelength to emit light of a longer wavelength 
(Figure 1.5A, left panel). In terms of quantum physics, a fluorophore that absorbs a pho-
ton of a specific energy is lifted to an electronic excited state (photoexcitation). Because 
the excited state is unstable, the fluorophore will spontaneously return to its ground state 
by releasing a photon with less energy than the excitation photon (photoemission). The 
energy difference between the absorbed and the emitted photon is reflected as a red shift 
of the emitted light with respect to the absorbed light (STOKES shift). These processes are 
schematized as JABŁOŃSKI diagrams to illustrate the allowed electronic states of the fluo-
rophore and its energy transitions associated with photon absorption and emission 
(Jablonski, 1933). 
Theodor Förster first mathematically described a radiation-free energy transfer from an 
excited fluorophore, the fluorescence donor, to an adjacent fluorophore, the fluorescence 
acceptor (Förster, 1948) (Figure 1.5A, middle panel). As the energy transfer occurs by 
means of electromagnetic resonance of the interacting chromophores’ electronic dipoles, 
no photon is emitted during the process. The commonly used term “fluorescence resonan-
ce energy transfer” is therefore misleading, and FÖRSTER resonance energy transfer 
(FRET) should be used instead. Förster’s formula shows that the efficiency of resonance 
energy transfer (FRET efficiency) decays with the sixths power of the distance between 
the two fluorophores, leading to a steep decay of FRET efficiency around a so-called 
FÖRSTER radius, R0, where FRET efficiency equals 50% (Figure 1.5C). The FÖRSTER ra-
dius of a FRET pair depends on the overlap integral between the donor emission and the 
acceptor excitation spectra, the donor fluorescence lifetime, as well as the refractive index 
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FIGURE 1.5| Basic Concepts in Fluorescence Microscopy and FRET. A, JABLONSKI diagrams illustrating 
different modes of fluorescence. A fluorophore can assume different electronic energy states, illustrated as 
horizontal lines in the JABLONSKI diagram. Left panel: During normal fluorescence, a photon of appropriate 
energy (dark blue wavy arrow) is absorbed by a fluorophore, lifting it from the ground state S0 to its first 
excited state S1 (straight dark blue upward arrow). Some energy gets lost by vibrational relaxation (black 
wavy arrow) before a photon is emitted for final relaxation (straight light blue downward arrow). The emit-
ted photon has less energy than the absorbed photon (STOKES shift). Middle panel: During FÖRSTER reso-
nance energy transfer, an excited donor fluorophore (light blue diagram) may relax by passing its energy on 
to an adjacent acceptor fluorophore (yellow diagram) by means of radiationless electronic dipole coupling 
(FRET). The FRET acceptor fluorophore becomes excited by the energy transfer and relaxes through vibra-
tional relaxation and emission of a photon. Right panel: 2-photon excitation is the process of exciting a 
fluorophore by the almost concomitant absorption of two photons which together provide the energy for full 
excitation of the fluorophore. Relaxation occurs by normal vibrational relaxation and photoemission. B, 
Comparison of single-photon and two-photon excitation modes. A focused laser beam has the highest pho-
ton density for excitation (ex.) at its focal point, declining away from the focal point as the beam diameter 
increases. Emission (em.) is directly proportional to excitation photon intensity in single-photon excitation 
mode but in two-photon excitation mode it is evoked at the focal point only because of the quadratic rela-
tion between excitation and emission. (after Cahalan et al., 2002) C, Distance dependency of FRET. FRET 
efficiency drops with the sixths power of the distance (r) between the donor and acceptor fluorophores. The 
FÖRSTER radius of 5 nm defines the distance of half-maximal FRET efficiency between a hypothetical 
FRET pair. D, Mathematical description and pictorial illustrations of FRET parameters. The FRET transfer 
rate k T expressed by equation I depends on the donor fluorescence lifetime D, the FÖRSTER radius R 0, and 
the 6th power of the distance r between the two interacting fluorophores. Equation II describes dependence 
of R 0 on the orientation factor, refractive index of intervening medium, donor quantum yield, and the spec-
tral overlap between the two interacting fluorophores. Picture diagrams illustrate high (left diagram; white 
curved arrows represent FRET) vs. low FRET conditions (right diagram): short vs. long distance between 
fluorophores, parallel vs. perpendicular orientation, low vs. high intervening refractive indices, high vs. low 
donor quantum yields, and large vs. little spectral overlaps between donor emission and acceptor excitation.  
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of the surrounding medium (Figure 1.5D). For most biologically relevant fluorophore 
pairs, including fluorescent proteins and many synthetic dyes, with excitation and emissi-
on spectra in the visible range, FÖRSTER distances approximate 5 nm in aqueous solution. 
These FRET pairs are ideally suited for the design of chimeric sensors where fluorescent 
tags are attached to a protein of interest such that conformational changes of the protein of 
interest become amenable to measurements of FRET changes between the fluorescent 
tags (Campbell, 2009). 
1.6 Two-Photon Excitation Microscopy 
Based on Maria Göppert-Mayer’s theoretical concept of two-photon absorption 
(Göppert-Mayer, 1931), Winfried Denk and colleagues pioneered two-photon excitation 
laser scanning microscopy to observe biological samples (Denk et al., 1990). Two-photon 
absorption, in contrast to traditional fluorescence as described above, is a process where-
by the fluorophore becomes excited by the almost simultaneous absorption of two pho-
tons, which each provide half the required energy for its excitation (Figure 1.5A, right 
panel). Therefore, the two-photon excitation wavelength is approximately twice the con-
ventional (single-photon) excitation wavelength; for typical fluorophores that emit in the 
green and red spectral range, conventional fluorescence microscopy requires excitation in 
the blue and green spectral range, while two-photon excitation microscopy usually requi-
res excitation in the far-red or infrared spectral range. The incidence of two photons 
within a very brief amount of time (~10-16 s) to excite the fluorophore requires very high 
light intensities which can be achieved by pulsed lasers that release very short high-
energetic laser pulses (~100 femtoseconds long) at high frequencies (around 80 MHz). 
The probability of two photons impinging on a fluorophore molecule within the brief time 
span required for successful excitation is proportional to the squared light intensity (laser 
power per area, or the number of photons passing a unit area per unit of time). Because 
the power of a laser beam remains constant throughout its light path, the light intensity 
grows with decreasing cross-section, reaching its maximum at the focus of a focused laser 
beam. Sufficient laser intensity to excite a fluorophore by two-photon absorption is thus 
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only reached within a volume extending ~0.3 µm radially and ~0.9 µm axially around the 
focal spot of a microscope objective, practically eliminating out-of-focus excitation 
(Figure 1.5B). The red-shifted excitation laser wavelength also allows deeper tissue pe-
netration with less scattering compared to conventional (single-photon) fluorescence mic-
roscopy (So, 2001, Cahalan et al., 2002, Zipfel et al., 2003). 
1.7 Aim of This Work 
Previous work from our lab established that RA is critically involved in the biochemi-
cal signaling cascade underlying homeostatic synaptic plasticity, but the precise time 
course and location of intracellular RA signaling, as well as its relevance in vivo are far 
less understood. The objective of this work was to test transcription- or FRET-based bio-
reporter methods for their compatibility with (1) long-term expression, making them sui-
table for in vivo applications, and (2) spatiotemporally resolved RA detection, making 
them useful to determine subcellular compartments of RA synthesis during homeostatic 
synaptic plasticity. To this end we explored existing methods and developed novel appro-
aches which would allow us to address these important open questions in future experi-
ments.  
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2. MATERIALS AND METHODS 
2.1 Materials, Consumables and Reagents 
Hippocampal Rat Neuron Culture Consumables 
Reagent   Supplier Catalog # 
Neurobasal Medium (NB) Gibco 21103 
Neurobasal Medium, phenol red-free   Gibco 12348 
Fetal bovine serum, Optima (FCS) Atlanta Biological S12450 
B-27 media supplement (B-27) Invitrogen 17504044 
GlutaMAXTM (GlutaMAX) Gibco 35050 
Cytosine -D-arabinofuranoside hydrochloride (Ara-C) Sigma C6645 
Minimum Essential Medium + Earle’s Salts (MEM) Gibco 11090 
Hank’s Balanced Salt Solution (HBSS) Gibco 14170 
Poly-L lysine (PLL) Sigma P2636-500MG 
Trypsin   Sigma T1005 
HEPES   Gibco 15630-080 
24-well tissue culture dishes   Falcon 353047 
Cover glasses, 12 mm, thickness 0.09-0.12 mm (CS) Carolina 633009 
HEK and HEK 293T Cell Culture Consumables 
Reagent   Supplier Catalog # 
Dulbecco’s Modified Essential Medium (DMEM) Gibco 11965 
Fetal bovine serum, Optima (FCS) Atlanta Biological S12450 
Tissue culture dishes, 100 mm   Falcon 353003 
24-well tissue culture dishes   Sarstedt (TPP) 92424 
Microscope cover glasses No. 1, 13 mm (CS) Marienstedt GmbH 01 115 30 
Gelatin from porcine skin, type A (Gelatin) Sigma G1890-100G 
Trypsin/EDTA Solution (10x) (Trypsin) Millipore L2153 
Chemicals, Reagents and Drugs 
Reagent Chem. Formula Supplier Catalog # 
Agar   Sigma A1296-1KG 
Agarose C24H38O19 Lonza 50005 
Aldi-6   Mochli-Rosen Lab   
Ampicillin (anhydrous)   Sigma A9393-5G 
Boric acid H3BO3 Merck/Millipore 1001650500 
Calcium chloride (anhydrous) CaCl2 Merck/Millipore 1023782500 
CNQX C9H4N4O4 Tocris 0190 
4-Diethylaminobenzaldehyde (DEAB) (C2H5)2NC6H4CHO Sigma D86256 
DABCO C6H12N2 Sigma D27802-25G 
Dimethyl sulfoxide (DMSO) (CH3)2SO Sigma 276855-250ML 
Disodium hydrogen phosphate heptahydrate Na2HPO4*7 H2O Merck/Millipore 1065751000 
Disodium tetraborate decahydrate Na2B4O7*10 H2O Merck/Millipore 1063081000 
FK506   Tocris 3631 
FK1012   Graeff Lab   
TABLE 2.1| Materials, Consumables and Reagents. Tissue culture consumables categorized by cell type. 
Chemicals listed in alphabetical order. 
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Fluoromount G®   Southern Biotech 0100-01 
D(+)-Glucose-monohydrate C6H12O6*H2O Merck/Millipore 40740500 
Glycerol C3H8O3 Merck/Millipore 1040931000 
HEPES C8H18N2O4S Sigma H3375-1KG 
Hydrochloric acid, 37% (fuming) HCl Sigma H1758-500ML 
Kanamycin sulfate   Sigma B5264-250MG 
LB broth base powder   Invitrogen 12780-029 
Lipofectamine® 2000   Invitrogen 11668-019 
Magnesium sulfate heptahydrate MgSO4*7 H2O  Merck/Millipore 1058860500 
Mowiol 4-88   Fluka 81381 
Paraformaldehyde (PFA) (CH2O)n Merck/Millipore 1040051000 
Potassium chloride KCl Calbiochem 529552-250GM  
Potassium dihydrogen phosphate KH2PO4 Merck/Millipore 1048731000 
all-trans Retinoic acid C20H28O2 Sigma R2625 
Sodium bicarbonate NaHCO3 Merck/Millipore 1063920500 
Sodium chloride NaCl Merck/Millipore 1370175000 
Sodium dihydrogen phosphate monohydrate NaH2PO4*H2O Merck/Millipore 1063491000 
Sodium hydroxide (pellets) NaOH Sigma 795429-1KG-D 
Tetrodotoxin citrate (TTX)   Abcam ab120055 
Tris Base C4H11NO3 Pharma Biotech 17-1321-01 
TABLE 2.1| Materials, Consumables and Reagents (continued) 
Chemicals, Reagents and Drugs (continued) 
Reagent Chem. Formula Supplier Catalog # 
MATERIALS AND METHODS  21 
2.3 Drugs 
TABLE 2.4| Concentrations of Drugs Used in This Study 
Drugs Drug stocks Final concentrations 
Aldi-6 1 mM in DMSO 1 µM in cell culture media 
Ara-C 4 mM in H2O 4 µM in cell culture media 
CNQX 50 mM in DMSO 5 µM in cell culture media 
DEAB 10 mM in DMSO 10 µM in cell culture media 
FK506 50 mM in DMSO 5 µM in cell culture media 
FK1012 45 µM in ethanol 100 nM in cell culture media 
RA 10 mM in DMSO 1 µM in cell culture media 
TTX 1 mM in H2O 1 µM in cell culture media 
Ampicillin 100 mg/mL in H2O 100 µg/mL in LB broth or LB agar 
Kanamycin 50 mg/mL in H2O 50 µg/mL in LB broth or LB agar 
Solution Composition (all reagents dissolved in H2O unless otherwise specified) 
Borate buffer 50 mM H3BO3, 12.5 mM Na2B4O7*10 H2O 
PLL for coating 0.5 mg/mL PLL in borate buffer 
Gelatin for coating 0.5 g/L gelatin in H2O 
2x HEPES buffer 1.4 mM Na2HPO4*7 H2O, 140 mM NaCl, 50 mM HEPES, pH 7.05 
2.5 M calcium chloride 2.5 M CaCl2 
1 M calcium chloride 1 M CaCl2 
10x PBS 1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4*7 H2O, 28 mM KH2PO4 
1x PBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4*7 H2O, 2.8 mM KH2PO4 
0.5x PBS 68.5 mM NaCl, 1.35 mM KCl, 5 mM Na2HPO4*7 H2O, 1.4 mM KH2PO4 
2p-Imaging solution 100 mM NaCl, 2.5 mM KCl, 1.3 mM MgSO4*7 H2O, 1 mM NaH2PO4*H2O, 
26.2 mM NaHCO3, 110 mM glucose, 2.5 mM CaCl2 
PFA fixation medium 4% PFA (w/v) in PBS 
Mowiol mounting medium 6 g glycerol, 2.4 g Mowiol, 6 mL H2O, 12 mL Tris (200 mM, pH 8.5), 2.5% 
(w/v) DABCO 
2.2 Cell Culture Media and Solutions 
TABLE 2.2| Cell Culture Media Compositions 
Cell Culture Media   Media Compositions and Additives 
High Glucose MEM   200 mL MEM 
+ 51 g glucose 
Serum Neuron Media (SNM) 500 mL MEM 
+ 8 mL High Glucose MEM 
+ 5 mL GlutaMAXTM 
+ 27.5 mL FCS 
+ 1:40 B-27 
Neurobasal Growth Media (NGM) NB 
+ 1:50 B-27 
+ 1:400 GlutaMAXTM 
HEK Cell Media   DMEM 
+ 10% FCS 
TABLE 2.3| Compositions of Solutions Used in This Study 
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2.4 Methods 
2.4.1 Dissociated Rat Hippocampal Neuron Culture 
E22 rat embryos were collected by Caesarian section (after CO2 anaesthesia and cervi-
cal dislocation of the mother, in accordance with Stanford Administrative Panel on Labo-
ratory Animal Care) of timed-pregnant Sprague Dawley rats (Charles River Laboratories). 
Brains from embryos were collected in PETRI dishes containing pre-warmed and equi-
librated high glucose HBSS in which hippocampi were dissected out. Hippocampal neu-
rons were dissociated by trituration following trypsin digestion (19 min. at 37°C) and we-
re then plated on PLL-coated coverslips in 24-well plates at 1x 105 cells per well. Dissoci-
ated hippocampal cells were seeded in serum neuronal media (SNM), and at 1 day in vitro 
(DIV 1), 70% of SNM were replaced with neurobasal growth media (NGM). From DIV 7 
on, 50% media changes were performed at 7-day intervals with fresh NGM, and AraC 
was maintained at 4 µM final concentration to inhibit proliferation of glia and dentate gy-
rus granule cells. 
2.4.2 RARE-TK::EGFP Reporter Assay in Neurons 
Neurons grown on coverslips as described above were transfected between DIV 10 and 
13 with 0.8 µg of the RARE-TK::EGFP reporter plasmid per well using the lipofectami-
ne™ 2000 method. Before transfection, 510 µL of neuron culture media were removed 
and stored at 37°C. For transfection, 0.8 µg of DNA and 0.5 µL of lipofectamine per well 
were dissolved separately into 25 µL of OptiMEM media each and incubated at ambient 
temperature for 5 min. Contents of DNA- and lipofectamine-containing tubes were then 
combined and mixed well, incubated at room temperature for another 20 min. before 50 
µL of the mixture were added into the remaining 490 µL per well of the neuron culture. 
After an incubation period of 2 hours at 37°C and 5% CO2, transfection media were aspi-
rated and replaced with 500 µL of pre-conditioned media per well, supplemented with 
drugs as indicated. Neurons were incubated for 13 hours at 37°C and 5% CO2 to allow for 
EGFP expression from the reporter plasmid, and cells were then fixed with 4% PFA in 
PBS for 20 min. at ambient temperature. After three washes with PBS, coverslips were 
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mounted onto glass slides using a drop of Fluoromount G® mounting media, and stored at 
room temperature until imaging. For imaging, coverslips were screened using an upright 
confocal microscope BX61WI with a 60x oil immersion objective (Olympus PlanApo N 
60x/1.42 Oil). Cells exhibiting a clear nuclear green fluorescence at least as bright as cy-
tosolic fluorescence level were identified as transfected and EGFP-expressing neurons, 
and images thereof were acquired using the confocal mode. At least ten cells on at least 
two coverslips were imaged per treatment group for every experiment. For each image, a 
stack of at least 4 slices at 0.5 µm steps in the Z direction was acquired, and stacks were  
Z-projected by pixel-wise maximum intensity projection. Flattened images were analyzed 
using the MatLab software package. After thresholding to eliminate background fluores-
cence, the cell soma was outlined to measure average intensity. Fluorescence intensities 
of all imaged cells are expressed as fold-values of the average of the respective DMSO-
treated control group within the same experiment (normalized GFP fluorescence). 
2.4.3 UAS-E4TATA::EGFP-fLuc Reporter Assay in Neurons 
Neurons grown on coverslips as described above were cotransfected between DIV 7 
and 12 with 0.5 µg of the UAS-E4TATA::EGFP-fLuc reporter plasmid and 0.2-0.3 µg of 
the Gal4-RARx receptor plasmid per well using the lipofectamine™ 2000 method. Before 
transfection, 500 µL of neuron culture media were removed and stored at 37°C. For trans-
fection, mixed reporter and receptor DNAs and 0.5 µL of lipofectamine per well were dis-
solved separately into 25 µL of OptiMEM media each and incubated at ambient tempera-
ture for 5 min. Contents of DNA- and lipofectamine-containing tubes were then combined 
and mixed well, incubated at room temperature for another 20 min. before 50 µL of the 
mix were added into the remaining 500 µL per well of the neuron culture. After an incu-
bation period of 2 hours at 37°C and 5% CO2, transfection media were aspirated and 
replaced with 495 µL of pre-conditioned media per well. 2-6 days post-transfection, drugs 
as indicated were diluted in fresh NGM at 2x final concentration and 500 µL of drug-
containing NGM were added to the wells. After incubation of cells with drugs for 24h at 
37°C and 5% CO2 coverslips were fixed, mounted and imaged as described above (see 
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RARE-TK::EGFP reporter assay in neurons). 
2.4.4 aGEPRA G Imaging in Living Neurons 
For live cell imaging, dissociated neurons were plated on nunc™ 8-chambered cover 
glasses at a density of 2.8 x 104 cells per well. Cells were maintained as described under 
“Dissociated Rat Hippocampal Neuron Culture” except that phenol red-free NGM was 
used. Between DIV 10 and DIV 14, cells were transfected with aGEPRA G expression 
vector using per well of a chambered cover glass 0.175 µL of Lipofectamine 2000 and 
0.175 µg of plasmid in 4.5 µL OptiMEM each. 9 µL of transfection mixture were added 
to 180 µL of NGM per well. Lipofectamine-containing media were aspirated after 2-3 
hours and replaced with 360 µL pre-conditioned and fresh NGM at a 1:1 ratio. 2 days 
post-transfection, wells were supplied with 360 µL equilibrated, fresh NGM and imaged 
on an inverted Zeiss LSM 710 confocal microscope equipped with an oil-immersion ob-
jective (Carl Zeiss Plan-Apochromat 63x/1.40 Oil DIC) and an environmental control 
chamber. During image acquisition, temperature was maintained at 37°C and CO2 was 
5%. aGEPRA-expressing cells were thoroughly examined for healthy dendritic morpholo-
gy and absence of fluorescent aggregates before selection for long-term imaging. For each 
cell, ten baseline images were recorded at 1 minute intervals, followed by drug applicati-
on (TTX+CNQX or DMSO) and recording of 24 images at 5 minute intervals to yield 
120 minutes total imaging time in the presence of the drug. Last, 1 µM RA was applied 
and another ten images were recorded at 1 minute intervals. For drug application, envi-
ronmental control chamber was opened to access the nunc 8-well chamber, and 40 µL of 
phenol red-free NGM with indicated drugs at 10x dilution were added to the appropriate 
well to yield 400 µL of NGM containing a final 1x drug concentration. Final concentrati-
ons of drugs were CNQX, 10 µM (prepared as a 50 mM 5000x stock in DMSO); TTX, 1 
µM (prepared as a 1 mM 1000x stock); DMSO 1:1000. At each time point, images were 
acquired in three channels; with 458 nm laser excitation we simultaneously recorded the 
CFP emission (475 nm - 500 nm emission window) and the FRET channel (516 nm - 590 
nm), followed by the YFP emission channel (516 nm - 590 nm emission window) under 
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514 nm laser excitation. The confocal pinhole was completely open to maximize signal 
intensity, and Z-stacks with 1 - 2 µm step size were obtained for cells thicker than 3 µm. 
Image analysis was done using the imageJ-based Fiji application. Images were converted 
to 32-bit and smoothened using the Fiji smoothen function. Z-stacks were Z-projected for 
each channel by pixel-wise maximum intensity projection. The FRET channel was then 
thresholded using the thresholding tool by applying the “Triangle” method. Where neces-
sary, the automatic threshold was manually adjusted to reduce background noise. Sub-
threshold pixel values were set to NaN (“not a number”) to be excluded from further ana-
lysis. Ratiometric CFP/YFP images were calculated as CFP emission channel pixel value 
over thresholded FRET channel pixel value using the Ratio Plus ImageJ plugin without 
further thresholds or multiplication factors. For measurements of individual channel in-
tensities (Figure 3.8), the CFP emission channel was separately thresholded using the 
“Triangle” thresholding method. The soma of the neuron was outlined in the ratiometric 
image as well as the thresholded CFP and FRET channels and the average pixel intensity 
was measured for each image of CFP emission, FRET emission, and CFPem/YFPem ratio 
channels for the entire time stack . Because ratiometric images exhibited some variability 
even within the same cell (see Figure 5D), each value (CFP, FRET, ratio) was separately 
normalized to its corresponding average baseline intensity value (average of the first 10 
images). The resulting normalized time-lapse traces for all recordings are shown in Figu-
res 3.6 and 3.7. 
2.4.5 HEK 293T Cell Culture and UAS-E4TATA::EGFP-fLuc Reporter Assay 
in HEK 293T Cells 
HEK or HEK 293T cells were maintained in DMEM + 10% FCS without antibiotics in 
tissue culture plastic dishes. At 3-4 day intervals, cells were detached from the growth 
surface and dissociated using a brief trypsin treatment. Cell suspensions were split at a 
1:10 to 1:15 ratio and reseeded into fresh tissue culture plastic dishes. For the UAS-
E4TATA::EGFP-fLuc reporter assay, HEK 293T cells were seeded on gelatin-coated glass 
coverslips in a 24-well plate at a density of 75,000 cells per well. Cotransfection of repor-
ter and receptor DNAs (1.5 µg per well of UAS-E4TATA::EGFP-fLuc reporter plasmid and 
MATERIALS AND METHODS  26 
either 100 ng of Gal4-RARx-VP16 receptor plasmid per well or 200 ng of Gal4-RARx 
receptor plasmid per well) was performed the evening after plating using the calcium 
phosphate method. Plasmid DNA was mixed with 2.5 µL of a 2.5 M CaCl2 solution and 
the volume was adjusted to 25 µL with H2O. DNA-calcium solution was then added drop-
wise into 25 µL of 2x HEPES buffer and the mix was set at room temperature for 20 min. 
to allow formation of microcrystals. Total 50 µL of the resulting solution was then added 
drop-wise to the cells plated the day before. After overnight incubation at 37°C and 5% 
CO2, transfection media was aspirated and replaced with fresh HEK cell media. 24h after 
transfection, cell culture media was replaced and cells were incubated for 24h in the dark 
with either 250 nM RA or 1:40,000 DMSO as vehicle control. Coverslips were then fixed 
using 4% PFA in PBS for 20 min. at room temperature and mounted using Mowiol moun-
ting media. Coverslips were imaged using an upright epifluorescence microscope (Leica 
DMRB) equipped with a 40x objective lens. For quantification of GFP fluorescence in-
tensity, color images were background thresholded using the Fiji “Color Threshold” ad-
justment tool with a lower brightness threshold between 7 and 15, using the same value 
for all images throughout the same experiment. The thresholded areas were loaded into 
the Fiji Particle Analyzer with a minimum particle size cutoff of 300 px to exclude 
speckles and noise. The remaining particles were outlined and overlayed over the original 
image as selection for quantification of GFP brightness by the “Average Intensity” mea-
surement from the Fiji “Measure” tool. 
2.4.6 Two-Photon Microscopy for Ratiometric FRET Measurements in HEK 
293T Cells 
HEK 293T cells for 2-photon microscopy were seeded on gelatin-coated coverslips in 
24-well cell culture dishes at a density of 75,000 cells per well. The day after plating, 
cells were transfected with 1 µg of expression plasmid per well using the calcium phos-
phate method as described above. In separate wells we expressed either fluorophore indi-
vidually (i.e. CFP4, YPet, Clover, mRuby2), or the FRET constructs (i.e. aGEPRA G, 
Clover-mRuby2 fusion). 
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Coverslips were submerged in 2 mL 2p-imaging buffer and placed on a custom-built 
two-photon microscope (based on an upright Olympus BX-61W microscope) equipped 
with a 40x water-dipping objective (Olympus LUMPlanFl W/IR-2, NA 0.8). A Mai Tai 
HP Deep See Ti:sapphire laser (Spectra Physics, Inc.), tunable from 690 to 1040 nm, was 
used at 15 mW laser output power for 2-photon excitation. All 2-photon microscopy re-
cordings were done at ambient temperature. 2-photon laser excitation spectra for Clover, 
mRuby2, and the Clover-mRuby2 fusion FRET construct were recorded between 740 nm 
and 1040 nm at 5 nm steps with emission filter sets 525/70 (Clover) and 607/45 
(mRuby2), separated by a 575 dichroic. 2-photon laser excitation spectra for CFP4, YPet, 
and the aGEPRA G FRET construct were recorded between 690 nm and 1040 nm at 5 nm 
steps with emission filter sets 480/40 (CFP4) and 535/50 (YPet), separated by a 505 di-
chroic. After a spectrum of aGEPRA G-expressing cells was obtained, 200 µL of 2p-
imaging buffer supplemented with 10 µM RA was added to the cells by pipetting, yield-
ing a final RA concentration of 1 µM. 5 min. after addition of RA, the second spectrum 
was obtained from the same cells. 
Images were analyzed using Fiji image analysis software. Brightness was measured at 
cytosolic regions of interest in cells exhibiting intermediate levels of fluorescence. Inten-
sity values were normalized to peak fluorescence and plotted against 2-photon laser exci-
tation wavelength as described in the results section, where the method for quantification 
of FRET is also derived and explained (“3.5 Ratiometric FRET Measurements by Two-
Photon Microscopy”). 
2.4.7 Spectrophotometry of FRET Constructs in HEK Cell Lysates 
To obtain cell lysates containing the FRET-based RA reporter proteins, we seeded 2x 
106 HEK cells on a 100 mm tissue culture plate. The next morning, HEK cells were trans-
fected with 12 µg of reporter plasmid DNA using the calcium phosphate method. Plasmid 
DNA was mixed with 25 µL of a 2.5 M CaCl2 solution and the volume was adjusted to 
250 µL with H2O. DNA-calcium solution was then added drop-wise into 250 µL of 2x 
HEPES buffer and the mix was set at room temperature for 20 min. to allow formation of 
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microcrystals. Total 500 µL of the resulting solution was then added drop-wise to the 
HEK cells plated the day before. After 6-8 h incubation at 37°C and 5% CO2, transfection 
media was aspirated and replaced with fresh HEK cell media. Cells were allowed to ex-
press the FRET constructs for 48 h, after which cells were dissociated by trypsin treat-
ment and harvested by centrifugation (250x g, 5 min.). Cells were washed once by re-
suspending in 0.5x PBS and centrifugation, and the resulting cell pellets were then re-
suspended in 450 µL H2O per pellet, snap-frozen in liquid nitrogen and stored at -80°C 
until further use. After thawing on ice, 50 µL of 10x PBS were added to adjust salt con-
centration of the lysates to 1x PBS; lysates were then cleared by centrifugation in a table-
top centrifuge (13,200 x g for 10 min.) to eliminate cell nuclei and debris. 
150 µL of cleared lysate were filled into a quartz cuvette with a path length of 1 cm 
and the fluorescence emission spectrum was obtained between 430 nm and 630 nm at  
1 nm steps (5 nm slit width) under 434 nm excitation using a spectrophotometer (Horiba 
Jovin Yvon Fluoromax-4). Next, 15 µL of the same lysate were supplemented with  
10 µM RA and added into the cuvette and mixed by pipetting to yield a final RA con-
centration of 1 µM. A second spectrum in the presence of 1 µM RA was then recorded as 
above. The two spectra without and with 1 µM RA were normalized to peak CFP emissi-
on at 477 nm and overlayed to visualize FRET changes induced by RA. 
2.4.8 Construction of Gal4-RARx-VP16 Chimeric Receptors and UAS-
E4TATA::fLuc-EGFP Reporter 
To construct the Gal4-RARx-VP16 chimeric receptors, the Gal4 DBD and a tandem 
repeat of 2x VP16 transactivator domain were separately synthesized as double-stranded 
linear DNA elements (gBlocks, Integrated DNA Technologies). The 2x VP16 gBlock was 
designed to contain a multiple cloning site preceding the coding sequence of the VP16 
tandem repeat to facilitate future use of the construct. The Gal4-DBD gBlock was cloned 
into the pEGFP-N1 plasmid using the NheI and NotI restriction sites, replacing the EGFP 
as well as the vector’s multiple cloning site. Five colonies were selected for DNA sequen-
cing, none of which contained an insert completely matching the designed Gal4-DBD se-
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quence. The colony containing the K43R mutation was identified as the most conservati-
ve (or structurally least disruptive) amino acid exchange and was hence selected for 
further experiments. Subsequently, the 2x VP16 tandem repeat insert was intdroduced 
into the Gal4-DBD plasmid using the EcoRI and NotI restriction enzymes. This afforded 
the Gal4-2x VP16 chimeric transcriptional activator plasmid with a multiple cloning site 
which served as a platform for making the Gal4-RARx-VP16 chimeric receptor 
constructs. RAR sequences were PCR-amplified from plasmids containing the full-length 
rat RAR, mouse RAR, or rat RAR and were then introduced into Gal4-2x VP16 plas-
mid. For the rat RAR and RAR LBD sequences, EcoRI and BamHI restriction enzyme 
sites were used, and for the mouse RAR LBD, AgeI and BamHI restriction enzyme sites 
were used. Gal4-RARx chimeric receptor constructs were derived from the respective 
Gal4-RARx-VP16 plasmids by excising the 2x VP16 tandem repeat using BamHI and 
BglII restriction enzymes and religating the two compatible ends. 
To build the UAS-E4TATA::fLuc-EGFP reporter plasmid, we first PCR-amplified the 
UAS-E4TATA regulatory sequence from the UAS5-E4TATA::fluc plasmid (Paulmurugan et 
al., 2009) (a kind gift from the Paulmurugan lab) and subcloned it into the pEYFP plas-
mid using the AseI and AgeI restriction enzyme sites. A sequence encoding for a fLuc-
EGFP fusion protein PCR-amplified from the pFluc(G4S)3-GFP plasmid (kind gift from 
the Paulmurugan lab) was introduced into the resulting plasmid using the AgeI and NotI 
restriction enzyme sites, thereby replacing the YFP. This finally yielded the complete 
UAS-E4TATA::fLuc-EGFP reporter plasmid used for cotransfection with the Gal4-RAR 
chimeric receptors. 
2.4.9 Construction of Modular FRET Sensors for RA 
Modular FRET sensors (Figure 3.4) were constructed in the pmCFP-N1 vector. mYFP 
and RAR LBD were PCR-amplified and sequentially introduced into the pmCFP-N1 
vector using NheI and XhoI for mYFP, and XhoI and BamHI restriction enzyme sites for 
the RAR LBD. mCFP was subsequently PCR-amplified with a forward primer contai-
ning a BamHI restriction enzyme site and then seamlessly ligated into the previously ob-
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tained plasmid to eliminate the remaining sites from the endogenous multiple cloning site. 
NR boxes with long and short linkers as well as AxxAA binding-incompetent NR box 
mutants were synthesized as a gBlock (Integrated DNA Technolgies) and introduced 
using XhoI and BglII restriction enzyme sites. This afforded plasmids containing modular 
FRET sensors for RA with domains separated by restriction enzyme sites and the general 
domain structure (NheI)-mYFP-(XhoI)-NR box-(BglII)-RAR LBD-(BamHI)-mCFP-
(NotI). The I393Q mutation was introduced by mutagenesis PCR using complementary 
mutagenic primers spanning the desired mutation on a plasmid containing the wild-type 
RAR LBD sequence. The resulting PCR product was then digested with methylation-
sensitive restriction enzyme DpnI which only destroys the methylated wild-type PCR 
template, leaving the non-methylated PCR product intact. This PCR product was then 
transformed into bacteria (XL10-Gold chemically competent Escherichia coli, strain  
DH5, Agilent Technologies # 200315). Plasmid DNA was prepared from 3-5 mL of 
bacterial overnight culture using Genejet Plasmid Miniprep Kit (ThermoFisher # K0503) 
and correct sequences were confirmed by DNA sequencing (ElimBio). 
2.4.10 Polymerase Chain Reaction (PCR) 
PCR is the method of choice to selectively and efficiently generate large amounts of 
target DNA by enzymatic amplification of a given DNA template. Short oligonucleotide 
primers (typically 18-30 nucleotides long) flanking the DNA region to be amplified are 
designed such that primer extension in the 3’ direction by the action of a DNA polymera-
se yields DNA fragments identical to the template. The sequence-specific incorporation 
of dNTPs into the growing strand follows the rule of complementary base pairing, ensu-
ring specificity and accuracy of the reaction. Repeated cycles (usually 35 cycles) of hea-
ting and cooling provide optimal reaction conditions for sequential DNA double strand 
break-up (“melting” at 98°C), primer binding (“annealing” at a primer-specific Tm, usu-
ally between 58°C and 67°C) and primer extension by a heat-stable DNA polymerase 
(“extension” at 68°C). The amount of PCR product grows exponentially with increasing 
cycle number because all DNA strands, including those synthesized during the reaction 
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itself, may serve as templates for subsequent rounds of amplification. 
PCR reaction mixtures were set up at 50 µL total volume per reaction. Primers were 
ordered from ElimBio and dissolved at a concentration of 100 µM. Final primer con-
centration in the PCR reaction mix was 0.5 µM. Primer Tm was calculated with the Tm 
calculator tool on the ThermoFisher Scientific website, and for any reaction the lowest 
calculated Tm of the primers used in the reaction was applied. Primer extension time per 
PCR cycle was calculated as 30 s/kbp of PCR product length. 
MATERIALS AND METHODS  32 
C
h
en
 L
ab
 
p
ri
m
er
 #
 
S
eq
u
en
ce
 
(c
ap
it
al
 l
et
te
rs
 a
re
 c
o
m
p
le
m
en
ta
ry
 t
o
 t
ar
g
et
) 
R
es
tr
ic
ti
o
n
 
en
zy
m
e 
si
te
s 
D
es
cr
ip
ti
on
 
1
4
1
6
 
g
a
g
g
g
c
t
c
t
c
t
c
c
t
a
c
t
c
a
a
g
c
t
t
c
t
t
c
g
t
g
c
t
t
c
t
g
g
a
 
t
c
c
G
T
G
A
G
C
A
A
G
G
G
C
G
A
G
G
A
G
C
T
G
 
B
a
m
H
I 
fo
rw
ar
d
 p
ri
m
er
 t
o
 a
m
p
li
fy
 X
F
P
; 
u
se
d
 t
o
 i
n
tr
o
d
u
ce
 C
-t
er
m
in
al
 C
F
P
 i
n
to
 
F
R
E
T
 c
o
n
st
ru
ct
 
1
4
1
7
 
T
C
G
C
G
G
C
C
G
C
T
T
T
A
C
T
T
G
T
A
C
 
N
o
tI
 
re
v
er
se
 p
ri
m
er
 t
o
 a
m
p
li
fy
 X
F
P
; 
u
se
d
 t
o
 i
n
tr
o
d
u
ce
 C
-t
er
m
in
al
 C
F
P
 i
n
to
 
F
R
E
T
 c
o
n
st
ru
ct
 
1
5
3
9
 
c
a
t
t
a
c
g
c
t
a
g
c
A
T
G
G
T
G
A
G
C
A
A
G
G
G
C
G
A
G
G
A
G
 
N
h
eI
 
fo
rw
ar
d
 p
ri
m
er
 t
o
 a
m
p
li
fy
 X
F
P
; 
u
se
d
 t
o
 i
n
cl
u
d
e 
N
-t
er
m
in
al
 Y
F
P
 i
n
to
 F
R
E
T
 
co
n
st
ru
ct
 
1
5
4
0
 
c
a
t
t
a
c
c
t
c
g
a
g
g
c
G
T
A
C
A
G
C
T
C
G
T
C
C
A
T
G
C
C
G
A
G
 
X
h
o
I 
re
v
er
se
 p
ri
m
er
 t
o
 a
m
p
li
fy
 X
F
P
; 
u
se
d
 t
o
 i
n
cl
u
d
e 
N
-t
er
m
in
al
 Y
F
P
 i
n
to
 F
R
E
T
 
co
n
st
ru
ct
 
1
5
4
5
 
a
t
g
g
a
t
c
c
t
g
t
c
c
g
g
A
C
T
T
G
T
A
C
A
G
C
T
C
G
T
C
C
A
T
G
C
C
G
 
B
a
m
H
I,
 B
sp
E
I 
re
v
er
se
 p
ri
m
er
 t
o
 a
m
p
li
fy
 X
F
P
; 
u
se
d
 t
o
 i
n
cl
u
d
e 
N
-t
er
m
in
al
 X
F
P
 i
n
to
 t
an
-
d
em
 C
F
P
-Y
F
P
 o
r 
Y
F
P
-C
F
P
 F
R
E
T
 a
s 
F
R
E
T
 p
o
si
ti
v
e 
co
n
tr
o
ls
; 
ca
n
 b
e 
u
se
d
 
in
 c
o
m
b
in
at
io
n
 w
it
h
 1
4
1
1
 o
r 
1
5
3
9
 
1
5
5
6
 
c
a
c
t
c
g
a
g
A
G
C
a
g
a
t
c
t
G
A
G
C
T
A
C
A
C
G
C
T
G
A
C
A
C
C
 
X
h
o
I,
 B
g
lI
I 
F
o
rw
ar
d
 p
ri
m
er
 t
o
 i
n
tr
o
d
u
ce
 R
A
R

 L
B
D
 i
n
to
 f
li
p
p
ed
 F
R
E
T
 c
o
n
st
ru
ct
s,
 C
-
te
rm
in
al
 t
o
 N
R
 b
o
x
 
1
5
5
7
 
a
c
g
g
a
t
c
c
G
T
C
C
A
A
G
C
C
C
T
C
A
G
A
G
T
T
C
 
B
a
m
H
I 
R
ev
er
se
 p
ri
m
er
 t
o
 i
n
tr
o
d
u
ce
 R
A
R

 L
B
D
 i
n
to
 f
li
p
p
ed
 F
R
E
T
 c
o
n
st
ru
ct
s,
 C
-
te
rm
in
al
 t
o
 N
R
 b
o
x
 
1
5
5
8
 
a
c
g
g
a
t
c
c
A
G
A
T
T
G
A
G
T
G
G
C
T
G
G
G
C
 
B
a
m
H
I 
R
ev
er
se
 p
ri
m
er
 t
o
 i
n
tr
o
d
u
ce
 R
A
R

 L
B
D
-F
 i
n
to
 F
R
E
T
 c
o
n
st
ru
ct
s,
 C
-
te
rm
in
al
 t
o
 N
R
 b
o
x
 
1
5
6
8
 
C
T
C
A
C
A
T
G
T
T
T
C
C
A
A
A
G
A
T
C
c
T
A
A
T
G
A
A
A
A
T
C
A
C
t
G
A
T
C
 
T
C
C
G
C
A
G
C
A
T
C
 
 
to
 r
em
o
v
e 
n
at
u
ra
ll
y 
o
cc
u
rr
in
g
 B
g
lI
I 
si
te
s 
w
it
h
in
 t
h
e 
m
o
u
se
 R
A
R

 L
B
D
 
1
5
6
9
 
G
A
T
G
C
T
G
C
G
G
A
G
A
T
C
a
G
T
G
A
T
T
T
T
C
A
T
T
A
g
G
A
T
C
T
T
T
G
G
 
A
A
A
C
A
T
G
T
G
A
G
 
 
to
 r
em
o
v
e 
n
at
u
ra
ll
y 
o
cc
u
rr
in
g
 B
g
lI
I 
si
te
s 
w
it
h
in
 t
h
e 
m
o
u
se
 R
A
R

 L
B
D
 
1
5
7
0
 
G
C
T
G
A
A
C
G
G
G
T
G
c
a
g
A
C
A
T
T
G
A
A
G
A
T
G
G
A
G
A
T
C
 
 
fo
rw
ar
d
 p
ri
m
er
 t
o
 i
n
tr
o
d
u
ce
 I
3
9
3
Q
 p
o
in
t 
m
u
ta
ti
on
 i
n
to
 r
at
 R
A
R

 L
B
D
 
1
5
7
1
 
C
C
A
T
C
T
T
C
A
A
T
G
T
c
t
g
C
A
C
C
C
G
T
T
C
A
G
C
T
T
C
C
C
 
 
re
v
er
se
 p
ri
m
er
 t
o
 i
n
tr
o
d
u
ce
 I
3
9
3
Q
 p
o
in
t 
m
u
ta
ti
o
n
 i
n
to
 r
at
 R
A
R

 L
B
D
 
1
5
7
5
 
G
C
G
C
A
C
C
G
G
T
G
G
A
T
C
C
C
A
T
G
G
T
G
A
G
C
 
A
g
eI
, 
B
a
m
H
I 
U
se
d
 t
o
 a
m
p
li
fy
 G
E
P
R
A
 c
o
n
st
ru
ct
s 
to
 c
lo
n
e 
in
to
 p
E
X
F
P
-N
1
 v
ec
to
rs
 
1
5
7
6
 
A
G
T
C
G
C
G
G
C
C
G
C
T
C
G
A
G
T
T
A
C
T
T
G
T
A
C
A
G
C
T
C
G
T
T
C
A
T
G
 
N
o
tI
, 
X
h
o
I 
U
se
d
 t
o
 a
m
p
li
fy
 G
E
P
R
A
 B
 c
o
n
st
ru
ct
 t
o
 c
lo
n
e 
in
to
 p
E
X
F
P
-N
1
 v
ec
to
rs
 
1
5
8
4
 
c
c
a
t
g
a
g
c
t
c
T
T
C
A
T
G
T
C
C
T
T
C
A
G
A
A
T
T
C
T
C
C
 
S
a
cI
 
U
se
d
 t
o
 a
m
p
li
fy
 m
o
u
se
 R
A
R

 L
B
D
 f
ro
m
 G
E
P
R
A
 G
 a
n
d
 A
A
 c
o
n
st
ru
ct
s 
1
5
8
5
 
c
g
c
c
c
g
c
a
t
g
c
a
t
G
A
G
A
G
C
T
A
T
G
A
G
A
T
G
A
C
A
G
C
 
S
p
h
I 
U
se
d
 t
o
 a
m
p
li
fy
 m
o
u
se
 R
A
R

 L
B
D
 f
ro
m
 G
E
P
R
A
 G
 a
n
d
 A
A
 c
o
n
st
ru
ct
s 
1
6
2
1
 
A
G
T
T
A
T
T
A
A
T
C
C
C
G
A
G
C
T
C
A
T
T
T
A
G
G
T
G
A
C
A
C
T
A
T
A
G
 
A
se
I,
 S
a
cI
 
T
o
 a
m
p
li
fy
 U
A
S
5
-E
4
T
A
T
A
 p
ro
m
o
te
r/
en
h
an
ce
r 
re
g
io
n
 f
ro
m
 U
A
S
-E
4
-f
lu
c 
v
ec
to
r 
fo
r 
cl
o
n
in
g
 i
n
to
 E
X
F
P
-N
1
 
TABLE 2.5| PCR Primers Used in This Study 
MATERIALS AND METHODS  33 
C
h
en
 L
ab
 
p
ri
m
er
 #
 
S
eq
u
en
ce
 
(c
ap
it
al
 l
et
te
rs
 a
re
 c
o
m
p
le
m
en
ta
ry
 t
o
 t
ar
g
et
) 
R
es
tr
ic
ti
o
n
 
en
zy
m
e 
si
te
s 
D
es
cr
ip
ti
on
 
1
6
2
2
 
G
G
C
G
A
C
C
G
G
T
C
C
C
C
T
C
G
A
G
A
C
A
C
C
A
C
T
C
G
A
C
A
C
G
G
C
A
C
C
 
A
g
eI
, 
X
h
o
I 
T
o
 a
m
p
li
fy
 U
A
S
5
-E
4
T
A
T
A
 p
ro
m
o
te
r/
en
h
an
ce
r 
re
g
io
n
 f
ro
m
 U
A
S
-E
4
-f
lu
c 
v
ec
to
r 
fo
r 
cl
o
n
in
g
 i
n
to
 E
X
F
P
-N
1
 
1
6
2
3
 
g
c
c
g
g
a
a
t
t
c
G
G
G
G
A
A
C
T
C
A
T
C
G
A
G
A
A
G
G
 
E
co
R
I 
T
o
 a
m
p
li
fy
 R
A
R

 L
B
D
 f
ro
m
 c
lo
n
e 
#
2
7
5
 f
o
r 
cl
on
in
g
 i
n
to
 G
al
4
-M
C
S
-V
P
1
6
 
(c
lo
n
e 
#
6
9
9
) 
1
6
2
4
 
g
g
g
c
g
g
a
t
c
c
G
C
C
C
T
C
A
G
A
G
T
T
C
T
C
C
A
A
C
 
B
a
m
H
I 
T
o
 a
m
p
li
fy
 R
A
R

 L
B
D
 f
ro
m
 c
lo
n
e 
#
2
7
5
 f
o
r 
cl
on
in
g
 i
n
to
 G
al
4
-M
C
S
-V
P
1
6
 
(c
lo
n
e 
#
6
9
9
) 
1
6
2
5
 
g
g
g
c
g
g
a
t
c
c
T
G
G
G
G
A
T
T
G
A
G
T
G
G
C
T
G
 
B
a
m
H
I 
T
o
 a
m
p
li
fy
 R
A
R

 L
B
D
+
F
 f
ro
m
 c
lo
n
e 
#
2
7
5
 f
o
r 
cl
o
n
in
g
 i
n
to
 G
al
4
-M
C
S
-
V
P
1
6
 (
cl
o
n
e 
#
6
9
9
) 
1
6
2
6
 
g
g
g
t
a
c
c
g
g
t
G
A
C
G
A
C
C
T
C
A
C
T
G
A
G
A
A
G
A
T
C
C
 
A
g
eI
 
T
o
 a
m
p
li
fy
 R
A
R

 L
B
D
 f
ro
m
 c
lo
n
e 
#
2
7
6
a 
fo
r 
cl
on
in
g
 i
n
to
 G
al
4
-M
C
S
-
V
P
1
6
 (
cl
o
n
e 
#
6
9
9
) 
1
6
2
7
 
g
g
g
c
g
g
a
t
c
c
T
C
C
T
T
C
A
G
A
A
T
T
C
T
C
C
A
G
C
A
T
T
 
B
a
m
H
I 
T
o
 a
m
p
li
fy
 R
A
R

 L
B
D
 f
ro
m
 c
lo
n
e 
#
2
7
6
a 
fo
r 
cl
on
in
g
 i
n
to
 G
al
4
-M
C
S
-
V
P
1
6
 (
cl
o
n
e 
#
6
9
9
) 
1
6
2
8
 
g
g
g
c
g
g
a
t
c
c
C
T
G
C
A
G
C
A
G
T
G
G
T
G
A
C
T
G
A
 
B
a
m
H
I 
T
o
 a
m
p
li
fy
 R
A
R

 L
B
D
+
F
 f
ro
m
 c
lo
n
e 
#
2
7
6
a 
fo
r 
cl
o
n
in
g
 i
n
to
 G
al
4
-M
C
S
-
V
P
1
6
 (
cl
o
n
e 
#
6
9
9
) 
1
6
2
9
 
g
c
c
g
g
a
a
t
t
c
G
A
G
G
A
G
C
T
C
A
T
C
A
C
C
A
A
G
G
T
C
 
E
co
R
I 
T
o
 a
m
p
li
fy
 R
A
R
 
L
B
D
 f
ro
m
 c
lo
n
e 
#
2
7
7
 f
o
r 
cl
o
n
in
g
 i
n
to
 G
al
4
-M
C
S
-V
P
1
6
 
(c
lo
n
e 
#
6
9
9
) 
1
6
3
0
 
g
g
g
c
g
g
a
t
c
c
C
A
T
C
T
C
A
G
G
G
T
T
C
T
C
C
A
G
C
A
T
C
 
B
a
m
H
I 
T
o
 a
m
p
li
fy
 R
A
R
 
L
B
D
 f
ro
m
 c
lo
n
e 
#
2
7
7
 f
o
r 
cl
o
n
in
g
 i
n
to
 G
al
4
-M
C
S
-V
P
1
6
 
(c
lo
n
e 
#
6
9
9
) 
1
6
3
1
 
g
g
g
c
g
g
a
t
c
c
G
G
G
G
C
C
C
T
G
G
T
C
A
G
G
 
B
a
m
H
I 
T
o
 a
m
p
li
fy
 R
A
R
 
L
B
D
+
F
 f
ro
m
 c
lo
n
e 
#
2
7
7
 f
o
r 
cl
o
n
in
g
 i
n
to
 G
al
4
-M
C
S
-
V
P
1
6
 (
cl
o
n
e 
#
6
9
9
) 
1
6
3
2
 
a
t
c
c
g
c
t
a
g
c
g
a
c
a
a
g
c
t
t
A
T
G
A
A
G
C
T
A
C
T
G
T
C
T
T
C
T
A
 
T
C
G
A
A
C
 
N
h
eI
, 
H
in
d
II
I 
T
o
 c
lo
n
e 
an
y 
G
al
4
-L
B
D
-V
P
1
6
 c
o
n
st
ru
ct
 i
n
to
 E
X
F
P
-N
1
 v
ec
to
r,
 r
ep
la
ci
n
g
 
E
G
F
P
 a
n
d
 m
u
lt
ip
le
 c
lo
n
in
g
 s
it
e 
1
6
3
3
 
a
g
t
c
g
c
g
g
c
c
g
c
T
T
A
A
A
C
G
G
G
C
C
C
T
C
T
A
G
A
T
C
T
A
G
A
G
 
N
o
tI
 
T
o
 c
lo
n
e 
an
y 
G
al
4
-L
B
D
-V
P
1
6
 c
o
n
st
ru
ct
 i
n
to
 E
X
F
P
-N
1
 v
ec
to
r,
 r
ep
la
ci
n
g
 
E
G
F
P
 a
n
d
 m
u
lt
ip
le
 c
lo
n
in
g
 s
it
e 
1
6
3
4
 
a
t
c
c
a
c
c
g
g
t
c
g
c
c
a
c
c
A
T
G
G
A
A
G
A
C
G
C
C
A
A
A
A
A
C
A
T
A
 
A
A
G
 
A
g
eI
 
T
o
 c
lo
n
e 
fL
u
c-
E
G
F
P
 f
ro
m
 P
au
lm
u
ru
g
an
’s
 v
ec
to
r 
in
to
 E
X
F
P
-N
1
, 
p
re
se
r-
v
in
g
 m
u
lt
ip
le
 c
lo
n
in
g
 s
it
e 
1
6
3
5
 
a
g
t
c
c
g
c
c
g
g
c
g
t
T
T
A
C
T
T
G
T
A
C
A
G
C
T
C
G
T
C
C
A
T
G
C
 
N
o
tI
 
T
o
 c
lo
n
e 
fL
u
c-
E
G
F
P
 f
ro
m
 P
au
lm
u
ru
g
an
’s
 v
ec
to
r 
in
to
 E
X
F
P
-N
1
, 
p
re
se
r-
v
in
g
 m
u
lt
ip
le
 c
lo
n
in
g
 s
it
e 
TABLE 2.5| PCR Primers Used in This Study (continued) 
MATERIALS AND METHODS  34 
C
h
en
 L
ab
 
p
ri
m
er
 #
 
S
eq
u
en
ce
 
(c
ap
it
al
 l
et
te
rs
 a
re
 c
o
m
p
le
m
en
ta
ry
 t
o
 t
ar
g
et
) 
R
es
tr
ic
ti
o
n
 
en
zy
m
e 
si
te
s 
D
es
cr
ip
ti
on
 
1
6
7
2
 
g
g
t
g
a
c
t
a
g
t
A
T
G
A
G
A
G
C
T
A
T
G
A
G
A
T
G
A
C
A
G
C
 
S
p
eI
 
C
lo
n
in
g
 C
-t
er
m
in
al
 a
G
E
P
R
A
 B
 (
R
A
R

 L
B
D
 +
 Y
P
et
);
 u
se
d
 t
o
g
et
h
er
 w
it
h
 
#
1
5
7
6
 a
s 
re
v
er
se
 p
ri
m
er
 
1
6
7
3
 
g
g
t
g
a
c
t
a
g
t
A
T
G
G
T
G
A
G
C
A
A
G
 
S
p
eI
 
C
lo
n
in
g
 N
-t
er
m
in
al
 a
G
E
P
R
A
 B
 (
C
F
P
 +
 R
A
R

 L
B
D
) 
1
6
7
4
 
t
a
t
a
c
t
c
g
a
g
t
t
a
T
T
C
A
T
G
T
C
C
T
T
C
A
G
A
A
T
T
C
T
C
C
 
X
h
o
I 
C
lo
n
in
g
 N
-t
er
m
in
al
 a
G
E
P
R
A
 B
 (
C
F
P
 +
 R
A
R

 L
B
D
) 
1
6
7
5
 
g
g
t
g
a
c
t
a
g
t
A
T
G
A
C
A
G
C
T
A
T
G
A
A
C
T
G
A
G
T
C
C
 
S
p
eI
 
C
lo
n
in
g
 C
-t
er
m
in
al
 a
G
E
P
R
A
 G
 (
R
A
R
 
L
B
D
 +
 Y
P
et
) 
1
6
7
6
 
t
a
t
a
g
a
a
t
t
c
T
T
A
G
T
C
C
T
C
G
A
T
G
T
T
G
T
G
 
E
co
R
I 
C
lo
n
in
g
 C
-t
er
m
in
al
 a
G
E
P
R
A
 G
 (
R
A
R
 
L
B
D
 +
 Y
P
et
) 
1
6
7
7
 
G
G
T
G
A
C
T
A
G
T
A
T
G
G
T
G
A
G
C
A
A
G
 
S
p
eI
 
C
lo
n
in
g
 N
-t
er
m
in
al
 a
G
E
P
R
A
 G
 (
C
F
P
 +
 R
A
R
 
L
B
D
) 
1
6
7
8
 
t
a
t
a
g
a
a
t
t
c
t
t
a
C
T
C
A
A
A
C
A
T
C
T
C
C
G
G
G
T
T
C
 
E
co
R
I 
C
lo
n
in
g
 N
-t
er
m
in
al
 a
G
E
P
R
A
 G
 (
C
F
P
 +
 R
A
R
 
L
B
D
) 
TABLE 2.5| PCR Primers Used in This Study (continued) 
MATERIALS AND METHODS  35 
Modular FRET Sensors for RA 
Chen Lab 
clone # Clone name Made by Species Description 
642 NR box gBlock Maik  tandem NR boxes gBlock cloned into 
pEYFP-N1 
664 flipFRET LBDnoF NRs Maik rat short linker 
665 flipFRET LBDnoF NRl Maik rat long linker 
666 flipFRET LBD+F NRs Maik rat short linker 
667 flipFRET LBD+F NRl Maik rat long linker 
668 flipFRET LBDnoF AAAs Maik rat binding-incompetent AxxAA NR box 
mutant; short linker 
669 flipFRET LBDnoF AAAl Maik rat binding-incompetent AxxAA NR box 
mutant; long linker 
670 flipFRET LBD+F AAAs Maik rat binding-incompetent AxxAA NR box 
mutant; short linker 
671 flipFRET LBD+F AAAl Maik rat binding-incompetent AxxAA NR box 
mutant; long linker 
672 flipFRETmut LBDnoF NRs Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #664 to 
abolish corepressor binding to apo-LBD 
673 flipFRETmut LBDnoF NRl Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #665 to 
abolish corepressor binding to apo-LBD 
674 flipFRETmut LBD+F NRs Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #666 to 
abolish corepressor binding to apo-LBD 
675 flipFRETmut LBD+F NRl Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #667 to 
abolish corepressor binding to apo-LBD 
676 flipFRETmut LBDnoF AAAs Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #668 to 
abolish corepressor binding to apo-LBD 
677 flipFRETmut LBDnoF AAAl Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #669 to 
abolish corepressor binding to apo-LBD 
678 flipFRETmut LBD+F AAAs Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #670 to 
abolish corepressor binding to apo-LBD 
679 flipFRETmut LBD+F AAAl Maik rat LBD I393Q point mutation introduced by 
primers 1570/1571 into clone #671 to 
abolish corepressor binding to apo-LBD 
TABLE 2.6| Plasmids Used in This Study 
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Gal4-RAR and UAS-E4TATA::fLuc-eGFP Reporter System 
Chen Lab 
clone # Clone name Made by Species Description 
694 pUAS5-E4TATA::fluc Paulmurugan 
Lab 
 Use primers #1621 and #1622 to amplify 
UAS5-E4TATA promoter/enhancer 
696 UAS5-E4TATA in clone #86 Maik  UAS5-E4TATA amplified from clone #694 
using primers #1621/1622 and cloned 
into clone #86 using AseI and AgeI sites 
697 pUAS5-E4TATA::fluc-EGFP Maik  Promoter/Enhancer region sequenced 
using primer #1636 
698 Gal4 DBD (K43R) Maik  gBlock of Gal4 DBD synthesized and 
cloned into pEYFP-N1 using NheI/NotI 
699 pGal4-MCS-VP16 Maik  gBlock of VP16x2 synthesized and clo-
ned into #698 using EcoRI/NotI 
700 pGal4-RARa-VP16 Maik rat 
RAR 
RAR alpha LBD 182-416 amplified from 
clone #275 using primers #1623/1624; 
PCR product cloned into clone #699 
using EcoRI/BamHI 
701 pGal4-RARaF-VP16 Maik rat 
RAR 
RAR alpha LBD+F 182-459 amplified 
from clone #275 using primers 
#1623/1625; PCR product cloned into 
clone #699 using EcoRI/BamHI 
702 pGal4-RARb-VP16 Maik mouse 
RAR 
RAR beta LBD 178-412 amplified from 
clone #276a using primers #1626/1627; 
PCR product cloned into clone #699 
using AgeI/BamHI 
703 pGal4-RARbF-VP16 Maik mouse 
RAR 
RAR beta LBD+F 178-448 amplified 
from clone #276a using primers 
#1626/1628; PCR product cloned into 
clone #699 using AgeI/BamHI 
704 pGal4-RARg-VP16 Maik rat 
RAR 
RAR gamma LBD 214-414 amplified 
from clone #277 using primers 
#1629/1630; PCR product cloned into 
clone #699 using EcoRI/BamHI 
705 pGal4-RARgF-VP16 Maik rat 
RAR 
RAR gamma LBD+F 214-485 amplified 
from clone #277 using primers 
#1629/1631; PCR product cloned into 
clone #699 using EcoRI/BamHI 
717 pGal4-RARa(noF)-no VP16 Maik/ 
Jinkyung 
rat 
RAR 
deleted VP16 domain from clone #700 
by Bglll-BamHI digestion and religation 
to itself  
718 pGal4-RARaF-no VP16 Maik/ 
Jinkyung 
rat 
RAR 
deleted VP16 domain from clone #701 
by Bglll-BamHI digestion and religation 
to itself  
719 pGal4-RARb(noF)-no VP16 Maik/ 
Jinkyung 
mouse 
RAR 
deleted VP16 domain from clone #702 
by Bglll-BamHI digestion and religation 
to itself  
720 pGal4-RARbF-no VP16 Maik/ 
Jinkyung 
mouse 
RAR 
deleted VP16 domain from clone #703 
by Bglll-BamHI digestion and religation 
to itself  
TABLE 2.6| Plasmids Used in This Study (continued) 
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GEPRA FRET Sensors for RA 
Chen Lab 
clone # Clone name Made by Species Description 
725 GEPRA AA Miyawaki Lab mouse Shimozono et al., 2013 
726 GEPRA B Miyawaki Lab mouse Shimozono et al., 2013 
727 GEPRA G Miyawaki Lab mouse Shimozono et al., 2013 
728 aGEPRA AA Miyawaki Lab mouse Plasmid #725 with solubility domain 
729 aGEPRA B Miyawaki Lab mouse Plasmid #726 with solubility domain 
730 aGEPRA G Miyawaki Lab mouse Plasmid #727 with solubility domain 
767 Nterm CFP4-aGEPRA B Maik mouse N-terminal part of aGEPRA B including 
CFP4 and solubility domain 
768 Cterm YPet-aGEPRA B Maik mouse C-terminal part of aGEPRA B including 
YPet and solubility domain 
769 Nterm CFP4-aGEPRA G Maik mouse N-terminal part of aGEPRA G including 
CFP4 and solubility domain 
770 Cterm cpYPet-aGEPRA G Maik mouse C-terminal part of aGEPRA G including 
cpYPet and solubility domain 
Clover and mRuby2 FRET Pair Plasmids 
Chen Lab 
clone # 
Clone name Made by  Description 
774 pcDNA3 Clover Michael Lin Lab  Clover in pcDNA3 expression vector 
775 pcDNA3 mRuby2 Michael Lin Lab  mRuby2 in pcDNA3 expression vector 
none pcDNA3 Clover-mRuby2 Clover-mRuby2 fusion protein in 
pcDNA3 expression vector 
Maik 
General Plasmids  
Chen Lab 
clone # 
Clone name Made by Species Description 
86 pEYFP-N1 (mYFP A206K) Christine Nam  Contains frame shift mutation 
86a pEYFP-N1 (mYFP A206K) Maik  Monomeric YFP (A206K mutation); clo-
ne #86 mutagenised using primers 1537 
and 1538 
87 pEYFP-N1 (mCFP A206K)   Monomeric CFP (A206K mutation) 
275 Rat RARalpha - GFP Jason Aoto rat amplified from rat cDNA using an inter-
nal primer that introduced a silent mutati-
on T1017C to generate an internal XbaI 
site - sequencing OK 
276 Mouse RARbeta-GFP Jason Aoto mouse amplified mRAR from mouse hippo-
campal cDNA - we used a natural EcoRV 
internal restriction site to amplify two 
fragments - full sequence OK 
276a Mouse RARbeta(mutant)-
GFP 
Maik mouse internal BglII restriction sites within 
RAR LBD from clone #276 abolished 
by silent nucleotide mutations T1111C 
and A1125T using primers 1568/1569; 
RAR full sequence OK 
277 rat RARgamma-GFP Jason Aoto rat amplified from rat cDNA as a single PCR 
fragment - no stop codon 
496 RARalpha FL in pGEX-KG Mike Poon rat Amplified RAR from rat brain; cloned 
into pGEX KG with BamHI/EcoRI 
TABLE 2.6| Plasmids Used in This Study (continued) 
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3. RESULTS 
3.1 Calcineurin Regulates RA-Dependent Homeostatic Synaptic Plas-
ticity 
We showed in a previous study that intracellular calcium levels maintained during nor-
mal synaptic transmission suppress RA production, and a drop in intracellular calcium 
level is sufficient to induce RA-dependent homeostatic synaptic strengthening. Additio-
nally, this study showed that the intracellular calcium regulation and the following RA-
dependent homeostatic synaptic strengthening occur cell-autonomously (Wang et al., 
2011). We therefore wanted to investigate how intracellular calcium levels and RA-
dependent homeostatic synaptic plasticity are linked. Based on the hypothesis that the cal-
cium-dependent effect of RA synthesis might be regulated through calcium-dependent 
phosphatase or kinase signaling pathways, we investigated the effects of pharmacological 
protein phosphatase blockers on synaptic transmission. We found that FK506 and cyc-
losporin A (CsA), two drugs that specifically block the activity of the calcium-dependent 
protein phosphatase calcineurin (CaN, also called protein phosphatase 2B, PP2B), both 
lead to an increase in excitatory synaptic transmission while reducing inhibitory synaptic 
transmission (Arendt et al., 2015). Application of these calcineurin inhibitors can thus 
mimic the electrophysiological phenotype of RA-dependent homeostatic synaptic plastici-
ty. By contrast, okadaic acid, a blocker of the calcium-independent protein phosphatases 
types 1 and 2A, had no such effect on synaptic transmission (Arendt et al., 2015). We 
concluded from these experiments that calcineurin might be responsible for the homeosta-
tic adjustment of synaptic transmission when intracellular calcium levels are decreased. 
To confirm our hypothesis that calcineurin mediates homeostatic synaptic plasticity 
through the regulation of RA synthesis we utilized a transcription-based RA reporter to 
observe RA level changes in reporter-expressing neurons after calcineurin-blocking drug 
treatments. Our reporter contains a GFP which is expressed under the regulation of three 
repeats of a RA response element, and a weak thymidine kinase promoter from human 
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FIGURE 3.1| RARE-TK::GFP Reporter Activation in Neurons after Calcineurin Blockade. A, Schemat-
ics of the RARE-TK::GFP reporter. GFP is driven by a weak TK promoter and regulated by 3 repeats of a 
retinoic acid response element. B, Quantification of GFP fluorescence in reporter-expressing cultured hip-
pocampal neurons with different drug treatments. Expression levels normalized to DMSO controls are 
(average ± SEM): DEAB, 80.61 ± 9.00% (N=4, n=51 neurons); Aldi-6, 75.05 ± 12.43% (3/25); FK506, 
154.57 ± 8.94% (9/133); FK506+DEAB, 78.48 ± 6.70% (4/52); FK506+Aldi-6, 124.17 ± 16.34% (4/35); 
TTX+CNQX, 193.37 ± 10.07% (8/117); TTX+CNQX+DEAB, 79.72 ± 8.82% (4/45); TTX+CNQX+Aldi-
6, 114.10 ± 12.25% (3/30); RA, 256.20 ± 11.40% (9/69); FK1012, 79.11 ± 7.28% (7/62). *P < 0.05; ***P < 
0.001, student’s t-test. C, Sample images of GFP intensities in reporter-expressing neurons. Scale bar, 10 
µm. (Modified after Arendt et al., 2015) 
Herpes simplex virus; altogether we refer to this reporter construct as RARE-TK::GFP 
(Aoto et al., 2008) (Figure 3.1A). We found that RARE-TK::GFP reporter expression in 
FK506-treated cells was significantly increased by almost 50% when compared to repor-
ter levels in DMSO-treated control cells, comparable to treatment with the network activi-
ty-blocking drugs TTX+CNQX (Figure 3.1B and C). Moreover, we tested whether inhibi-
ting the cellular RA synthesis pathway is sufficient to block the increase in reporter acti-
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vity induced by calcineurin inhibitors or neuronal network activity blockers. We applied 
two mechanistically and structurally distinct inhibitors of retinaldehyde dehydrogenase 
(RALDH), the enzyme that catalyzes the last oxidative step of cellular RA synthesis. We 
found that DEAB, a competitive inhibitor of RALDH, completely blocked RARE-
TK::GFP reporter activation, while Aldi-6, a suicide inhibitor of RALDH, significantly 
reduced the increase in reporter activity (Figure 3.1B and C). 
The RARE-TK::GFP reporter robustly indicates differences in cellular RA concentrati-
on when transfected into dissociated neuron cultures. However, differences between RA-
treated and DMSO-treated reporter-expressing cells can only be detected within about 10-
16 hours after transfection (data not shown). At earlier time points, GFP expression is too 
low to exceed autofluorescence background, while at later time points even DMSO-
treated cells quickly reach saturated GFP fluorescence levels. Similarly, the reporter lost 
its indicative power when it was delivered to neurons by means of viral infection, either 
by lentiviral or adeno-associated viral vectors (data not shown). We therefore tried to de-
velop an improved reporter version that could overcome these limitations, thus allowing 
the use of such RA reporter system for in vivo applications in living and behaving animal 
brains. 
3.2 Development of a Novel Transcription-Based Reporter for RA 
Based on the modular structure of retinoid receptors and the observation that their dif-
ferent biochemical functions are located in distinct protein domains (Bourguet et al., 
2000a, Brelivet et al., 2012) (Figure 3.2A, top panel), we engineered a chimeric receptor 
containing the Gal4 DNA-binding domain (Gal4-DBD) fused to different variants of reti-
noic acid receptor ligand-binding domains (RAR-LBD) with or without their respective F 
domains, and added a twofold tandem repeat of the Herpes simplex virus protein VP16-
transactivation domain (Sadowski et al., 1988) for enhanced transcriptional activity of the 
artificial receptor chimeras (Gal4-RAR-VP16, Figure 3.2A). These chimeric receptors 
can only function together with a reporter construct from which our luciferase-EGFP re-
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FIGURE 3.2| Development of a Novel Transcription-Based RA Reporter System. A, Schematics of the 
reporter system. Domain structure of a prototypical retinoid receptor is illustrated in the top panel with 
ligand-independent activation function AF-1 and ligand-dependent AF-2 indicated. N-terminal portion of 
the receptor including AF-1 and the DNA-binding domain (DBD) was replaced with the DBD from yeast 
transcription factor Gal4 to yield the chimeric Gal4-RAR receptors. Receptors including or lacking the re-
spective F-domains or VP16 viral transactivator domain (labeled in parentheses) were tested for transcrip-
tional activity and inducibility by ligands. Reporter DNA contains a luciferase-GFP fusion protein (fLuc-
EGFP) driven by a weak viral E4 TATA box minimal promoter under the regulation of 5 repeats of the 
yeast “upstream activating sequence” (5x UAS) to which the Gal4-DBD can bind (orange curved arrow). 
The Gal4-RAR chimeric receptor and the UAS-E4TATA::fLuc-EGFP reporter together constitute the novel 
transcription-based RA reporter system (beige box). B, Quantification of GFP fluorescence in HEK 293T 
cells cotransfected with UAS-E4::fLuc-EGFP reporter and different variations of Gal4-RAR chimeric re-
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porter protein is expressed under the control of an adenoviral E4 TATA box minimal pro-
moter and the “upstream activator sequence” (UAS) to which the Gal4-DBD can bind. 
We combined the TATA box minimal promoter and 5 repeats of UAS to regulate the ex-
pression of the luciferase-EGFP reporter protein (UAS-E4TATA::fLuc-EGFP). While the 
Gal4-DBD thus confers the unique DNA-binding properties of the receptor, the RAR-
LBD contributes to the ligand specificity. Together with the UAS-E4TATA::fLuc-EGFP 
reporter DNA, the chimeric Gal4-RAR receptor should form a reporter system that speci-
fically and exclusively responds to retinoic acid or potentially other RAR ligands (Figure 
3.2A, beige box). 
We first tested this reporter system with different variants of Gal4-RAR chimeras with 
and without the VP16-transactivation domain by cotransfection of reporter and receptor 
constructs in HEK 293T cells (Figure 3.2B and C). Transfected cells were stimulated by 
direct application of 250 nM all-trans retinoic acid (RA) at 24-48 hours post-transfection. 
We found that cells transfected with VP16-containing receptors appeared brighter in ge-
neral, but the high background reporter activity in DMSO-treated control cells partially 
obscured further reporter activation by RA and thus reduced overall reporter sensitivity. 
Nevertheless, all but one VP16-containing receptor chimera induced a robust increase of 
reporter expression in the presence of RA; only the RAR receptor chimera with the F 
domain (Gal4-RARbF-VP16) altogether failed to respond to RA (Figure 3.2B). The best 
responses were obtained with the two receptor constructs Gal4-RARaF-VP16 and Gal4-
RARb-VP16, yielding 3-fold and almost 4-fold increases of reporter levels, respectively. 
Because of the high baseline fluorescence levels caused by the VP16-containing receptor 
ceptors, as indicated. Expression levels of cells treated with 250 nM RA for 24h (black bars) were normal-
ized to DMSO controls (white bars; averages ± SEM of 9 images obtained from 3 independent experiments 
for each group): Gal4-RAR-VP16, 174.14 ± 17.12%; Gal4-RARF-VP16, 286.77 ± 62.18%; Gal4-RAR
-VP16, 371.38 ± 74.08%; Gal4-RARF-VP16, 117.28 ± 22.19%; Gal4-RAR-VP16, 180.49 ± 33.08%; 
Gal4-RARF-VP16, 275.69 ± 26.86%; Gal4-RAR, 394.15 ± 124.15%; Gal4-RARF, 664.48 ± 104.38%; 
Gal4-RAR, 273.25 ± 29.41%; Gal4-RARF, 239.58 ± 43.70%. C, Representative images of GFP intensi-
ties in reporter-expressing HEK 293T cells. Regions outlined in red were selected by background threshold-
ing for quantification of GFP intensities as shown in panel B. Scale bar, 50 µm. 
FIGURE 3.2| Development of a Novel Transcription-Based RA Reporter System. (continued) 
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FIGURE 3.3| UAS-E4::fLuc-EGFP Reporter Activation in Neurons after Calcineurin Blockade. A, 
Time course of reporter expression (hatched bars) and drug treatment (shaded bars) compared between 
RARE-TK::GFP (top) and UAS-E4TATA::fLuc-EGFP reporters (bottom). B, Quantification of GFP fluores-
cence in reporter-expressing cultured hippocampal neurons subjected to different drug treatments. Expres-
sion levels normalized to DMSO controls are (average ± SEM): Gal4-RAR receptor: TTX+CNQX, 221.89 
± 17.17% (N=7, n=103 neurons); RA, 210.00 ± 15.46% (7/103); TTX+CNQX+DEAB, 99.90 ± 9.06% 
(5/74); FK506, 182.89 ± 11.77% (2/32); Gal4-RARF receptor: TTX+CNQX, 262.98 ± 38.53% (2/26); 
RA, 351.55 ± 49.43% (2/26); TTX+CNQX+ DEAB, 147.92 ± 18.47% (2/32). *P < 0.05; ***P < 0.001; #P 
< 0.01 (Gal4-RARF receptor: TTX/CNQX/DEAB vs. TTX/CNQX groups) student’s t-test. C, Sample 
images of GFP intensities in reporter-expressing neurons. Scale bar, 15 µm.  
chimeras even in the absence of RA, we next tested the four receptor chimeras derived 
from RAR and RAR without the VP16-transactivation domain. This modification im-
proved the relative RA-induced response generated by the Gal4-RARa and the Gal4-
RARaF receptor chimeras without the VP16-transactivation domains which yielded a 4-
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fold and 6.5-fold increase of reporter expression upon RA-stimulation, respectively. By 
contrast, the RA-stimulated responses induced by RAR-derived receptor chimeras did 
not improve after removal of the VP16-transactivation domain. (Figure 3.2B). 
Having established the RA responsiveness of our chimeric reporters in HEK 293T 
cells, we examined the two most responsive constructs in neurons to test whether respon-
siveness could be maintained over extended times of reporter expression. We therefore 
cotransfected the UAS-E4TATA::fLuc-EGFP reporter with either the Gal4-RARa or the 
Gal4-RARaF receptor chimeras into dissociated hippocampal neurons between 7 and 12 
days in vitro (DIV), and tested the responsiveness of the reporter between 3 and 5 days 
post-transfection (DIV 13-15, Figure 3.3A). Our data show that reporter-expressing neu-
rons are highly responsive to direct treatment with RA, as well as RA-inducing neuronal 
activity blockers; reporter activation could also be blocked with DEAB (Figure 3.3B and 
C). Moreover, the responses obtained with the UAS-E4TATA::fLuc-EGFP reporters are 
comparable to results from our previously established RARE-TK::GFP reporter assay (cf. 
Figure 3.1B). Consistent with our observations in HEK 293T cells, the RAR-derived 
receptor chimera including the F-domain yielded the strongest response to RA or RA-
inducing drug treatments. Compared to the DMSO-treated control group, the Gal4-
RARaF chimera yielded a 3.5-fold higher GFP expression level in RA-treated neurons. 
The increase of GFP expression in TTX/CNQX-treated neurons was 2.6-fold of DMSO 
baseline level and could be reduced to 1.5-fold of baseline (p = 0.03) by the addition of 
DEAB, an inhibitor of RA-synthesizing enzymes of the RALDH family. The Gal4-RARa 
chimera without the F-domain yielded a 2.1-fold increase of GFP expression with RA. 
The 2.2-fold increase induced by treatment with TTX/CNQX could be completely blo-
cked when DEAB was coapplied (1.00 ± 0.09; p = 0.99). We also tested the Gal4-RARa 
chimeric reporter response to the calcineurin inhibitor FK506 and found a 1.8-fold signifi-
cant increase of GFP expression in FK506-treated cells. All treatments yielded statistical-
ly highly significant results (p < 0.0005), except where otherwise stated. 
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3.3 Designing Modular FRET Sensors for RA 
After having established calcineurin inhibition as another step of the biochemical cas-
cade preceding the production of RA during homeostatic synaptic plasticity, we wondered 
how RA synthesis is regulated in time and space with respect to subcellular neuronal 
compartments and biochemical or signaling events. The overarching question is whether 
RA is produced globally or at defined subcellular compartments such as specific dendritic 
branches. To address the question of speed and location of RA synthesis upon synaptic 
activity blockade, we needed a tool that could indicate the concentration of RA with a 
high spatiotemporal resolution. We therefore aimed to develop a FRET-based RA repor-
ter that would sense and indicate the presence of RA in real-time with a subcellular spatial 
resolution. 
Our first approach was to develop a FRET sensor for RA according to a modular de-
sign as suggested by Umezawa and colleagues, whose concept exploited the fact that nuc-
lear receptors such as estrogen receptor can recruit transcription co-activators upon acti-
vation by their ligands (Awais et al., 2004). The authors constructed a chimera protein 
consisting of the nuclear receptor itself (estrogen receptor in their case) linked to a NR 
box, the binding motif found in a transcriptional co-activator. The NR box is separated 
from the nuclear receptor by a flexible linker domain. Additionally, a YFP is tagged to the 
N-terminal, and a CFP to the C-terminal end of the chimera. In this modular protein, the 
nuclear receptor co-factor binding motif acts as an intramolecular tethered ligand: In the 
presence of receptor agonist, the tethered ligand binds to the nuclear receptor, positioning 
the YFP and CFP in close proximity to one another to yield a significant increase in the 
observed FRET signal. In analogy to the estrogen receptor-based design of Umezawa and 
colleagues, we developed a FRET sensor based on retinoic acid receptor alpha  
(RAR), because within the retinoid receptor protein family RAR has the highest affini-
ty for all-trans retinoic acid (Repa et al., 1993) (Figure 3.4A, top panel). Similar to Ume-
zawa’s construct, our reporter should undergo a conformational change that increases 
FRET upon ligand binding (Figure 3.4B, bottom panel). The “NR box” is a conserved 
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FIGURE 3.4| Designing Modular FRET Sensors for RA. A, Construct design for a modular FRET sensor 
for RA. Top panel illustrates the domain structure of modular FRET sensors: Mouse RAR LBD was con-
nected by a linker domain to a cofactor binding motif (NR box). YFP and CFP are fused to the N- and C-
terminals, respectively, allowing the detection of FRET. Linker lengths and residue positions of RAR 
LBD fragments (referring to full-length rat RAR) are indicated above. Bottom panel illustrates the princi-
ple of RA detection. In the absence of RA, the detector assumes an extended conformation, and CFP and 
YFP are far apart. When RA is bound, the RAR LBD can recruit the tethered NR box, bringing CFP and 
YFP into close proximity, thereby increasing FRET (white curved arrow). B, Emission spectra obtained 
between 430 nm - 630 nm from lysates of HEK cells expressing FRET constructs illustrated in panel A. 
Spectra were obtained under specific CFP excitation at 434 nm and showed clearly distinguishable CFP and 
YFP emission peaks at 477 nm and 527 nm, respectively. Spectra were overlayed after normalization to 
CFP peak emission at 477 nm; lysates containing separately expressed CFP and YFP (black dashed line) or 
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interaction motif of transcriptional co-activators containing a consensus “LxxLL” amino 
acid sequence, where L indicates leucine and x indicates any amino acid (Heery et al., 
1997). A comparison of a number of natural and synthetic NR box peptides and their bin-
ding behavior to liganded and unliganded nuclear receptors revealed a peptide termed 
“D22” that shows the best differential binding behavior between unliganded RAR (very 
little binding) and liganded RAR (very strong binding) (Chang et al., 1999). Mutating 
the essential leucines within the NR box consensus motif to other amino acids abolishes 
the ability to bind nuclear receptors. Hence, leucine-to-alanine “AxxAA” mutants of the 
D22 peptide could serve as powerful negative controls for the construct function. 
Based on the general design principle mYFP-NR box-linker-RAR(LBD)-mCFP 
(Figure 3.4A), we obtained 8 constructs with their respective “AxxAA” negative controls. 
We chose to examine 3 parameters for their influence on FRET efficiencies of the 
constructs: 1. linker length (short linker, 5 amino acids: GGNGG; or long linker, 23 ami-
no acids: [GGN]7GG), 2. the F-domain (RAR LBD with or without F-domain), and 3. a 
beta sheet-destabilizing RAR LBD I393Q point mutation (RAR LBD wt or RAR LBD 
I393Q). The latter mutation renders the LBD incapable of binding nuclear co-repressors (le 
Maire et al., 2010), thereby potentially enhancing its ability to differentially bind the 
tethered intramolecular D22 NR box peptide. 
To test whether these reporter constructs could respond with an increase of FRET effi-
ciency when RA is added, we obtained crude protein extracts from HEK 293T cells ex-
pressing the constructs. Using a spectrophotometer, the lysates were excited with 415 nm 
a CFP-YFP fusion protein (black solid line) served as FRET negative and positive controls, respectively; 
emission of CFP alone is plotted for comparison (dashed blue line). YFP emission of modular RA sensors 
falls in between FRET negative and positive controls (beige shaded area). C, Lysates of HEK cells express-
ing different FRET sensor variants based on the design principle illustrated in panel A were tested by spec-
trophotometry as described in panel B. Bar graph shows YFP peak emission at 527 nm in spectra normal-
ized to CFP peak emission at 477 nm. White and colored bars represent ratios determined in the absence or 
presence of 1 µM RA, respectively. Red and green bars refer to constructs containing the LxxLL wild type 
NR box or the AxxAA binding-incompetent NR box, respectively, and darker and lighter hues indicate 
short (5 residues) or long linkers (23 residues), respectively, between the RAR LBD and the NR box. D, 
Overlays of emission spectra for all tested constructs without (red line) or with 1 µM RA (blue line).  
FIGURE 3.4| Designing Modular FRET Sensors for RA. (continued) 
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light, and emission spectra were obtained between 430 nm and 630 nm in 5 nm steps. The 
emission spectra we obtained from our FRET constructs exhibit two peaks, one CFP 
emission peak at 475 nm and a YFP emission peak at 530 nm. We plotted the spectra and 
normalized the emission values to the CFP peak at 475 nm (Figure 3.4B). Because 415 
nm excitation excites CFP without directly causing YFP excitation, we can assume that 
the emission spectra reflect directly excited CFP with its emission peaking at 475 nm, and 
the YFP indirectly excited from CFP through FRET, with YFP emission peaking at 530 
nm. This assumption was confirmed by obtaining emission spectra from lysates of cells 
coexpressing CFP and YFP as separate proteins where no FRET is expected to occur bet-
ween the fluorophores. In this lysate the 530 nm YFP peak is indeed reduced to a barely 
noticeable shoulder on top of the CFP emission spectrum (Figure 3.4B, dashed black li-
ne). When we measured spectra from cells expressing a CFP-YFP tandem fusion protein 
with high expected FRET efficiency between the fluorophores, we detected a very high 
YFP peak (Figure 3.4B, solid black line). The YFP emission peaks of all our RAR-
derived FRET constructs fall in between the CFP + YFP (no FRET) value and the CFP-
YFP tandem protein (high FRET) value and can therefore be considered to represent in-
termediate FRET efficiencies (Figure 3.4B, beige shaded area). 
All spectra obtained from our RAR-derived FRET constructs exhibit intermediate 
FRET values for the wild-type NR box-containing constructs, while their inactive AxxAA 
NR box mutants consistently show less FRET than their LxxLL counterparts. We also 
noticed that FRET decreased with increasing linker length between the fluorophores, and 
observed a general trend that the FRET efficiencies for any variant of the RAR LBD 
ranged in the order LxxLL (short linker) > LxxLL (long linker) > AxxAA (short linker) > 
AxxAA (long linker) (Figure 3.4C and D). The FRET efficiency thus showed a clear cor-
relation with the linker length separating the NR box from the RAR LBD. The other two 
factors we examined, F-domain and I393Q mutation, had a less pronounced effect on 
FRET efficiencies. While the presence of the F-domain very mildly increased FRET effi-
ciency in the wild-type RAR LBD construct, it decreased FRET efficiency in the RAR 
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LBD I393Q mutants. Despite the differences in FRET efficiencies between the various 
constructs we tested, none of our constructs showed by itself a response to RA beyond the 
variability within the assay (Figure 3.4C and D). While the YFP emission peaks of the 
AxxAA constructs are reduced by around 10% - 20% compared to their LxxLL counter-
parts, the RA-induced differences we observed for any construct were consistently below 
5%. Moreover, the FRET changes we observed with the active LxxLL NR box constructs 
appeared generally similar in magnitude to their inactive AxxAA counterparts. Important-
ly, the expected change with the addition of RA would be a FRET increase, but we obser-
ved random changes, including increases and decreases, of FRET efficiencies upon RA 
addition to our constructs (Figure 3.4C). The reason why none of our various constructs 
respond to RA remains obscure; reduced FRET in the AxxAA mutants as compared to the 
LxxLL wild-type NR box constructs indicates that specific interaction between the RAR 
LBD and the NR box does indeed occur. Interestingly, a commercial kit (LanthaScreen, 
ThermoFisher #PV4409) to probe RAR ligands for coactivator recruitment is reported 
to exhibit clear RA-dependent binding of the D22 peptide to the RAR LBD with compo-
nents almost identical to the domains included in our FRET sensor, though the commerci-
al kit uses the RAR LBD in combination with a molecularly separated D22 NR box pep-
tide instead of intramolecular FRET. 
3.4 aGEPRA RA Reporter Activity in Living Hippocampal Neurons 
It has been firmly established that retinoic acid is both necessary and sufficient for a 
specific form of homeostatic synaptic plasticity (HSP). An important open question is 
when and where exactly within a neuron the synthesis and release of RA take place. The 
answer to this question is not only relevant to understand RA-mediated HSP, but would 
also allow a deeper understanding of the mechanisms of HSP in general, specifically how 
“local” (e.g. single dendritic branches) or “global” (i.e. involving the entire neuron) the 
homeostatic regulation of synaptic strength within a given neuron can be. 
Because none of our own FRET-based sensor designs responded to RA (Figure 3.4), 
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FIGURE 3.5| GEPRA RA FRET Sensor Expression in Hippocampal Neurons. A, Principle of GEPRA 
FRET sensors for RA showing high FRET in the absence of RA and low FRET after RA binding 
(Shimozono et al., 2013). B, Toxicity of GEPRA FRET sensors is illustrated by unhealthy morphology and 
fluorescent aggregates forming inside GEPRA-expressing neurons (middle panel), as opposed to a YFP-
expressing control neuron (left panel). GEPRA sensors were modified by adding an N-terminal solubility 
domain to generate aGEPRA. Toxicity of aGEPRA was greatly reduced as demonstrated by healthy mor-
phology of aGEPRA-expressing neurons (right panel). Scale bar, 20 µm. C, Overlays of emission spectra 
from HEK cell lysates were obtained as described in Fig. 3.4B. Spectra obtained from all aGEPRA con-
structs without (red line) or with 1 µM RA (blue line) show reduced YFP emission after addition of RA, 
indicating lower FRET in the presence of RA. D, Example CFPem/YFPem ratio traces obtained from two 
aGEPRA B-expressing neurons by life cell confocal microscopy. Acute administration of 1 µM RA evokes 
an immediate response in CFPem/YFPem ratio of the FRET sensor in the soma and all dendrites. E, Heat map 
sample images before (left panel) and after addition of 1 µM RA (right panel) of the neuron shown in panel 
D2 clearly illustrate a response to RA throughout the entire cell. 
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we used a different, recently published FRET-based RA sensor termed “Genetically En-
coded Probe for RA”, or GEPRA, to localize RA concentrations within living neurons 
(Shimozono et al., 2013). GEPRA is a fusion protein where a retinoic acid receptor ligand-
binding domain is directly sandwiched between CFP4 and cpYPet (a CFP variant, and a 
circularly permuted YFP variant, respectively). In contrast to our modular FRET sensor 
design, GEPRA responds to RA with a decrease in FRET efficiency (Shimozono et al., 
2013) (Figure 3.5A). Expression of GEPRA in dissociated hippocampal neurons was not 
possible because of the toxicity of the sensor protein, evidenced by morphological chan-
ges, fluorescent aggregates near the nucleus, and eventual cell death (Figure 3.5B). Miya-
waki et al. therefore introduced an N-terminal solubility domain to facilitate solubility of 
the protein in mammalian neurons, and termed the new construct “aGEPRA” (Figure 
3.5B). aGEPRA responsiveness to RA was first confirmed by analyzing crude lysates 
from aGEPRA-expressing HEK cells by spectrophotometry; the FRET efficiency decrea-
ses upon RA addition to the lysates, which is reflected by a decrease of YPet peak emissi-
on relative to the normalized CFP peak emission (Figure 3.5C). To further test how 
aGEPRA responds to RA in the context of an intact neuron, we transfected dissociated 
hippocampal neurons with aGEPRA B (the RAR-derived variant of aGEPRA) and re-
corded CFP and YPet fluorescence emission while only exciting CFP directly with 458 
nm laser light. We calculated the CFPem/YFPem ratio image on a pixel-by-pixel basis. We 
selected dendritic regions of interest and the soma to plot CFPem/YFPem ratios over time 
(Figure 3.5D and E). When neurons transfected with aGEPRA B were incubated with 1 
µM RA, the CFPem/YFPem ratio increased by about 10% both in the soma and in the 
dendrites, as shown in the plots (Figure 3.5D) and the ratiometric CFPem/YFPem ratio 
images (Figure 3.5E). 
We next proceeded to transfect aGEPRA G (a RAR-derived GEPRA variant) into dis-
sociated hippocampal rat neuron cultures between 10 and 14 days in vitro to observe cel-
lular RA concentration in living cells while pharmacologically blocking synaptic trans-
mission. 2 days post-transfection, we added a synaptic activity blocking TTX/CNQX 
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FIGURE 3.6| aGEPRA RA Reporter Activity in Living Hippocampal Neurons. A, Time course of 
aGEPRA transfection (top panel) and imaging (bottom panel) of dissociated hippocampal neurons. Neurons 
were imaged for 120 minutes at a 5 min. image acquisition rate in the presence of TTX/CNQX to block 
synaptic transmission or DMSO as a control. Application of 1 µM RA at the end of each imaging session 
was to test for sensor saturation. B, CFPem/YFPem ratios were recorded for individual TTX/CNQX-treated 
neurons and baseline-normalized ratios were plotted (left panels). TTX and CNQX were present during the 
entire imaging period of 130 min. as indicated below each plot. RA was supplied for the last 10 minutes in 
addition to TTX and CNQX which remained in the bath. Two subgroups of cells responding differently to 
drug treatments became apparent: “non-responders” (dashed lines) showed declining CFPem/YFPem ratios 
during TTX/CNQX treatment and a sharply increasing CFPem/YFPem ratios after RA administration, 
“responders” (solid lines) showed constant or increasing CFPem/YFPem ratios during TTX/CNQX treatment 
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cocktail to the cultures while observing aGEPRA G-expressing neurons by fluorescence 
microscopy in real time over 120 minutes. Our imaging protocol included a sequence of 
10 baseline images (1 min. intervals) followed by addition of drugs (either activity blo-
ckers TTX + CNQX or vehicle control DMSO) and recording fluorescence images in 5 
min. intervals over 120 minutes. To test whether the FRET sensor was saturated by RA at 
the end of the imaging session, we last added 1 µM RA and recorded another 10 images, 
again at 1 min. intervals (Figure 3.6A). Because changes in intracellular RA concentrati-
ons [RA]i should proportionally translate into changes of the CFPem/YFPem ratio in 
aGEPRA G-expressing cells, we plotted the baseline-normalized CFPem/YFPem ratios re-
corded from each cell to visualize [RA]i changes while synaptic activity-blocking drugs 
or DMSO as a vehicle control were applied to the cultures (Figure 3.6B and C, left pa-
nels). 
We could classify cells treated with TTX/CNQX into two distinct subgroups based on 
their CFPem/YFPem time courses: in 9 of 16 recorded cells (56% of cells) formed the first 
subgroup, exhibiting continuously increasing CFPem/YFPem during the treatment period, 
while the 7 cells (44%) forming the second subgroup showed a CFPem/YFPem ratios 
(Figure 3.6B, left panel). Moreover, the group 2 cells responded with a strong increase 
when 1 µM RA was applied at the end of the imaging session, while group 1 cells showed 
little or no response to 1 µM RA treatment. The separation of the two groups became 
even clearer when the relative changes of the aGEPRA sensor “RA response” (i.e. the dif-
without appreciable responses to the final administration of RA. RA vs. TTX/CNQX and RA vs. 
DMSO plots (right panel) were generated by plotting the differences observed during 120 minutes drug 
treatment (average of the first minus average of last three images obtained during drug administration) 
against the differences induced by acute administration of RA (last three images before RA minus last three 
images after RA). Groups of “non-responders” (gray squares) and “responders” (black circles) are clearly 
separated. C, Same as panel B, but with DMSO treatment instead of TTX/CNQX treatment. No DMSO-
treated cell showed a decline in CFPem/YFPem ratio, and only few cells responded moderately with an in-
crease of CFPem/YFPem ratio after RA was added at the end of the imaging session (blue squares in right 
panel). D, Overlay of CFPem/YFPem ratios from individual cells of all treatment groups, color coded by drug 
treatment and response group. Traces show partial overlap between TTX/CNQX “responder” group (solid 
black lines) and DMSO-treated control group (blue lines), but both groups are clearly separated from cells 
of the TTX/CNQX “non-responder” subgroup (dashed black lines). Averages (right panel, averages ± SEM 
[shading]) show clear separation between all groups.  
FIGURE 3.6| aGEPRA RA Reporter Activity in Living Hippocampal Neurons. (continued) 
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ference between CFPem/YFPem ratio after the addition of RA compared to the time points 
immediately before RA application) was plotted against the relative change of the “drug 
response” (i.e. the values at the end of the drug treatment compared to the values at the 
beginning of drug treatment) (Figure 3.6B, right panel). We therefore termed the two 
groups “responders” (subgroup 1) and “non-responders” (subgroup 2), according to the 
responses of the aGEPRA G sensor signals during TTX/CNQX administration. 
“Responders” showed an increase in [RA]i which presumably reached saturating levels of 
the aGEPRA G dynamic range such that the sensor signal could not be further increased 
by exogenously applied RA, while “non-responders” showed no increase or, perhaps, a 
decrease in [RA]i. 
When we applied DMSO as a vehicle control to another set of cells, we observed diffe-
rent responses (Figure 3.6C). The most obvious difference was that all cells responded 
with an increasing or at least stable CFPem/YFPem ratio while none of the DMSO-treated 
cells showed an appreciable decrease in CFPem/YFPem ratio (Figure 3.6C, left panel); only 
29% of the cells (5/17) showed a marked response when 1 µM RA was added at the end 
of the imaging session (Figure 3.6C, right panel, squares). These observations resemble 
the responses of the “responder” group of TTX/CNQX-treated cells. The overlay of the 
TTX/CNQX- and DMSO-treated cells shows that the two groups differ considerably. 
Most individual cell traces from the DMSO group fall within the same range as the inc-
reases observed for the “responder” group of the TTX/CNQX-treated cells, but the avera-
ge increase in CFPem/YFPem ratio in the DMSO group is higher than in the TTX/CNQX-
treated cells (Figure 3.6D). 
To exclude the possibility that photobleaching might have contributed to the differen-
ces between TTX/CNQX-treated and DMSO-treated cells, we plotted the average traces 
of individual fluorescence channels to compare how they differed between groups. The 
changes observed in single channels are consistent with CFPem/YFPem ratio changes. The 
TTX/CNQX “non-responder” group exhibited a roughly constant CFP fluorescence and a 
parallel YFP fluorescence in the FRET channel, and the strong increase in CFPem/YFPem 
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FIGURE 3.7| Photobleaching Cannot Explain Different aGEPRA G Responses between Treatment 
Groups. A, Averages of individual fluorescence channels (CFP emission and FRET channels) obtained 
from TTX/CNQX-treated groups were plotted against image number, separated between “non-responder” 
and “responder” subgroups. Both groups exhibited signal fluctuation of less than 10% in either channel; the 
parallel changes apparent both channels occuring at the time of TTX/CNQX application in the “non-
responder” subgroup were likely due to minor changes in focal planes of the sample cells caused by manual 
drug administration. B, Same as panel A, but for DMSO-treated group. Again, signals remained stable 
within a ±10% window around baseline. C, Overlay of channels obtained in all groups shows overall con-
formity and stability for signals in all groups. D, Overlay of YFP fluorescence channel signals (YFP emis-
sion under direct YFP excitation) from individual cells of all treatment groups, color coded by drug treat-
ment and response group. TTX/CNQX “non-responders” and “responders” (dashed and solid black lines, 
respectively) as well as DMSO-treated cells (blue lines) all fall within a completely overlapping region of 
signal fluctuation. Averages of TTX/CNQX and DMSO groups (thick black and blue traces, respectively) 
are virtually identical and show no signs of photobleaching during the time course of image acquisition. 
Traces and shaded areas represent averages ± SEM for all plots.  
ratio after RA addition is well reflected by the increase in CFP emission with a concomi-
tant decrease in the YFP (FRET) channel. The TTX/CNQX “responder” group however 
showed a constant CFP emission with a slight decrease in YFP (FRET) channel signal, 
but both channels showed a parallel decrease after RA addition, thus not altering CFPem/
YFPem ratio any further (Figure 3.7A). The DMSO-treated cells exhibited roughly 
constant levels of both CFP and YFP (FRET) emission over the course of the treatment, 
again the slight increase of CFP emission with a reduction of YFP (FRET) emission re-
flecting the increase of the CFPem/YFPem ratio. CFP emission increased by about 9% after 
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RA addition without detectable changes in average YFP (FRET) emission signal, con-
sistent with a noticeable average increase in CFPem/YFPem ratio after RA addition (Figure 
3.7B). An overlay of all fluorescence channels of all groups demonstrates that averages of 
individual fluorescence channels fluctuate within a range of ± 10% around the normalized 
baseline intensity (Figure 3.7C). Because the CFP and YFP (FRET) channels both are di-
rectly influenced by FRET, they do not reliably reflect the direct contribution of pho-
tobleaching. We thus also recorded a YFP fluorescence channel where YFP is directly 
excited by a 514 nm laser and the YFP emission signal is detected with the same emission 
settings as used for the FRET channel. We plotted this YFP emission signal for each cell 
over the time course of the imaging sessions and calculated the averages for all three 
groups (TTX/CNQX responders, TTX/CNQX non-responders, DMSO control group). 
Figure 3.7D clearly shows that all individual cells show fluorescence levels that scatter 
within a range of ± 25% around the normalized baseline intensity, with only two outliers 
showing an increase of up to 40% of YFP fluorescence. This figure also demonstrates that 
no photobleaching occurred during the imaging, as average YFP fluorescence rather inc-
reased by about 10% throughout the imaging session, with TTX/CNQX-treated and 
DMSO-treated cells showing virtually identical traces (Figure 3.7D). 
3.5 Ratiometric FRET Measurements by Two-Photon Microscopy 
Two-photon excitation comes with the advantage of deeper tissue penetration with less 
scattering and out-of-focus photobleaching compared to single-photon excitation, thereby 
allowing for the observation of neurons in semi-intact thick tissue sections with preserved 
circuitry, or even in vivo. However, two-photon excitation is modulated by tuning the ex-
citation laser wavelength and collecting the emitted fluorescence through fixed filter sets. 
Since many fluorescent proteins have broad single-photon excitation spectra, and even 
broader two-photon excitation spectra, the advantages of two-photon laser excitation may 
come at the cost of substantial crosstalk between different FRET fluorophores, thus limi-
ting the feasibility of ratiometric FRET measurements. 
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FIGURE 3.8| Ratiometric FRET Measurements by 2-Photon Microscopy. A-C, excitation spectra of Clo-
ver, mRuby2, and Clover-mRuby2 fusion protein obtained between 740 nm and 1040 nm. Spectra for both 
fluorophores were normalized to excitation maxima in the appropriate emission channels (solid green and 
red lines), and Clover-mRuby2 fusion protein excitation spectrum was normalized to Clover excitation 
maximum at 940 nm (solid black lines). Bleed-through spectra obtained for all fluorophores in the opposite 
emission channel was scaled according to scaling factors applied for normalization in the first channel. 
Panel C shows a magnification of the signals between 920 nm and 1040 nm relevant for the calculation of 
FRET contribution to total donor emission signal; see main text for detailed calculations. Filter sets for 
emission were 525/70 (Clover) and 607/45 (mRuby2), separated by a 575 dichroic. D-F, Same as A-C, but 
with excitation spectra obtained between 690 nm and 1040 nm for CFP4, YPet, and the aGEPRA G FRET 
sensor. Normalization was performed as described for panels A-C, except that spectra obtained in the YPet 
channel for the FRET construct were normalized to the secondary YPet emission peak at 1020 nm. Panel F 
shows a magnification of the signals between 740 nm and 890 nm which are relevant for FRET observation. 
Filter sets for emission were 480/40 (CFP4) and 535/50 (YPet), separated by a 505 dichroic. 
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We therefore wanted to explore the possibility of ratiometrically measuring FRET effi-
ciencies with direct two-photon excitation of the donor fluorophore. Our FRET probe for 
RA, aGEPRA, is based on the CFP/YPet FRET pair which emit in cyan and yellow, 
respectively. However, we first wanted to observe FRET with the spectrally better separa-
ted Clover/mRuby2 FRET pair (green/red) to minimize the potential problems of channel 
crosstalk (Lam et al., 2012). In order to observe FRET from the Clover/mRuby2 FRET 
pair, we measured cells separately expressing each individual fluorophore and cells ex-
pressing a tandem fusion between the Clover FRET donor and mRuby2 FRET acceptor 
(Clover-mRuby2) that should yield substantial FRET to serve as a positive control. 
We first confirmed low spectral excitation overlap in the 2-photon excitation mode for 
the Clover/mRuby2 FRET pair. We found that mRuby2 is directly excited mostly at wa-
velengths between 760 nm and 810 nm whereas Clover is excited mostly between 920-
980 nm (Figure 3.8A). We next tested the Clover-mRuby2 tandem fusion construct as a 
FRET positive control to compare its excitation spectrum with the two single fluoropho-
res. The excitation spectra of the fusion protein grossly resemble the individual green and 
red fluorophores with the major difference that fluorescence in the red emission channel 
is increased in the longer wavelength region of 920-1040 nm when compared to the mRu-
by2 alone (Figure 3.8B). Because direct excitation of the Clover FRET donor is very effi-
cient and direct mRuby2 FRET acceptor excitation is low in this spectral region, these 
longer excitation wavelengths provide favorable conditions for calculating FRET efficien-
cy. Generally, emission in the FRET channel needs to be corrected for donor bleed-
through (DBT) and acceptor cross talk (ACT) to estimate the net FRET value: 
 
The large spectral separation of the Clover/mRuby2 FRET pair allows for specific ex-
citation of either FRET donor or FRET acceptor at specific wavelengths, and the wave-
length-specific contributions of DBT and ACT can be approximated by two formulas as 
below: 
 
RESULTS  59 
where DBT is the excitation wavelength-specific donor bleed-through into the FRET 
emission channel. FRET(raw) represents the emission of the FRET construct into the 
green emission channel at the specific excitation laser wavelength, and Clover(red) and 
Clover(green) represent the emissions of Clover alone into the red and green emission 
channels, respectively, under excitation at the specific laser wavelength. At wavelengths 
between 860 nm and 1040 nm where mainly the Clover FRET donor is excited, the donor 
bleed-through of the FRET construct should be the same as the bleed-through of only 
Clover into the FRET emission channel which can be calculated for any wavelength and 
then scaled by the signal intensity in the green channel obtained for the actual FRET 
construct at that wavelength. 
 
 
where ACT is the excitation wavelength-specific acceptor crosstalk, or direct excitation 
of the FRET acceptor by the respective two-photon laser wavelength. mRuby2(red) is 
the emission of mRuby2 alone when excited at the specific laser wavelength, and FRET
(red_raw)770nm and mRuby2(red)770nm represent the emissions in the red channel of the 
FRET construct, and mRuby2 alone, respectively, at 770 nm laser excitation wavelength 
where only specific mRuby2 excitation occurs without direct Clover excitation. The red 
channel emission signal at 770 nm excitation is purely contributed by mRuby2 emission; 
scaling the mRuby2 excitation spectrum to the emission recorded from the FRET 
construct at 770 nm excitation should therefore be a good estimate for mRuby2 crosstalk 
at any excitation wavelength throughout the FRET spectrum. 
According to our calculations, FRET contributed approximately 30% to the total emis-
sion in the red channel between 920 nm and 1040 nm where mostly the Clover FRET do-
nor is directly excited (Figure 3.8C, compare dash-dotted net FRET line to dashed raw 
FRET line). 
On the contrary, the broad excitation spectra of CFP4 and YPet exhibit substantial 
overlap, leading to a unimodal emission spectrum of the examined CFP4-YPet fusion 
RESULTS  60 
construct (which is our FRET probe aGEPRA G) and thus impeding quantification of 
FRET (Figure 3.8D). Nevertheless, there is a spectral region between 760 nm and 880 nm 
where predominantly CFP4 excitation occurs with only minor direct excitation of YPet, 
offering acceptable conditions for ratiometric FRET measurements. It is noteworthy that 
with the fluorescence emission parameters chosen for this experiment, the CFP4 fluo-
rophore did cause a substantial bleed-through into the yellow emission channel (compare 
dotted and solid cyan lines in Figure 3.8D-F). 
We next wanted to test whether we were able to measure ratiometric changes in FRET 
efficiency of our aGEPRA G FRET sensor under 2p laser excitation. The aGEPRA sensor 
exhibits high FRET under basal conditions and responds with a decrease in FRET effi-
ciency in the presence of RA (cf. Figure 3.5C). To test whether we could observe changes 
in FRET ratio under 2p laser excitation, we obtained the 2p laser excitation spectra of 
cells expressing aGEPRA in the absence and in the presence of 1 µM RA (Figure 3.8E 
and F). 
To better visualize the differences between unstimulated and RA-stimulated aGEPRA 
G-expressing cells, we normalized the FRET excitation spectra to the YPet excitation 
peak at 1020 nm where no direct CFP4 excitation is detectable (Figure 3.8D, solid arrow-
head). The stimulated and unstimulated FRET excitation curves overlap completely in the 
excitation region between 960 nm and 1040 nm where only direct YPet excitation occurs 
(Figure 3.8D, empty arrowheads), but they deviate at wavelengths below 960 nm with 
substantial CFP4 FRET donor excitation. In the relevant FRET region between 760 nm 
and 880 nm where the 2p laser mainly excites the donor fluorophore CFP4 with only mi-
nor direct excitation of YPet, normalized aGEPRA G raw FRET values are reduced in the 
presence of RA (Figure 3.8E and F, compare red and dark blue dashed lines), indicating a 
reduction in FRET as expected. 
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4. DISCUSSION 
4.1 Calcineurin Regulates RA-Dependent Homeostatic Synaptic Plas-
ticity 
Our data presented in this study show that CaN mediates homeostatic synaptic plastici-
ty by regulating RA synthesis (Figures 3.1 and 3.3). This novel function of CaN seems to 
be independent of its known role in regulating postsynaptic neurotransmitter receptor traf-
ficking, as the effect was unaltered in phospho-deficient mutants of the GluA1 glutamate 
receptor subunit (not shown) (Arendt et al., 2015). The results presented in Figure 3.3 al-
so demonstrate that our novel RA reporter system could successfully detect changes in 
intracellular RA levels with similar sensitivity as our previously used RARE-TK::GFP 
reporter (cf. Figure 3.1). Using either one of two structurally and mechanistically unrela-
ted RA-synthesizing enzyme inhibitors, DEAB or Aldi-6, reporter activity could be redu-
ced to baseline levels, indicating that our reporter is specific for RA and that pharmacolo-
gical blockade of calcineurin activity increases reporter expression indeed due to cellular 
RA synthesis. 
4.2 Transcription-Based Reporter Assays for RA 
We developed a novel transcriptional assay for RA based on the transcription-
activating function of holo-RARs (Figure 3.2A). Because our previously used RARE-
TK::GFP reporter reaches saturating GFP levels shortly after transfection (after 14-15 
hours, data not shown), we developed a modified reporter system to eliminate that prob-
lem. We reasoned that the natural RARE in our previously used reporter might get occu-
pied by endogenous RARs, thereby potentially causing ligand-independent basal reporter 
transcription (Nagpal et al., 1993). We therefore fused the DNA-binding domain from the 
yeast transcription factor Gal4 (Gal4-DBD) to different RAR ligand-binding domains 
(RARx-LBDs) to yield a chimeric receptor that combines Gal4 DNA-binding specificity 
with RAR ligand-binding specificity. Together with a firefly luciferase-EGFP fusion re-
porter gene located downstream of the Gal4-binding “upstream activating sequen-
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ce” (UAS), such chimeric Gal4-RAR receptors allowed regulated reporter expression de-
pendent on RA concentration (Figure 3.2). The variants of the chimeric Gal4-RAR recep-
tors we tested showed substantial differences in their responsiveness to RA, consistent 
with reports describing variable ligand affinities (Repa et al., 1993), transcriptional activi-
ties (Nagpal et al., 1992), and transcription cofactor binding (Wei, 2003), between diffe-
rent retinoic acid receptors. Our newly developed reporter system has two major advanta-
ges over our previously used RARE-TK::GFP reporter, namely (1) the use of yeast UAS 
foreign to the mouse genome should alleviate recruitment of endogenous transcription 
factors, and (2) deletion of the RAR N-terminal and DNA-binding domains from the Gal4
-RAR chimeric receptors eliminates the ligand-independent activating function AF-1, the-
reby reducing basal activity (Nagpal et al., 1993). The initial chimeric receptor constructs 
contain a Herpes simplex virus VP16 transactivator domain because we designed our re-
porter following a recently published titratable transgene expression system based on a 
chimeric transcription factor consisting of the estrogen receptor ligand-binding domain 
sandwiched between the Gal4 DNA binding domain and a VP16 transactivator domain 
(Gal4-ER-VP16) (Paulmurugan et al., 2009). Our initial tests revealed noticeable GFP 
expression already in the absence of RA when VP16-containing receptors were used for 
reporter activation; hence we chose VP16-lacking receptor chimeras for further testing in 
neuron cultures because they displayed less baseline activity and therefore higher induci-
bility in HEK 293T cells. The most responsive receptor was the Gal4-RARF chimera, 
mostly because it showed a low baseline activity while being highly inducible by RA, 
consistent with a report suggesting active repression of RAR-mediated transcription by 
its specific F-domain in the absence of ligand (Farboud and Privalsky, 2004) (Figure 3.2B 
and C). 
Our new reporter thus exhibits low baseline GFP expression in neurons even several 
days post-transfection and hence extends the applicability of transcription-based RA de-
tection beyond our previously used RARE-TK::GFP reporter. This novel RA detection 
assay offers the possibility to temporally uncouple reporter delivery from RA detection to 
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overcome the tight limitations imposed by quick saturation of the previously used RARE-
TK::GFP reporter assay. The new reporter is hence feasible for viral delivery and stable 
expression in cultured cells, which are prerequisites for reporter use in high-throughput 
screens to identify further components of the RA-mediated homeostatic synaptic signa-
ling cascade in reporter-expressing neuronal cell cultures. The reporter has been designed 
to express a fusion protein of firefly luciferase and EGFP (fLuc-EGFP) to facilitate such 
high-throughput approaches, allowing either the overall population-wide detection of RA 
by measuring luciferase-activity or the examination of RA production in individual cells 
by observing cellular EGFP fluorescence. Another attractive option is viral delivery of 
only the Gal4-RAR chimeric receptor into a universal reporter mouse where either 
EGFP (Niu et al., 2015) or luciferase are expressed under the control of the yeast 
“upstream activating sequence” (Pichler et al., 2008), providing means of studying RA 
production in vivo by fluorescence microscopy or by non-invasive luminescence imaging 
of living subjects. 
4.3 RA Detection in Living aGEPRA G-Expressing Neurons 
Our data presented in Figure 3.6B show that TTX/CNQX-treated aGEPRA G-
expressing hippocampal neurons clearly segregate into two subgroups according to their 
FRET ratio changes induced by synaptic activity blockers followed by subsequent satura-
ting RA application. The first subgroup displays a high response to TTX/CNQX treatment 
and a very low or no response to the subsequent addition of saturating RA (“responders”) 
while the other group shows low response during the TTX/CNQX treatment and a high 
RA response at the end (“non-responders”). As shown in Figure 3.6C, we observed a si-
milar response pattern in the DMSO-treated group which even showed a trend towards a 
stronger average “response” of the aGEPRA signal to the DMSO treatment with less pro-
nounced responses to the final saturating RA addition. The overlay of all individual traces 
in Figure 3.6D (left panel) clearly shows that most cells from both groups fall into an 
overlapping region where normalized CFPem/YFPem ratios remain between 1.0 and 1.3 
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during the drug treatment period. Only three outliers from the DMSO control group rise 
above a ratio of 1.3, while all cells identified as “non-responders” (dashed lines) exhibit 
falling ratios dropping to values between 0.75 and 0.95, at the end of the drug treatment. 
However, the ratios of all cells from the “non-responder” group return to the region bet-
ween 1.0 and 1.3 where the ratios of almost all cells were recorded after the final, satura-
ting RA treatment. The overlay of the averages of the three identified response groups 
clearly visualizes how similarly DMSO-treated and TTX/CNQX-treated groups behaved 
with the exception of the cells from the TTX/CNQX-treated “non-responder” subgroup. 
Further analysis of our data confirmed that photobleaching effects could not explain 
the differences between cells from different groups, because all individual fluorescence 
channels remained stably within ± 10% around the initially recorded (normalized) intensi-
ties (Figure 3.7A-C). The YFP channel where YPet emission is recorded under direct ex-
citation by a 514 nm laser provides the most valuable readout of photobleaching because 
the signal in this channel is unaffected by FRET. When we plotted the traces obtained in 
this channel we observed complete overlap of cells from all groups, and the averages bet-
ween the TTX/CNQX-treated and DMSO-treated groups are virtually identical. To our 
surprise, we even noticed a trend towards a slight increase of about 10% over the whole 
imaging sessions (Figure 3.7D). 
Possible explanations for our inability to detect increasing RA levels in TTX/CNQX-
treated cells include (1) a treatment time too short to allow cellular RA synthesis to occur, 
(2) the assay sensitivity being too low to detect endogenous RA level changes, or (3) cel-
lular RA synthesis occuring in a more localized and potentially transient fashion at 
dendrites and synapses, below the spatio-temporal resolution of our imaging protocol. 
(1) The time course of RA production during synaptic activity blockade of neuronal 
networks is unclear, and our 2 hour time course might have been insufficient to observe 
the onset of cellular RA synthesis. However, RA-mediated homeostatic synaptic plasticity 
is transcription-independent (Aoto et al., 2008), and synaptic activity blockade stimulates 
RA synthesis most likely through post-translational modifications of signaling networks. 
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Enhanced local dendritic translation and insertion of synaptic glutamate receptors can be 
observed after as little as 1 hour of synaptic activity blockade by TTX/CNQX/APV-
treatment (Sutton et al., 2004, Sutton et al., 2006). Because RA production is required for 
enhanced dendritic glutamate receptor translation and synaptic insertion (Aoto et al., 
2008), it needs to occur well within the 2 hour time course of our imaging protocol. 
(2) The sensitivity of our assay is dependent on sensor affinity for the RA, FRET ratio 
changes induced by RA binding, and sensor expression level inside the recorded cells. 
Sensor affinity and ratio changes have been reported in the original publication where 
three variants of GEPRA based on RAR and RAR were tested (Shimozono et al., 
2013). The authors reported that the RAR-based GEPRA B had a higher affinity but lo-
wer FRET change (R/R ~50%) than RAR-based GEPRA G (R/R ~100%). The repor-
ted FRET ratio changes are in good agreement with the changes we observed with our 
slightly modified variants of the originally published constructs (see Figure 3.5C). Howe-
ver, homeostatic synaptic plasticity is mainly if not exclusively mediated through RAR, 
and this receptor has a tenfold higher affinity for RA than RAR upon which aGEPRA G 
is based (Repa et al., 1993). Homeostatic synaptic plasticity thus possibly functions with 
RA levels below the sensitivity of the aGEPRA G FRET sensor. This problem is further 
exacerbated by the remaining toxicity of the aGEPRA probes limiting sensor expression 
to low levels and potentially increasing background fluorescence noise during the measu-
rements. Even though adding an N-terminal solubility domain to the orginal GEPRA sen-
sors to generate aGEPRAs dramatically reduced cell toxicity, the modified sensors ne-
vertheless caused abnormalities in some transfected neurons (such cells were excluded 
from analysis). 
(3) The third important point of concern is the subcellular localization of cellular RA 
synthesis which may have obscured possible differences between the treatment groups. 
For the data presented in Figures 3.6 and 3.7, we chose to plot fluorescence values only 
from cell somata because somatic fluorescence signals were clearly detectable and remai-
ned stable over the entire recording periods. Due to the low sensor expression levels we 
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could not always visualize fine dendritic branches and only rarely synaptic spines. Howe-
ver, wherever cellular sensor expression levels allowed faithful detection and analysis of 
dendritic CFPem/YFPem ratios, their time courses always paralleled the ratios we obtained 
from the somata (data not shown). Moreover, because TTX/CNQX-induced neuronal RA 
production can be detected in trans by HEK 293 cells expressing the RARE-TK::GFP 
reporter (Aoto et al., 2008), it should also be detectable within the somata of the RA-
producing aGEPRA-expressing neurons themselves – again under the assumption of simi-
lar or identical sensitivities of both reporter systems. 
From these observations we conclude that no biologically relevant differences in cellu-
lar RA production are detectable between the TTX/CNQX-treated and DMSO-treated 
groups under our assay conditions. 
4.4 Ratiometric FRET Measurements by Two-Photon Microscopy 
Our data presented in Figure 3.8 demonstrate that ratiometric FRET measurements are 
feasible with 2-photon excitation microscopy. Because the Clover and mRuby2 fluo-
rophores are spectrally very well separated, even under 2-photon excitation (Figure 3.8A), 
we could select excitation wavelengths where either Clover or mRuby2 are selectively 
excited. This, in combination with the spectra obtained from the isolated fluorophores, 
allowed us to determine a FRET contribution of approximately 10% to the total emission 
of a Clover-mRuby2 fusion protein into the mRuby2 channel at wavelengths where only 
Clover gets directly excited (Figure 3.8C). 
We also showed the ratiometric detection of FRET changes induced in aGEPRA G 
sensor-expressing HEK 293T cells by adding RA. However, the CFP4 and YPet 2-photon 
excitation spectra show a higher degree of overlap compared to the Clover/mRuby2 
FRET pair (compare Figures 3.8D and 3.8A), making absolute quantification impossible 
without thorough calibration of the method with cells expressing CFP4 and YPet at equi-
molar concentrations as a FRET-negative bleed-through control. Because aGEPRA G-
transfected cells respond reliably and reproducibly to the addition of exogenous RA, they 
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are nevertheless a useful tool to examine how well the changes in the FRET ratio are de-
tectable under 2-photon excitation. Since donor and acceptor fluorophores are linked in a 
single polypeptide chain, they are always expressed at an equimolar ratio, justifying the 
assumption that reporter expression level can be estimated by specific YPet excitation at 
1020 nm where no direct CFP4 excitation is detectable (Figure 3.8E, black arrowhead). A 
region near the YFP excitation peak shows complete overlap of normalized untreated and 
RA-treated aGEPRA G excitation spectra between 960 nm and 1040 nm, suggesting that 
this region is devoid of CFP4 excitation and FRET (Figure 3.8E, empty arrowheads). In 
the spectral region between 760 nm and 880 nm where CFP4 excitation is dominant, we 
observed a reduction of signal in the yellow fluorescence channel after addition of RA, 
indicating reduced FRET. The normalized CFP4 emission channel signals, however, 
show only minor differences between untreated and RA-treated aGEPRA G-expressing 
cells (Figure 3.8E and F, compare red and dark blue solid lines). We therefore conclude 
that the reduction in the yellow channel upon RA-stimulation is mostly caused by reduced 
YPet emission, despite the major bleed-through of CFP4 into the yellow emission channel 
(approximately 76%) at excitation wavelengths between 760 nm and 880 nm (Figure 3.8E 
and F, compare solid and dashed cyan lines). The assumption of YPet emission domina-
ting the total signal collected in the yellow emission channel is strongly supported by the 
fact that YPet emission is much brighter than CFP4 emission in the CFP4/YPet FRET 
pair under single-photon excitation, even when only CFP4 is directly excited (Nguyen 
and Daugherty, 2005) (cf. Figure 3.5C). 
From our measurements of FRET under 2-photon excitation we conclude that detecti-
on and quantification should be feasible when the donor and acceptor fluorophores are 
spectrally well resolved (as is the case for the Clover/mRuby2 FRET pair), and that FRET 
changes can be detected at least qualitatively with less well-resolved FRET pairs (Fan et 
al., 1999, Okamoto et al., 2004, Svoboda and Yasuda, 2006) (such as aGEPRA G with 
the CFP4/YPet FRET pair), even though precise quantification could only be achieved 
with thorough calibration of the method and subtraction of bleed-through and crosstalk 
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between channels using FRET positive (tandem fusion of donor and acceptor) and negati-
ve controls (molecularly separated donor and acceptor at equimolar concentrations). 
4.5 Conclusion 
We developed a novel transcription-based method that allows faithful detection of RA 
in reporter-expressing cells after long-term reporter expression. This will make the 
method useful for viral delivery, allowing its use in high-throughput methods or in vivo 
applications. 
Using a non-integrating reporter to detect endogenous RA levels in neurons after syn-
aptic activity blockade yielded uninterpretable results, either because of insufficient sensi-
tivity of the reporter for low RA levels, or because of the volatile nature of RA itself, pre-
venting the activation of a sufficient number of reporter molecules for a duration long 
enough to permit detection. 
We therefore conclude that integrating, transcription-based reporter methods allow for 
a faithful detection of RA at the expense of subcellular spatial and temporal sensitivity, 
whereas the non-integrating aGEPRA reporters are an attractive means to indicate suffi-
ciently high levels of RA but fail to detect cellular RA levels produced during the induc-
tion of homeostatic synaptic plasticity. 
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Appendix 3: List of Abbreviations 
% per cent 
> larger 
°C degrees Celsius 
µg microgram 
µL microliter 
µm micrometer 
2p two-photon 
ACT acceptor cross talk 
AF activating function 
AID autoinhibitory domain 
AIP autoinhibitory peptide 
AKAP A-kinase anchoring protein 
AMPA -amino-3-hydroxy-5-methyl-4-isoxazole proprionate 
AMPAR AMPA-type glutamate receptor 
APV 2-amino-5-phosphonovaleric acid 
Ara-C cytosine -D-arabinofuranoside 
avg average 
BBH calcineurin B binding helix 
CaM calmodulin 
CaMB calmodulin-binding 
CaMKII calmodulin-dependent protein kinase II 
CaN calcineurin 
cf. confer 
CnA calcineurin, A subunit 
CnB calcineurin, B subunit 
CNQX 6-cyano-7-nitroquinoxaline-2,3-dione 
CO2 carbon dioxide 
cpYPet circularly permuted yellow fluorescent protein for energy transfer 
CS cover glass 
CsA cyclosporin A 
C-terminal carboxy-terminal 
ctrl. control 
 difference 
DBD DNA-binding domain 
DBT donor bleed-through 
DEAB 4-diethylaminobenzaldehyde 
DIC differential interference contrast 
DIV day in vitro 
DMEM DUBECCO’s modified essential medium 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP deoxyribonucleotide trisphosphate 
R/R normalized ratio change 
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e.g. for example 
ECFP enhanced cyan fluorescent protein 
EGFP enhanced green fluorescent protein 
em emission 
ER estrogen receptor 
et al. and others 
ex excitation 
EYFP enhanced yellow fluorescent protein 
F-actin filamentous (polymeric) actin 
FCS fetal bovine serum (fetal calf serum) 
 D  donor quantum yield 
fLuc firefly luciferase 
FRET FÖRSTER resonance energy transfer 
G conductance 
g gram 
GABA -amino-butyric acid 
GABAAR A-type GABA receptor 
G-actin globular (monomeric) actin 
Gal4 regulatory yeast protein GAL4 
GEPRA genetically engineered probe for RA 
GFP green fluorescent protein 
GluA1 AMPA-type glutamate receptor subunit 1 
GluN2A NMDA-type glutamate receptor subunit 2A 
H helix 
HBSS HANK’s balanced salt solution 
HEK cells human  embryonic kidney cell line 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HSP homeostatic synaptic plasticity 
i.e. that is 
I-1 protein phosphatase inhibitor 1 
J () spectral overlap integral between fluorophores 
 2  orientation factor between fluorophores 
kbp kilo basepairs 
kT energy transfer rate 
L liter 
 wavelength 
LBD ligand-binding domain 
LSM laser-scanning microscope 
LTD (synaptic) long-term depression 
LTP (synaptic) long-term potentiation 
M molar 
MAGUK membrane-associated guanylate kinase 
mCFP monomeric cyan fluorescent protein 
MCS multiple cloning site 
MEM minimum essential medium 
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mEPSC miniature  excitatory postsynaptic current 
mg milligram 
MHz mega Hertz 
min. minute 
mL milliliter 
mm millimeter 
mRNA messenger ribonucleic acid 
mYFP monomeric yellow fluorescent protein 
N number of independent experiments 
n number of events observed 
n refractive index 
NAD+ nicotinamide adenine dinucleotide (oxidized form) 
NADH nicotinamide adenine dinucleotide (reduced form) 
NaN not a number 
NB neurobasal medium 
ng nanogram 
NGM neurobasal growth media 
nm nanometer 
nM nanomolar 
NMDA N-methyl-D-aspartate 
NMDAR NMDA-type glutamate receptor 
non-resp. non-responder 
norm. normalized 
NR nuclear receptor 
N-terminal amino-terminal 
p plasmid 
P p value 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PKA protein kinase A 
PKC protein kinase C 
PLL poly-L lysine 
PP1 protein phosphatase 1 
PP2B protein phosphatase 2B (calcineurin) 
PSD post-synaptic density 
r distance between fluorophores 
R0 FÖRSTER radius 
RA all-trans retinoic acid 
RALDH retinaldehyde dehydrogenase 
RAR retinoic acid receptor 
RARE retinoic acid response element 
resp. responder 
RNA ribonucleic acid 
ROLDH retinol dehydrogenase 
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RXR retinoid X receptor 
s second 
S0 electronic ground state 
S1 first electronic excited state 
SEM standard error of the mean 
SNM serum neuron media 
syn synaptic 
t time 
TA transactivator 
 D  donor fluorescence lifetime 
TK thymidine kinase 
Tm primer annealing temperature 
TTX tetrodotoxin 
UAS  upstream activating sequence 
V voltage 
VP16 Herpes simplex viral protein 16 
vs. versus 
x fold 
XFP fluorescent protein of any color 
YPet  yellow fluorescent protein for energy transfer 
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Appendix 4: Sequences of DNA Constructs Used in This Study 
1. Gal4-RAR-VP16 chimeric receptor constructs 
Gal4-MCS-VP16 cloning vector sequence 
TCC GCT AGC GAC AAG CTT ATG AAG CTA CTG TCT TCT ATC GAA CAA GCA TGC GAT ATT TGC  
                        Met Lys Leu Leu Ser Ser Ile Glu Gln Ala Cys Asp Ile Cys  
    NheI        HindIII 
 
CGA CTT AAA AAG CTC AAG TGC TCC AAA GAA AAA CCG AAG TGC GCC AAG TGT CTG AAG AAC  
Arg Leu Lys Lys Leu Lys Cys Ser Lys Glu Lys Pro Lys Cys Ala Lys Cys Leu Lys Asn  
 
AAC TGG GAG TGT CGC TAC TCT CCC AGA ACC AAA AGG TCT CCG CTG ACT AGG GCA CAT CTG  
Asn Trp Glu Cys Arg Tyr Ser Pro Arg Thr Lys Arg Ser Pro Leu Thr Arg Ala His Leu  
 
ACA GAA GTG GAA TCA AGG CTA GAA AGA CTG GAA CAG CTA TTT CTA CTG ATT TTT CCT CGT  
Thr Glu Val Glu Ser Arg Leu Glu Arg Leu Glu Gln Leu Phe Leu Leu Ile Phe Pro Arg  
 
GAA GAC CTT GAC ATG ATT TTG AAA ATG GAT TCT TTA CAG GAT ATA AAA GCA TTG TTG ACA  
Glu Asp Leu Asp Met Ile Leu Lys Met Asp Ser Leu Gln Asp Ile Lys Ala Leu Leu Thr  
 
GGA TTA TTT GTT CAA GAT AAT GTG AAT AAA GAT GCC GTC ACA GAT AGA TTG GCT TCA GTG  
Gly Leu Phe Val Gln Asp Asn Val Asn Lys Asp Ala Val Thr Asp Arg Leu Ala Ser Val  
 
GAG ACT GAT ATG CCT CTA ACA TTG AGA CAG CAT AGA ATA AGT GCG ACA TCA TCA TCG GAA  
Glu Thr Asp Met Pro Leu Thr Leu Arg Gln His Arg Ile Ser Ala Thr Ser Ser Ser Glu  
 
GAG AGT AGT AAC AAA GGT CAA AGA CAG TTG ACT GTA TCG CCG GAA TTC CTG CAG CCC GGG  
Glu Ser Ser Asn Lys Gly Gln Arg Gln Leu Thr Val Ser Pro Glu Phe Leu Gln Pro Gly  
                                                        EcoRI   PstI    XmaI 
                                                                        SmaI 
 
GGT ACC GGT AGC GGA TCC GCC CCA CCG ACC GAT GTC TCA CTG GGA GAC GAG CTC CAT TTA  
Gly Thr Gly Ser Gly Ser Ala Pro Pro Thr Asp Val Ser Leu Gly Asp Glu Leu His Leu  
Acc65I          BamHI 
KpnI  AgeI 
 
GAC GGT GAG GAC GTG GCT ATG GCA CAT GCC GAC GCA CTA GAC GAT TTC GAT CTA GAC ATG  
Asp Gly Glu Asp Val Ala Met Ala His Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met  
 
TTG GGA GAC GGT GAT TCC CCA GGT CCT aga tcc GCA CCT CCG ACC GAT GTC AGC CTG GGT  
Leu Gly Asp Gly Asp Ser Pro Gly Pro Arg Ser Ala Pro Pro Thr Asp Val Ser Leu Gly  
 
GAC GAG CTC CAC TTG GAC GGT GAG GAC GTG GCG ATG GCT CAT GCC GAC GCG CTA GAC GAC  
Asp Glu Leu His Leu Asp Gly Glu Asp Val Ala Met Ala His Ala Asp Ala Leu Asp Asp  
 
TTC GAT CTA GAC ATG TTG GGT GAC GGA GAT TCA CCA GGT CCG aga tcc tct aga tct aga  
Phe Asp Leu Asp Met Leu Gly Asp Gly Asp Ser Pro Gly Pro Arg Ser Ser Arg Ser Arg  
                                                                    BglII 
 
ggg ccc gtt taa GCG GCC GCG ACT  
Gly Pro Val END 
ApaI            NotI 
 
The construct was synthesized as two separate gBlock fragments (Integrated DNA Tech-
nologies, Inc.) and was cloned into the pEGFP-N1 plasmid backbone using the NheI and 
NotI restriction enzyme sites. Amino acid sequences of Gal4-DBD and the 2x VP16 tan-
dem repeats are color indicated in bold print. The Gal4 K43R mutation is highlighted in 
red. All restriction enzyme sites indicated are unique. 
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RAR insert sequences 
Sequence stretches [ … ] between indicated insertion sites correspond to GenBank entries 
XM_017597011.1 (rat RAR), NM_001289762.1 (mouse RAR), NM_001135250.1 (rat 
RAR). 
RAR182-416 (LBD)  
CCG GAA TTC GGG GAA CTC [ ... ] TCT GAG GGC GGA TCC GCC  
Pro Glu Phe Gly Glu Leu [ ... ] Ser Glu Gly Gly Ser Ala  
    EcoRI                                   BamHI 
 
RAR182-459 (LBD + F domain) 
CCG GAA TTC GGG GAA CTC [ ... ] CAA TCC CCA GGA TCC GCC 
Pro Glu Phe Gly Glu Leu [ ... ] Gln Ser Pro Gly Ser Ala 
    EcoRI                                   BamHI 
 
RAR178-412 (LBD)  
GGT ACC GGT GAC GAC CTC [ ... ] TCT GAA GGA GGA TCC GCC 
Gly Thr Gly Asp Asp Leu [ ... ] Ser Glu Gly Gly Ser Ala 
    AgeI                                    BamHI 
 
RAR182-448 (LBD + F domain) 
GGT ACC GGT GAC GAC CTC [ ... ] CTG CTG CAG GGA TCC GCC 
Gly Thr Gly Asp Asp Leu [ ... ] Leu Leu Gln Gly Ser Ala 
    AgeI                                    BamHI 
 
RAR214-448 (LBD)  
CCG GAA TTC GAG GAG CTC [ ... ] CCT GAG ATG GGA TCC GCC 
Pro Glu Phe Glu Glu Leu [ ... ] Pro Glu Met Gly Ser Ala 
    EcoRI                                   BamHI 
 
RAR214-485 (LBD + F domain) 
CCG GAA TTC GAG GAG CTC [ ... ] CAG GGC CCC GGA TCC GCC 
Pro Glu Phe Glu Glu Leu [ ... ] Gln Gly Pro Gly Ser Ala 
    EcoRI                                   BamHI 
 
Amino acid sequences of RARs are indicated in bold print, along with the flanking re-
striction enzyme sites used for insertion into the Gal4-MCS-VP16 cloning vector. 
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2. UAS-E4TATA::fLuc-EGFP reporter construct 
UAS-E4TATA::fLuc-EGFP reporter construct 
CAT GCA TTA GTT att aat ccc gag ctc att tag gtg aca cta tag AAT ACA AGC TTG CAT  
                VspI        SacI 
 
GCC TGC AGG TCc tCG GAG GAC AGT ACT CCG ctC GGA GGA CAG TAC TCC Gct CGG AGG ACA  
 SbfI 
  PstI 
 
GTA CTC CGc tCG GAG GAC AGT ACT CCG ctC GGA GGA CAG TAC TCC Gac TCT AGA GGA TCC 
                                                                        BamHI  
 
CCA GTC CTA TAT ATA CTC GCT CTG CAC TTG GCC CTT TTT TAC ACT GTG ACT GAT TGA GCT  
 
GGT GCC GTG TCG AGT GGT GTC TCG AGG GGA CCG GTc gcc acc ATG GAA GAC GCC AAA AAC  
                                                        Met Glu Asp Ala Lys Asn  
                          XhoI        AgeI 
 
ATA AAG AAA GGC CCG GCG CCA TTC TAT CCT CTA GAG GAT GGA ACC GCT GGA GAG CAA CTG  
Ile Lys Lys Gly Pro Ala Pro Phe Tyr Pro Leu Glu Asp Gly Thr Ala Gly Glu Gln Leu  
 
CAT AAG GCT ATG AAG AGA TAC GCC CTG GTT CCT GGA ACA ATT GCT TTT ACA GAT GCA CAT  
His Lys Ala Met Lys Arg Tyr Ala Leu Val Pro Gly Thr Ile Ala Phe Thr Asp Ala His  
 
ATC GAG GTG AAC ATC ACG TAC GCG GAA TAC TTC GAA ATG TCC GTT CGG TTG GCA GAA GCT  
Ile Glu Val Asn Ile Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala Glu Ala  
 
ATG AAA CGA TAT GGG CTG AAT ACA AAT CAC AGA ATC GTC GTA TGC AGT GAA AAC TCT CTT  
Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg Ile Val Val Cys Ser Glu Asn Ser Leu  
 
CAA TTC TTT ATG CCG GTG TTG GGC GCG TTA TTT ATC GGA GTT GCA GTT GCG CCC GCG AAC  
Gln Phe Phe Met Pro Val Leu Gly Ala Leu Phe Ile Gly Val Ala Val Ala Pro Ala Asn  
 
GAC ATT TAT AAT GAA CGT GAA TTG CTC AAC AGT ATG AAC ATT TCG CAG CCT ACC GTA GTG  
Asp Ile Tyr Asn Glu Arg Glu Leu Leu Asn Ser Met Asn Ile Ser Gln Pro Thr Val Val  
 
TTT GTT TCC AAA AAG GGG TTG CAA AAA ATT TTG AAC GTG CAA AAA AAA TTA CCA ATA ATC  
Phe Val Ser Lys Lys Gly Leu Gln Lys Ile Leu Asn Val Gln Lys Lys Leu Pro Ile Ile  
 
CAG AAA ATT ATT ATC ATG GAT TCT AAA ACG GAT TAC CAG GGA TTT CAG TCG ATG TAC ACG  
Gln Lys Ile Ile Ile Met Asp Ser Lys Thr Asp Tyr Gln Gly Phe Gln Ser Met Tyr Thr  
 
TTC GTC ACA TCT CAT CTA CCT CCC GGT TTT AAT GAA TAC GAT TTT GTA CCA GAG TCC TTT  
Phe Val Thr Ser His Leu Pro Pro Gly Phe Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe  
 
GAT CGT GAC AAA ACA ATT GCA CTG ATA ATG AAT TCC TCT GGA TCT ACT GGG TTA CCT AAG  
Asp Arg Asp Lys Thr Ile Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys  
 
GGT GTG GCC CTT CCG CAT AGA GCT GCC TGC GTC AGA TTC TCG CAT GCC AGA GAT CCT ATT  
Gly Val Ala Leu Pro His Arg Ala Ala Cys Val Arg Phe Ser His Ala Arg Asp Pro Ile  
 
TTT GGC AAT CAA ATC GCT CCG GAT ACT GCG ATT TTA AGT GTT GTT CCA TTC CAT CAC GGT  
Phe Gly Asn Gln Ile Ala Pro Asp Thr Ala Ile Leu Ser Val Val Pro Phe His His Gly  
 
TTT GGA ATG TTT ACT ACA CTC GGA TAT TTG ATA TGT GGA TTT CGA GTC GTC TTA ATG TAT  
Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu Ile Cys Gly Phe Arg Val Val Leu Met Tyr  
 
AGA TTT GAA GAA GAG CTG TTT TTA CGA TCC CTT CAG GAT TAC AAA ATT CAA AGT GCG TTG  
Arg Phe Glu Glu Glu Leu Phe Leu Arg Ser Leu Gln Asp Tyr Lys Ile Gln Ser Ala Leu  
 
CTA GTA CCA ACC CTA TTT TCA TTC CTG GCC AAA AGC ACT CTG ATT GAC AAA TAC GAT TTA  
Leu Val Pro Thr Leu Phe Ser Phe Leu Ala Lys Ser Thr Leu Ile Asp Lys Tyr Asp Leu  
 
TCT AAT TTA CAC GAA ATT GCT TCT GGG GGC GCA CCT CTT TCG AAA GAA GTC GGG GAA GCG  
Ser Asn Leu His Glu Ile Ala Ser Gly Gly Ala Pro Leu Ser Lys Glu Val Gly Glu Ala  
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UAS-E4TATA::fLuc-EGFP reporter construct (continued) 
GTT GCA AAA CGC TTC CAT CTT CCA GGG ATA CGA CAA GGA TAT GGG CTC ACT GAG ACT ACA  
Val Ala Lys Arg Phe His Leu Pro Gly Ile Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr  
 
TCA GCT ATT CTG ATT ACA CCC AAG GGG GAT GAT AAA CCG GGC GCG GTC GGT AAA GTT GTT  
Ser Ala Ile Leu Ile Thr Pro Lys Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val  
 
CCA TTT TTT GAA GCG AAG GTT GTG GAT CTG GAT ACC GGG AAA ACG CTG GGC GTT AAT CAG  
Pro Phe Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val Asn Gln  
 
AGA GGC GAA TTA TGT GTC AGA GGA CCT ATG ATT ATG TCC GGT TAT GTA AAC AAT CCG GAA  
Arg Gly Glu Leu Cys Val Arg Gly Pro Met Ile Met Ser Gly Tyr Val Asn Asn Pro Glu  
 
GCG ACC AAC GCC TTG ATT GAC AAG GAT GGA TGG CTA CAT TCT GGA GAC ATA GCT TAC TGG  
Ala Thr Asn Ala Leu Ile Asp Lys Asp Gly Trp Leu His Ser Gly Asp Ile Ala Tyr Trp  
 
GAC GAA GAC GAA CAC TTC TTC ATA GTT GAC CGC TTG AAG TCT TTA ATT AAA TAC AAA GGA  
Asp Glu Asp Glu His Phe Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly  
 
TAT CAG GTG GCC CCC GCT GAA TTG GAA TCG ATA TTG TTA CAA CAC CCC AAC ATC TTC GAC  
Tyr Gln Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Asn Ile Phe Asp  
 
GCG GGC GTG GCA GGT CTT CCC GAC GAT GAC GCC GGT GAA CTT CCC GCC GCC GTT GTT GTT  
Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu Pro Ala Ala Val Val Val  
 
TTG GAG CAC GGA AAG ACG ATG ACG GAA AAA GAG ATC GTG GAT TAC GTC GCC AGT CAA GTA  
Leu Glu His Gly Lys Thr Met Thr Glu Lys Glu Ile Val Asp Tyr Val Ala Ser Gln Val  
 
ACA ACC GCG AAA AAG TTG CGC GGA GGA GTT GTG TTT GTG GAC GAA GTA CCG AAA GGT CTT  
Thr Thr Ala Lys Lys Leu Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu  
 
ACC GGA AAA CTC GAC GCA AGA AAA ATC AGA GAG ATC CTC ATA AAG GCC AAG AAG GGC GGA  
Thr Gly Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala Lys Lys Gly Gly  
 
AAG TCC AAA TTG GGA TCC GGT GGC GGA GGT AGC GGT GGC GGA GGT AGC ATG GTG AGC AAG  
Lys Ser Lys Leu Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Met Val Ser Lys  
 
GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC GAG CTG GAC GGC GAC GTA AAC  
Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp Gly Asp Val Asn  
 
GGC CAC AAG TTC AGC GTG TCC GGC GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC  
Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr  
 
CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC  
Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
 
CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG CAG CAC GAC TTC  
Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His Asp Phe  
 
TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TTC TTC AAG GAC GAC  
Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp  
 
GGC AAC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC  
Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile  
 
GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC  
Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
 
AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC TAT TGT CTA AGC TTC TGT AAG AAC  
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Tyr Cys Leu Ser Phe Cys Lys Asn  
 
GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC GTG CAG CTC GCC  
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln Leu Ala  
 
GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC  
Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn His  
 
TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC  
Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val  
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UAS-E4TATA::fLuc-EGFP reporter construct (continued) 
CTG CTG GAG TTC GTG ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA  
Leu Leu Glu Phe Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys End  
 
aGC GGC CGC GAC 
 NotI  
 
The plasmid was made by PCR amplification of the UAS5-E4TATA regulatory sequences 
and cloning into the pEYFP-N1 plasmid backbone using the VspI and AgeI restriction en-
zyme sites. Next, fLuc-EGFP was amplified by PCR and cloned behind the regulatory 
sequences using the AgeI and NotI restriction enzyme sites, replacing the EYFP. 
The upstream activating sequence (UAS) is highlighted in yellow, with UAS repeats prin-
ted as capital letters and spacer nucleotides as small letters. The Herpes simplex virus E4 
TATA box minimal promoter is highlighted in cyan, and fLuc and EGFP amino acid 
sequence domains of the reporter gene are color indicated in bold print. All restriction 
enzyme sites indicated are unique. 
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3. Modular FRET sensors for RA 
NR box gBlock sequence 
acgGCTAGCatc tcg agc cta cct tat gaa ggc agc ctg ctg ctc aag ctg ctt aga gca  
             Ser Ser Leu Pro Tyr Glu Gly Ser Leu Leu Leu Lys Leu Leu Arg Ala  
   NheI*   XhoI 
 
cca gta gag gaa gtt gga ggc aat ggt gga gat ctg aTGTACAgcc tcg agt ctg cca tac  
Pro Val Glu Glu Val Gly Gly Asn Gly Gly Asp Leu            Ser Ser Leu Pro Tyr  
                                      BglII      BsrGI*  XhoI 
 
gag ggc tcg ctg ctg ctc aag ctg ctt aga gct cca gtt gaa gag gtc gga ggt aat ggc  
Glu Gly Ser Leu Leu Leu Lys Leu Leu Arg Ala Pro Val Glu Glu Val Gly Gly Asn Gly  
 
ggt aac ggc ggt aac gga ggc aac ggt ggc aat ggt ggc aat gga ggc aat ggt gga gat  
Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asp  
                                                                          BglII 
 
ctg gaGAATTCgcc tcg agt cta cct tac gag ggc agt ctg gct ctt aat gca gcc aga gca  
Leu             Ser Ser Leu Pro Tyr Glu Gly Ser Leu Ala Leu Asn Ala Ala Arg Ala  
      EcoRI*  XhoI 
 
cct gtg gag gag gtg ggt gga aac ggt gga gat ctg aGGATCCgcc tcg agt ctg cca tac  
Pro Val Glu Glu Val Gly Gly Asn Gly Gly Asp Leu            Ser Ser Leu Pro Tyr  
                                      BglII      BamHI*  XhoI 
 
gaa ggc agc ctg gcg ctc aag gcg gct agg gca cct gtg gag gaa gtg ggt ggc aac ggt  
Glu Gly Ser Leu Ala Leu Lys Ala Ala Arg Ala Pro Val Glu Glu Val Gly Gly Asn Gly  
 
ggc aat gga ggc aat ggc ggc aat gga ggt aac gga ggt aac ggc ggc aat ggc gga gat  
Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asn Gly Gly Asp  
                                                                          BglII 
 
ctg aGCGGCCGCatc  
Leu 
     NotI* 
 
The construct was synthesized as a gBlock fragment (Integrated DNA Technologies, Inc.) 
and was cloned into the pEGFP-N1 plasmid backbone using the NheI and NotI restriction 
enzyme sites. Amino acid sequences of NR boxes (corresponding to the D22 peptide, 
Chang et al., 1999) are indicated in bold print, with reading frames as in the final modular 
FRET sensor constructs. Essential Leucines are highlighted in red and the correspon-
ding mutated Alanines in the binding-deficient NR box mutants are highlighted in 
green. All NR boxes are flanked by XhoI and BglII restriction enzyme sites for cloning 
into the final modular FRET sensor constructs. For convenience, all NR box variants have 
been separated by unique restriction enzyme sites as indicated by capital letters. NR bo-
xes as desired were excised using appropriate unique restriction enzyme sites, then di-
gested with XhoI and BglII and introduced into the final modular FRET sensors. All 
restriction enzyme sites indicated with * are unique. 
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Rat RAR LBD + F domain sequence 
gga gat ctg agc tac acg ctg aca ccg gag gtg ggg gaa ctc atc gag aag gtg cgc aaa  
Gly Asp Leu Ser Tyr Thr Leu Thr Pro Glu Val Gly Glu Leu Ile Glu Lys Val Arg Lys  
  BglII 
 
gca cac cag gag acc ttc ccg gcc ctc tgc cag ctg ggc aag tac act acg aac aac agc  
Ala His Gln Glu Thr Phe Pro Ala Leu Cys Gln Leu Gly Lys Tyr Thr Thr Asn Asn Ser  
 
tca aaa caa cgt gtc tct ctg gac att gac ctc tgg gac aag ttc agt gaa ctc tcc acc  
Ser Lys Gln Arg Val Ser Leu Asp Ile Asp Leu Trp Asp Lys Phe Ser Glu Leu Ser Thr  
 
aag tgt atc att aag act gtg gag ttc gcc aag cag ctt ccc ggc ttc acc acc ctc acc  
Lys Cys Ile Ile Lys Thr Val Glu Phe Ala Lys Gln Leu Pro Gly Phe Thr Thr Leu Thr  
 
att gca gac cag att acc ctt ctc aag gct gcc tgc ctg gac atc ctg att ctg cga atc  
Ile Ala Asp Gln Ile Thr Leu Leu Lys Ala Ala Cys Leu Asp Ile Leu Ile Leu Arg Ile  
 
tgc acg cgg tac aca cct gag caa gac aca atg acc ttc tca gat gga ctg acc ctg aac  
Cys Thr Arg Tyr Thr Pro Glu Gln Asp Thr Met Thr Phe Ser Asp Gly Leu Thr Leu Asn  
 
cgg act cag atg cac aac gct ggc ttt ggc ccc ctc acc gac ttg gtc ttt gcc ttc gcc  
Arg Thr Gln Met His Asn Ala Gly Phe Gly Pro Leu Thr Asp Leu Val Phe Ala Phe Ala  
 
aac cag ctg ctg ccc ctg gag atg gac gat gct gag acc gga ctg ctc agt gcc atc tgc  
Asn Gln Leu Leu Pro Leu Glu Met Asp Asp Ala Glu Thr Gly Leu Leu Ser Ala Ile Cys  
 
ctc atc tgt gga gac cga cag gat cta gag cag cca gac aag gtg gac atg ctg cag gag  
Leu Ile Cys Gly Asp Arg Gln Asp Leu Glu Gln Pro Asp Lys Val Asp Met Leu Gln Glu  
 
ccg ctg ttg gaa gca ctg aaa gtc tat gtc cgg aaa cgg agg ccc agc cga ccc cac atg  
Pro Leu Leu Glu Ala Leu Lys Val Tyr Val Arg Lys Arg Arg Pro Ser Arg Pro His Met  
 
ttc ccc aag atg ctg atg aag atc acg gac ctt cgg agt atc agc gcc aag gga gct gaa  
Phe Pro Lys Met Leu Met Lys Ile Thr Asp Leu Arg Ser Ile Ser Ala Lys Gly Ala Glu  
 
        cag 
cgg gtg atc aca ttg aag atg gag atc cct ggt tcc atg cca cca ctt atc cag gaa atg  
Arg Val Ile Thr Leu Lys Met Glu Ile Pro Gly Ser Met Pro Pro Leu Ile Gln Glu Met  
        Gln 
 
ttg gag aac tct gag ggc ttg gac act cta agc gga cag tcg ggg ggc gga aca cga gat  
Leu Glu Asn Ser Glu Gly Leu Asp Thr Leu Ser Gly Gln Ser Gly Gly Gly Thr Arg Asp  
 
ggg ggt ggc ctg gcc cct cct ccg ggt agc tgt agc ccc agc ctc agt ccc agc tcc cac  
Gly Gly Gly Leu Ala Pro Pro Pro Gly Ser Cys Ser Pro Ser Leu Ser Pro Ser Ser His  
 
aga agc agc cca gcc act caa tct gga tcc gtg  
Arg Ser Ser Pro Ala Thr Gln Ser Gly Ser Val  
                                BamHI 
Amino acid sequence of the RAR LBD is indicated in bold print and the F domain in 
bold italic print, along with the flanking restriction enzyme sites used for insertion into 
the modular FRET sensor construct plasmids. The I393Q mutation is highlighted in red, 
with mutated nucleotide sequence indicated above and mutated amino acid residue below 
the wild-type sequence. All restriction enzyme sites indicated are unique. 
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Modular FRET sensor domain structure and variants 
Plasmid # NR box* Linker length** LBD*** F domain 
664 D22 (wt) Short linker wild-type LBD no F 
665 D22 (wt) Long linker wild-type LBD no F 
666 D22 (wt) Short linker wild-type LBD + F 
667 D22 (wt) Long linker wild-type LBD + F 
668 D22 (AAA) Short linker wild-type LBD no F 
669 D22 (AAA) Long linker wild-type LBD no F 
670 D22 (AAA) Short linker wild-type LBD + F 
671 D22 (AAA) Long linker wild-type LBD + F 
672 D22 (wt) Short linker mutant LBD (I393Q) no F 
673 D22 (wt) Long linker mutant LBD (I393Q) no F 
674 D22 (wt) Short linker mutant LBD (I393Q) + F 
675 D22 (wt) Long linker mutant LBD (I393Q) + F 
676 D22 (AAA) Short linker mutant LBD (I393Q) no F 
677 D22 (AAA) Long linker mutant LBD (I393Q) no F 
678 D22 (AAA) Short linker mutant LBD (I393Q) + F 
679 D22 (AAA) Long linker mutant LBD (I393Q) + F 
* D22 refers to a peptide identified to bind differentially to the ligand-bound vs. unligan-
ded RAR LBD in a peptide library screen (Chang et al., 1999). The wild-type variant, 
D22 (wt), with the amino acid sequence LPYEGSLLLKLLRAPVEEV, and the binding-
deficient variant, D22 (AAA), with the amino acid sequence LPYEGSLALKAARAP-
VEEV. 
** The short linker of 5 residues with the amino acid sequence GGNGG, and the long 
linker of 23 residues with the sequence [GGN]7GG. 
*** The LBD I393Q mutation acts as a beta sheet breaker and destabilizes the domain of 
the LBD that interacts with transcriptional co-repressors in the unliganded state (le Maire 
et al., 2010). 
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4. aGEPRA solubility domain 
aGEPRA solubility domain sequence 
aag gat ccc ATG GCT GAA GAA AGT GAC AAT GTG GAT TCT GCT GAT GCG GAG GAG GAT GAC  
            Met Ala Glu Glu Ser Asp Asn Val Asp Ser Ala Asp Ala Glu Glu Asp Asp  
  BamHI 
 
TCG GAT GTC TGG TGG GGC GGA GCA GAC ACA GAC TAT GCA GAT GGG AGT GAA GAC AAA GTA  
Ser Asp Val Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp Gly Ser Glu Asp Lys Val  
 
GTA GAA GTA GCA GAG GAG GAA GAA GTG GCT GAG GTG GAA GAA GAA GAA GCC GAT GAT GAC  
Val Glu Val Ala Glu Glu Glu Glu Val Ala Glu Val Glu Glu Glu Glu Ala Asp Asp Asp  
 
GAG GAC GAT GAG GAT GGT GAT GAG GTA GAG GAA GAG GCT GAG GAA CCC TAC GAA GAA GCC  
Glu Asp Asp Glu Asp Gly Asp Glu Val Glu Glu Glu Ala Glu Glu Pro Tyr Glu Glu Ala  
 
ACA GAG AGA ACC ACC AGC ATT GCC ACC ACC ACC ACC ACC ACC ACA GAG TCT GTG GAA GAG  
Thr Glu Arg Thr Thr Ser Ile Ala Thr Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu  
 
GTG act agt atg [ aGEPRA sequence ] 
Val Thr Ser Met [ aGEPRA sequence ] 
    SpeI 
 
Solubility domain amino acid sequence is indicated in bold print, along with flanking 
restriction enzyme sites. The Met residue at the end of the sequence is the first amino acid 
residue of the GEPRA variants to which the solubility domain was fused. Sequence of the 
GEPRA variants is as reported (Shimozono et al., 2013). All restriction enzyme sites indi-
cated are unique. 
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5. Clover-mRuby2 FRET pair 
pcDNA3-Clover sequence 
cca agc ttg gta ccg agc tcg gat cca cta gta acg gcc gcc agt gtg ctg gaa ttc ggc  
  HindIII                 BamHI                                     EcoRI 
 
ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG GTC GAG CTG GAC  
Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp  
 
GGC GAC GTA AAC GGC CAC AAG TTC AGC GTC CGC GGC GAG GGC GAG GGC GAT GCC ACC AAC  
Gly Asp Val Asn Gly His Lys Phe Ser Val Arg Gly Glu Gly Glu Gly Asp Ala Thr Asn  
 
GGC AAG CTG ACC CTG AAG TTC ATC TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC  
Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr  
 
CTC GTG ACC ACC TTC GGC TAC GGC GTG GCC TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG  
Leu Val Thr Thr Phe Gly Tyr Gly Val Ala Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
 
CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG CGC ACC ATC TCT  
Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Ser  
 
TTC AAG GAC GAC GGT ACC TAC AAG ACC CGC GCC GAG GTG AAG TTC GAG GGC GAC ACC CTG  
Phe Lys Asp Asp Gly Thr Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu  
 
GTG AAC CGC ATC GAG CTG AAG GGC ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC  
Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His  
 
AAG CTG GAG TAC AAC TTC AAC AGC CAC AAC GTC TAT ATC ACG GCC GAC AAG CAG AAG AAC  
Lys Leu Glu Tyr Asn Phe Asn Ser His Asn Val Tyr Ile Thr Ala Asp Lys Gln Lys Asn  
 
GGC ATC AAG GCT AAC TTC AAG ATC CGC CAC AAC GTT GAG GAC GGC AGC GTG CAG CTC GCC  
Gly Ile Lys Ala Asn Phe Lys Ile Arg His Asn Val Glu Asp Gly Ser Val Gln Leu Ala  
 
GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC CCC GTG CTG CTG CCC GAC AAC CAC  
Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn His  
 
TAC CTG AGC CAT CAG TCC GCC CTG AGC AAA GAC CCC AAC GAG AAG CGC GAT CAC ATG GTC  
Tyr Leu Ser His Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val  
 
CTG CTG GAG TTC GTG ACC GCC GCC GGG ATT ACA CAT GGC ATG GAC GAG CTG TAC AAG tct  
Leu Leu Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys Ser  
                                                                 BsrGI     XbaI 
 
aga ggg ccc tat tct ata gtg tca cct aaa tgc tag  
Arg Gly Pro Tyr Ser Ile Val Ser Pro Lys Cys End  
    ApaI 
    Bsp120I 
 
Clover amino acid sequence is indicated in bold print, along with flanking restriction en-
zyme sites in the pcDNA3 vector. All restriction enzyme sites indicated are unique. 
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pcDNA3-mRuby2 sequence 
aag ctt gcg gcc gcc acc atg gtg cgg ggt tct cat cat cat cat cat cat ggt atg gct  
HindIII NotI                                                               NheI 
 
agc atg act ggt gga cag caa atg ggt cgg gat ctg tac gac gat gac gat aag gat ccg  
                                                                      BamHI 
 
ATG GTG TCT AAG GGC GAA GAG CTG ATC AAG GAA AAT ATG CGT ATG AAG GTG GTC ATG GAA  
Met Val Ser Lys Gly Glu Glu Leu Ile Lys Glu Asn Met Arg Met Lys Val Val Met Glu  
 
GGT TCG GTC AAC GGC CAC CAA TTC AAA TGC ACA GGT GAA GGA GAA GGC AAT CCG TAC ATG  
Gly Ser Val Asn Gly His Gln Phe Lys Cys Thr Gly Glu Gly Glu Gly Asn Pro Tyr Met  
 
GGA ACT CAA ACC ATG AGG ATC AAA GTC ATC GAG GGA GGA CCC CTG CCA TTT GCC TTT GAC  
Gly Thr Gln Thr Met Arg Ile Lys Val Ile Glu Gly Gly Pro Leu Pro Phe Ala Phe Asp  
 
ATT CTT GCC ACG TCG TTC ATG TAT GGC AGC CGT ACT TTT ATC AAG TAC CCG AAA GGC ATT  
Ile Leu Ala Thr Ser Phe Met Tyr Gly Ser Arg Thr Phe Ile Lys Tyr Pro Lys Gly Ile  
 
CCT GAT TTC TTT AAA CAG TCC TTT CCT GAG GGT TTT ACT TGG GAA AGA GTT ACG AGA TAC  
Pro Asp Phe Phe Lys Gln Ser Phe Pro Glu Gly Phe Thr Trp Glu Arg Val Thr Arg Tyr  
 
GAA GAT GGT GGA GTC GTC ACC GTC ATG CAG GAC ACC AGC CTT GAG GAT GGC TGT CTC GTT  
Glu Asp Gly Gly Val Val Thr Val Met Gln Asp Thr Ser Leu Glu Asp Gly Cys Leu Val  
 
TAC CAC GTC CAA GTC AGA GGG GTA AAC TTT CCC TCC AAT GGT CCC GTG ATG CAG AAG AAG  
Tyr His Val Gln Val Arg Gly Val Asn Phe Pro Ser Asn Gly Pro Val Met Gln Lys Lys  
 
ACC AAG GGT TGG GAG CCT AAT ACA GAG ATG ATG TAT CCA GCA GAT GGT GGT CTG AGG GGA  
Thr Lys Gly Trp Glu Pro Asn Thr Glu Met Met Tyr Pro Ala Asp Gly Gly Leu Arg Gly  
 
TAC ACT CAT ATG GCA CTG AAA GTT GAT GGT GGT GGC CAT CTG TCT TGC TCT TTC GTA ACA  
Tyr Thr His Met Ala Leu Lys Val Asp Gly Gly Gly His Leu Ser Cys Ser Phe Val Thr  
 
ACT TAC AGG TCA AAA AAG ACC GTC GGG AAC ATC AAG ATG CCC GGT ATC CAT GCC GTT GAT  
Thr Tyr Arg Ser Lys Lys Thr Val Gly Asn Ile Lys Met Pro Gly Ile His Ala Val Asp  
 
CAC CGC CTG GAA AGG TTA GAG GAA AGT GAC AAT GAA ATG TTC GTA GTA CAA CGC GAA CAC  
His Arg Leu Glu Arg Leu Glu Glu Ser Asp Asn Glu Met Phe Val Val Gln Arg Glu His  
 
GCA GTT GCC AAG TTC GCC GGG CTT GGT GGT GGG ATG GAC GAG CTG TAC AAG TAA gaa ttc  
Ala Val Ala Lys Phe Ala Gly Leu Gly Gly Gly Met Asp Glu Leu Tyr Lys End 
                                                         BsrGI          EcoRI 
tct aga ggg ccc  
XbaI    ApaI 
        Bsp120I 
 
mRuby2 amino acid sequence is indicated in bold print, along with flanking restriction 
enzyme sites in the pcDNA3 vector. All restriction enzyme sites indicated are unique. 
 
pcDNA3-Clover-mRuby2 fusion vector sequence 
ATG [ ... ] TAC AAG tct agc atg act ggt gga cag caa atg ggt cgg gat ctg tac gac  
Met [ ... ] Tyr Lys Ser Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr Asp  
 
gat gac gat aag gat ccg ATG GTG [ ... ] AAG TAA gaa ttc tct aga ggg ccc 
Asp Asp Asp Lys Asp Pro Met Val [ ... ] Lys End         XbaI    ApaI 
 
mRuby2 was excised using NheI and ApaI and intoduced into the pcDNA3-Clover plas-
mid digested with XbaI and ApaI. Destroyed restriction enzyme sites from XbaI/NheI 
compatible ends ligation is indicated by dashed underline. Clover and mRuby2 amino 
acid sequence domains of the fusion protein are color indicated in bold print. All restricti-
on enzyme sites indicated are unique. 
